<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001059.pub4" GROUP_ID="PREG" ID="950699080413410487" MERGED_FROM="" MODIFIED="2014-06-19 14:18:10 +0100" MODIFIED_BY="Leanne Jones" REVIEW_NO="0164" REVMAN_SUB_VERSION="5.3.2 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2014-06-19 14:18:10 +0100" MODIFIED_BY="Leanne Jones">
<TITLE MODIFIED="2013-06-01 10:59:19 +0100" MODIFIED_BY="[Empty name]">Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems</TITLE>
<CONTACT MODIFIED="2014-06-19 14:18:10 +0100" MODIFIED_BY="Leanne Jones"><PERSON ID="15917" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>G Justus</FIRST_NAME><LAST_NAME>Hofmeyr</LAST_NAME><POSITION>Director/Hon. Professor, Effective Care Research Unit</POSITION><EMAIL_1>justhof@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology, East London Hospital Complex</DEPARTMENT><ORGANISATION>University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health</ORGANISATION><ADDRESS_1>Frere and Cecilia Makiwane Hospitals</ADDRESS_1><ADDRESS_2>Private Bag X 9047</ADDRESS_2><CITY>East London</CITY><ZIP>5200</ZIP><REGION>Eastern Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 43 7092483</PHONE_1><PHONE_2>+27 83 2809402</PHONE_2><FAX_1>+27 43 7092483</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-06-19 14:18:10 +0100" MODIFIED_BY="Leanne Jones"><PERSON ID="15917" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>G Justus</FIRST_NAME><LAST_NAME>Hofmeyr</LAST_NAME><POSITION>Director/Hon. Professor, Effective Care Research Unit</POSITION><EMAIL_1>justhof@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology, East London Hospital Complex</DEPARTMENT><ORGANISATION>University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health</ORGANISATION><ADDRESS_1>Frere and Cecilia Makiwane Hospitals</ADDRESS_1><ADDRESS_2>Private Bag X 9047</ADDRESS_2><CITY>East London</CITY><ZIP>5200</ZIP><REGION>Eastern Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 43 7092483</PHONE_1><PHONE_2>+27 83 2809402</PHONE_2><FAX_1>+27 43 7092483</FAX_1></ADDRESS></PERSON><PERSON ID="16495233707895187386090810093217" ROLE="AUTHOR"><FIRST_NAME>Theresa</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Lawrie</LAST_NAME><SUFFIX>MBBCH, PhD</SUFFIX><POSITION>Senior Researcher</POSITION><EMAIL_1>tess@lawrie.com</EMAIL_1><MOBILE_PHONE>+447826939464</MOBILE_PHONE><ADDRESS><DEPARTMENT>Cochrane Gynaecological Cancer Group</DEPARTMENT><ORGANISATION>Royal United Hospital</ORGANISATION><ADDRESS_1>Education Centre</ADDRESS_1><CITY>Bath</CITY><ZIP>BA13NG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1225 428021</PHONE_1></ADDRESS></PERSON><PERSON ID="5183" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Álvaro</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Atallah</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Director of Brazilian Cochrane Centre</POSITION><EMAIL_1>atallahmbe@uol.com.br</EMAIL_1><EMAIL_2>alvaro.atallah@gmail.com</EMAIL_2><URL>www.centrocochranedobrasil.org</URL><MOBILE_PHONE>+55 11 98173 0404</MOBILE_PHONE><ADDRESS><DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT><ORGANISATION>Centro de Estudos de Medicina Baseada em Evidências e Avaliação Tecnológica em Saúde</ORGANISATION><ADDRESS_1>R. Borges Lagoa, 564 cj 63</ADDRESS_1><ADDRESS_2>Vila Clementino</ADDRESS_2><CITY>São Paulo</CITY><ZIP>04038000</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5571 4721</PHONE_1><PHONE_2>+55 11 5575 2970</PHONE_2></ADDRESS></PERSON><PERSON ID="7397" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Lelia</FIRST_NAME><LAST_NAME>Duley</LAST_NAME><POSITION>Director/Professor of Clinical Trials Research</POSITION><EMAIL_1>lelia.duley@nottingham.ac.uk</EMAIL_1><MOBILE_PHONE>07979744934</MOBILE_PHONE><ADDRESS><DEPARTMENT>Nottingham Clinical Trials Unit</DEPARTMENT><ORGANISATION>Nottingham Health Science Partners</ORGANISATION><ADDRESS_1>C Floor, South Block</ADDRESS_1><ADDRESS_2>Queen's Medical Centre</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 115 8844919</PHONE_1><FAX_1>44 115 9194430</FAX_1></ADDRESS></PERSON><PERSON ID="01396860867413614443100406040617" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maria</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Torloni</LAST_NAME><SUFFIX>MD,PhD</SUFFIX><POSITION>Assistant Director / Coordinator of International Affairs</POSITION><EMAIL_1>ginecologia@terra.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT><ORGANISATION>Centro de Estudos de Medicina Baseada em Evidências e Avaliação Tecnológica em Saúde</ORGANISATION><ADDRESS_1>Rua Borges Lagoa 564 cj 63</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04038-000</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><PHONE_2>+55 11 5589 9118</PHONE_2><FAX_1>+55 11 5575 2970</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-06-13 15:03:51 +0100" MODIFIED_BY="Leanne V Jones">
<UP_TO_DATE>
<DATE DAY="24" MONTH="5" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="3" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="24" MONTH="7" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-06-02 11:36:15 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-06-02 11:36:15 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>Eleven studies have been included for this update (<LINK REF="STD-Almirante-1998" TYPE="STUDY">Almirante 1998</LINK>; <LINK REF="STD-Bassaw-1998" TYPE="STUDY">Bassaw 1998</LINK>; <LINK REF="STD-Cong-1995" TYPE="STUDY">Cong 1995</LINK>; <LINK REF="STD-Herrera-1998" TYPE="STUDY">Herrera 1998</LINK>; <LINK REF="STD-Herrera-2006" TYPE="STUDY">Herrera 2006</LINK>; <LINK REF="STD-Jarjou-2004" TYPE="STUDY">Jarjou 2004</LINK>; <LINK REF="STD-Li-2000" TYPE="STUDY">Li 2000</LINK>; <LINK REF="STD-Marya-1987" TYPE="STUDY">Marya 1987</LINK>; <LINK REF="STD-Rogers-1999" TYPE="STUDY">Rogers 1999</LINK>; <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>; <LINK REF="STD-Taherian-2002" TYPE="STUDY">Taherian 2002</LINK>).Ten studies of low-dose calcium added. New meta-analyses performed. Substantially changed conclusions.</P>
<P>Search updated in May 2014, six reports added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> (<LINK REF="STD-Asemi-2012" TYPE="STUDY">Asemi 2012</LINK>; <LINK REF="STD-Diogenes-2013" TYPE="STUDY">Diogenes 2013</LINK>; <LINK REF="STD-Goldberg-2013" TYPE="STUDY">Goldberg 2013</LINK>; <LINK REF="STD-Herrera-2006a" TYPE="STUDY">Herrera 2006a</LINK>; <LINK REF="STD-Jarjou-2013" TYPE="STUDY">Jarjou 2013</LINK>; <LINK REF="STD-Sulovic-2013" TYPE="STUDY">Sulovic 2013</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-05 13:09:04 +0000" MODIFIED_BY="Leanne V Jones">
<DATE DAY="28" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>Search updated. Methods updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-05-24 15:27:43 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2013-05-24 15:27:43 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="1" YEAR="2011"/>
<DESCRIPTION>
<P>Feedback from William Stones and Stephen Walkinshaw added with replies from the authors.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2011-01-06 13:51:06 +0000" MODIFIED_BY="Sonja L  Henderson">
<DATE DAY="5" MONTH="7" YEAR="2010"/>
<DESCRIPTION>
<P>New author helped to update the review. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-09-16 16:10:30 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>Search updated. Fifteen new reports identified: one new study (<LINK REF="STD-Kumar-2009" TYPE="STUDY">Kumar 2009</LINK>) included and four new trials excluded (<LINK REF="STD-de-Souza-2006" TYPE="STUDY">de Souza 2006</LINK>; <LINK REF="STD-Dizavandy-1998" TYPE="STUDY">Dizavandy 1998</LINK>; Herrera 1998a; <LINK REF="STD-Karandish-2003" TYPE="STUDY">Karandish 2003</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-17 11:08:00 +0000" MODIFIED_BY="Jill V Hampson">
<DATE DAY="31" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Search updated. Fourteen new reports added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-17 11:06:40 +0000" MODIFIED_BY="Jill V Hampson">
<DATE DAY="1" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-10-16 14:22:08 +0100" MODIFIED_BY="Sonja Henderson">
<DATE DAY="2" MONTH="3" YEAR="2006"/>
<DESCRIPTION>
<P>A large trial of calcium supplementation in communities with low dietary calcium intake has been added (<LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-16 14:26:27 +0100" MODIFIED_BY="Sonja Henderson">
<DATE DAY="2" MONTH="3" YEAR="2006"/>
<DESCRIPTION>
<P>Search updated. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-07-05 09:39:03 +0100" MODIFIED_BY="Sonja L  Henderson">
<INTERNAL_SOURCES MODIFIED="2010-07-05 09:39:03 +0100" MODIFIED_BY="Sonja L  Henderson">
<SOURCE>
<NAME>Universidade Federal de Sao Paulo/Escola Paulista de Medicina</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>(GJH) Effective Care Research Unit, University of the Witwatersrand/Fort Hare, Eastern Cape Department of Health</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-07-05 09:39:03 +0100" MODIFIED_BY="Sonja L  Henderson">
<SOURCE>
<NAME>UNDP/UNFPA/WHO/World Bank (HRP)</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-07-05 09:39:03 +0100" MODIFIED_BY="Sonja L  Henderson">
<NAME>NHS Programme for Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-06-19 14:06:29 +0100" MODIFIED_BY="Leanne V Jones">
<SUMMARY MODIFIED="2014-06-12 13:58:22 +0100" MODIFIED_BY="Heather Maxwell">
<TITLE MODIFIED="2008-09-01 14:12:30 +0100" MODIFIED_BY="[Empty name]">Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems</TITLE>
<SUMMARY_BODY MODIFIED="2014-06-12 13:58:22 +0100" MODIFIED_BY="Heather Maxwell">
<P>Evidence from randomised controlled trials shows that calcium supplements help prevent pre-eclampsia and preterm birth and lower the risk of a woman dying or having serious problems related to high blood pressure in pregnancy. This is particularly for women on low calcium diets.</P>
<P>Pre-eclampsia is evident as high blood pressure and protein in the urine. It is a major cause of death in pregnant women and newborn babies worldwide. Preterm birth (birth before 37 weeks) is often caused by high blood pressure and is the leading cause of newborn deaths, particularly in low-income countries. The review of 24 trials found good quality evidence that calcium supplementation with high doses (at least 1 g daily) during pregnancy (13 studies involving 15,730 women) is a safe and relatively cheap way of reducing the risk of pre-eclampsia, especially in women from communities with low dietary calcium and those at increased risk of pre-eclampsia. Women receiving calcium supplements were also less likely to die or have serious problems related to pre-eclampsia. Babies were less likely to be born preterm. No adverse effects have been found but further research is needed into the ideal dosage of supplementation. Limited evidence from 10 trials (2234 women) suggested that a relatively low dose may be effective although co-interventions such as vitamin D, linoleic acid or antioxidants were given in six of the included trials.</P>
<P>In settings of low dietary calcium where high-dose supplementation is not feasible, the option of lower dose supplements (500 to 600 mg/day) might be considered in preference to no supplementation.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-06-12 13:58:00 +0100" MODIFIED_BY="Heather Maxwell">
<ABS_BACKGROUND MODIFIED="2014-05-22 14:25:21 +0100" MODIFIED_BY="[Empty name]">
<P>Pre-eclampsia and eclampsia are common causes of serious morbidity and death. Calcium supplementation may reduce the risk of pre-eclampsia, and may help to prevent preterm birth.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of calcium supplementation during pregnancy on hypertensive disorders of pregnancy and related maternal and child outcomes.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-06-12 13:57:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (28 March 2013) and contacted study authors for more data where possible. We updated the search in May 2014 and added the results to the 'Awaiting Classification' section of the review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-06-12 13:57:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomised controlled trials (RCTs) comparing high-dose (at least 1 g daily of calcium) or low-dose calcium supplementation during pregnancy with placebo or no calcium.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We assessed eligibility and trial quality, extracted and double-entered data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-06-12 13:57:50 +0100" MODIFIED_BY="Heather Maxwell">
<P>
<I>High-dose calcium supplementation (</I>&#8805;<I>1 g/day)</I>
</P>
<P>We included 14 studies in the review, however one study contributed no data. We included 13 high-quality studies in our meta-analyses (15,730 women). The average risk of high blood pressure (BP) was reduced with calcium supplementation compared with placebo (12 trials, 15,470 women: risk ratio (RR) 0.65, 95% confidence interval (CI) 0.53 to 0.81; I² = 74%). There was also a significant reduction in the risk of pre-eclampsia associated with calcium supplementation (13 trials, 15,730 women: RR 0.45, 95% CI 0.31 to 0.65; I² = 70%). The effect was greatest for women with low calcium diets (eight trials, 10,678 women: average RR 0.36, 95% CI 0.20 to 0.65; I² = 76%) and women at high risk of pre-eclampsia (five trials, 587 women: average RR 0.22, 95% CI 0.12 to 0.42; I² = 0%). These data should be interpreted with caution because of the possibility of small-study effect or publication bias.</P>
<P>The composite outcome maternal death or serious morbidity was reduced (four trials, 9732 women; RR 0.80, 95% CI 0.65 to 0.97; I² = 0%). Maternal deaths were not significantly different (one trial of 8312 women: calcium group one death versus placebo group six deaths). There was an anomalous increase in the risk of HELLP (haemolysis, elevated liver enzymes and low platelets) syndrome (two trials, 12,901 women: RR 2.67, 95% CI 1.05 to 6.82; I² = 0%) in the calcium group, however, the absolute number of events was low (16 versus six).</P>
<P>The average risk of preterm birth was reduced in the calcium group (11 trials, 15,275 women: RR 0.76, 95% CI 0.60 to 0.97; I² = 60%) and amongst women at high risk of developing pre-eclampsia (four trials, 568 women: average RR 0.45, 95% CI 0.24 to 0.83; I² = 60%), but no significant reduction in neonatal high care admission. There was no overall effect on the risk of stillbirth or infant death before discharge from hospital (11 trials 15,665 babies: RR 0.90, 95% CI 0.74 to 1.09; I² = 0%).</P>
<P>One study showed a reduction in childhood systolic BP greater than 95th percentile among children exposed to calcium supplementation in utero (514 children: RR 0.59, 95% CI 0.39 to 0.91). In a subset of these children, dental caries at 12 years old was also reduced (195 children, RR 0.73, 95% CI 0.62 to 0.87).</P>
<P>
<I>Low-dose calcium supplementation (&lt; 1 g/day)</I>
</P>
<P>We included 10 trials (2234 women) that evaluated low-dose supplementation with calcium alone (4) or in association with vitamin D (3), linoleic acid (2), or antioxidants (1). Most studies recruited women at high risk for pre-eclampsia, and were at high risk of bias, thus the results should be interpreted with caution. Supplementation with low doses of calcium significantly reduced the risk of pre-eclampsia (RR 0.38, 95% CI 0.28 to 0.52; I² = 0%). There was also a reduction in hypertension, low birthweight and neonatal intensive care unit admission.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-06-12 13:58:00 +0100" MODIFIED_BY="Heather Maxwell">
<P>Calcium supplementation (&#8805; 1 g/day) is associated with a significant reduction in the risk of pre-eclampsia, particularly for women with low calcium diets. The treatment effect may be overestimated due to small-study effects or publication bias. It also reduces preterm birth and the occurrence of the composite outcome 'maternal death or serious morbidity'. We considered these benefits to outweigh the increased risk of HELLP syndrome, which was small in absolute numbers. The World Health Organization recommends calcium 1.5 g to 2 g daily for pregnant women with low dietary calcium intake.</P>
<P>The limited evidence on low-dose calcium supplementation suggests a reduction in pre-eclampsia, but needs to be confirmed by larger, high-quality trials. Pending such results, in settings of low dietary calcium where high-dose supplementation is not feasible, the option of lower-dose supplements (500 to 600 mg/day) might be considered in preference to no supplementation.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-06-19 14:06:29 +0100" MODIFIED_BY="Leanne V Jones">
<BACKGROUND MODIFIED="2014-06-12 13:58:46 +0100" MODIFIED_BY="Heather Maxwell">
<CONDITION MODIFIED="2014-06-12 13:58:34 +0100" MODIFIED_BY="Heather Maxwell">
<P>High blood pressure, with or without proteinuria, is a major causes of maternal death and morbidity (<LINK REF="REF-Betr_x00e1_n-2005" TYPE="REFERENCE">Betrán 2005</LINK>; <LINK REF="REF-Clark-2008" TYPE="REFERENCE">Clark 2008</LINK>; <LINK REF="REF-HMSO-1994" TYPE="REFERENCE">HMSO 1994</LINK>; <LINK REF="REF-Khan-2006" TYPE="REFERENCE">Khan 2006</LINK>; <LINK REF="REF-NHMRC-1993" TYPE="REFERENCE">NHMRC 1993</LINK>) and perinatal morbidity and mortality (<LINK REF="REF-Langenveld-2011" TYPE="REFERENCE">Langenveld 2011</LINK>; <LINK REF="REF-Ozkan-2011" TYPE="REFERENCE">Ozkan 2011</LINK>), worldwide. Hypertension has been estimated to complicate 5% of all pregnancies and 11% of first pregnancies, half associated with pre-eclampsia, and accounting for up to 40,000 maternal deaths annually (<LINK REF="REF-Villar-2004" TYPE="REFERENCE">Villar 2004</LINK>). For this reason, strategies to reduce the risk of hypertensive disorders of pregnancy have received considerable attention (<LINK REF="REF-Bucher-1996" TYPE="REFERENCE">Bucher 1996</LINK>; <LINK REF="REF-Carroli-1994" TYPE="REFERENCE">Carroli 1994</LINK>; <LINK REF="REF-CLASP-1994" TYPE="REFERENCE">CLASP 1994</LINK>; <LINK REF="REF-ECCPA-1996" TYPE="REFERENCE">ECCPA 1996</LINK>).</P>
<P>Preterm birth, spontaneous and medically induced, is commonly associated with hypertensive disorders. It is the leading cause of early neonatal death and infant mortality, particularly in low-income countries (<LINK REF="REF-Villar-1994" TYPE="REFERENCE">Villar 1994</LINK>). Preterm survivors are at high risk of significant morbidity, especially respiratory disease and its sequelae, and long-term neurological morbidity (<LINK REF="REF-Johnson-1993" TYPE="REFERENCE">Johnson 1993</LINK>). Interventions to reduce preterm birth have been reviewed by Villar et al (<LINK REF="REF-Villar-1998" TYPE="REFERENCE">Villar 1998</LINK>).</P>
<P>During early pregnancy, blood pressure normally falls, climbing slowly in later pregnancy to reach pre-pregnancy levels at term (<LINK REF="REF-Villar-1989" TYPE="REFERENCE">Villar 1989</LINK>). These normal changes in blood pressure make the diagnosis of hypertension during pregnancy difficult. Clinical methods of measuring blood pressure are also subject to considerable inaccuracy (<LINK REF="REF-Villar-2004" TYPE="REFERENCE">Villar 2004</LINK>). A widely accepted definition, however, is a diastolic blood pressure equal to or greater than 90 mmHg or systolic equal to or greater than 140 mmHg before the onset of labour (<LINK REF="REF-NHBPEP-2000" TYPE="REFERENCE">NHBPEP 2000</LINK>).The consequences of high blood pressure are more serious if there is associated proteinuria. Hypertension and significant proteinuria (1+ by dipstick testing, equal to or greater than 300 mg per 24 hours, or equal to or greater than 30 mg per dL) (<LINK REF="REF-NHBPEP-2000" TYPE="REFERENCE">NHBPEP 2000</LINK>) usually indicate the presence of pre-eclampsia. Recently, the urine protein to creatinine ratio has been used increasingly as a measure of proteinuria (<LINK REF="REF-Yamasmit-2004" TYPE="REFERENCE">Yamasmit 2004</LINK>). Predictors of poor outcome include low gestational age and high levels of proteinuria (<LINK REF="REF-von-Dadelszen-2004" TYPE="REFERENCE">von Dadelszen 2004</LINK>).</P>
</CONDITION>
<THEORY MODIFIED="2013-08-21 09:17:33 +0100" MODIFIED_BY="[Empty name]">
<P>An inverse relationship between calcium intake and hypertensive disorders of pregnancy was first described in 1980 (<LINK REF="REF-Belizan-1980" TYPE="REFERENCE">Belizan 1980</LINK>). This was based on the observation that Mayan Indians in Guatemala, who traditionally soak their corn in lime before cooking, had a high calcium intake and a low incidence of pre-eclampsia and eclampsia. A very low prevalence of pre-eclampsia had been reported from Ethiopia where the diet, among other features, contained high levels of calcium (<LINK REF="REF-Hamlin-1962" TYPE="REFERENCE">Hamlin 1962</LINK>). These observations were supported by other epidemiological and clinical studies (<LINK REF="REF-Belizan-1988" TYPE="REFERENCE">Belizan 1988</LINK>; <LINK REF="REF-Hamlin-1952" TYPE="REFERENCE">Hamlin 1952</LINK>; <LINK REF="REF-Repke-1991" TYPE="REFERENCE">Repke 1991</LINK>; <LINK REF="REF-Villar-1983" TYPE="REFERENCE">Villar 1983</LINK>; <LINK REF="STD-Villar-1987" TYPE="STUDY">Villar 1987</LINK>; <LINK REF="REF-Villar-1993" TYPE="REFERENCE">Villar 1993</LINK>), and led to the hypothesis that an increase in calcium intake during pregnancy might reduce the incidence of high blood pressure and pre-eclampsia among women with low calcium intake. An association has been found between pre-eclampsia and hypocalciuria (<LINK REF="REF-Segovia-2004" TYPE="REFERENCE">Segovia 2004</LINK>); lower urine calcium to creatinine ratio (<LINK REF="REF-Kazerooni-2003" TYPE="REFERENCE">Kazerooni 2003</LINK>); hypocalcaemia (<LINK REF="REF-Kumru-2003" TYPE="REFERENCE">Kumru 2003</LINK>); lower plasma and higher membranous calcium (<LINK REF="REF-Kisters-2000" TYPE="REFERENCE">Kisters 2000</LINK>); lower dietary milk intake (<LINK REF="REF-Duvekot-2002" TYPE="REFERENCE">Duvekot 2002</LINK>); and between eclampsia and hypocalcaemia (<LINK REF="REF-Isezuo-2004" TYPE="REFERENCE">Isezuo 2004</LINK>).</P>
<P>Low calcium intake may cause high blood pressure by stimulating either parathyroid hormone or renin release, thereby increasing intracellular calcium in vascular smooth muscle (<LINK REF="REF-Belizan-1988" TYPE="REFERENCE">Belizan 1988</LINK>) and leading to vasoconstriction. A possible mode of action for calcium supplementation is that it reduces parathyroid release and intracellular calcium, and so reduces smooth muscle contractility. By a similar mechanism, calcium supplementation could also reduce uterine smooth muscle contractility and prevent preterm labour and delivery (<LINK REF="STD-Villar-1990" TYPE="STUDY">Villar 1990</LINK>). Calcium might also have an indirect effect on smooth muscle function by increasing magnesium levels (<LINK REF="STD-Repke-1989" TYPE="STUDY">Repke 1989</LINK>). Recent evidence indicates that calcium supplementation affects uteroplacental blood flow (it lowers the resistance index in uterine and umbilical arteries) (<LINK REF="REF-Carroli-2010" TYPE="REFERENCE">Carroli 2010</LINK>). Supplementation in the second half of pregnancy appears to reduce blood pressure directly, rather than preventing the endothelial damage associated with pre-eclampsia (<LINK REF="REF-Hofmeyr-2008" TYPE="REFERENCE">Hofmeyr 2008</LINK>).</P>
<P>Calcium supplementation is attractive as a potential intervention to reduce the risk of a woman developing pre-eclampsia as it is cheap, readily available, and is likely to be safe for the woman and her child. In addition, there is a possibility that it may have a preventative effect on the risk of hypertension in offspring (<LINK REF="REF-Belizan-1997" TYPE="REFERENCE">Belizan 1997</LINK>). A theoretical risk of increased renal tract stone formation, or the occurrence of other adverse effects associated with calcium supplementation, has not been substantiated.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-06-12 13:58:46 +0100" MODIFIED_BY="Heather Maxwell">
<P>Calcium supplementation was tested in several randomised trials commencing in the late 1980s which suggested a promising beneficial effect on hypertensive disorders and related problems. The first systematic reviews (<LINK REF="REF-Carroli-1994" TYPE="REFERENCE">Carroli 1994</LINK>; <LINK REF="REF-Duley-1995" TYPE="REFERENCE">Duley 1995</LINK>) highlighted the need for larger trials to assess the effects on important clinical outcomes in addition to pre-eclampsia and preterm delivery, such as perinatal mortality. A subsequent systematic review (<LINK REF="REF-Bucher-1996" TYPE="REFERENCE">Bucher 1996</LINK>) came to more enthusiastic conclusions, but these findings were not confirmed by a large trial in the USA (<LINK REF="STD-CPEP-1997" TYPE="STUDY">CPEP 1997</LINK>), and the discrepancy elicited discussion (<LINK REF="REF-Villar-2000" TYPE="REFERENCE">Villar 2000</LINK>). Subsequently, a large trial conducted in communities with low dietary calcium intake has been reported (<LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK>). In 2012 the World Health Organization (WHO) published guidelines recommending calcium supplementation with 1.5 to 2 g elemental calcium daily for pregnant women with low dietary calcium. This recommendation has raised questions regarding the optimum dosage of calcium.</P>
<OL>
<LI>The WHO recommendation was based on available data from randomised trials. Most of the high-quality trials reviewed used 1.5 to 2 g of calcium daily, and there was little robust evidence regarding smaller dosages.</LI>
<LI>The dosage of 1.5 to 2 g calcium daily is well above the daily recommended dietary calcium of 1 to 1.2 g.</LI>
<LI>Logistically, calcium in this dosage is heavy to transport. Calcium carbonate plus glycine tablets containing 1.5 g elemental calcium and glycine daily (= 3750 mg calcium carbonate plus glycine) weigh about 200 g for a four-week supply (84 tablets). This would amount to about 1 kg of tablets for 20 weeks, therefore, a clinic seeing 1000 pregnant women per year would need to receive 1000 kg of tablets each year.</LI>
<LI>The cost of calcium is moderately high (compared with supplements such as iron and folate), and the dosage thus has important cost implications.</LI>
<LI>A 2010 report from the Gambia study (<LINK REF="STD-Jarjou-2004" TYPE="STUDY">Jarjou 2004</LINK>a) has suggested that calcium at the dosage of 1.5 g daily during pregnancy may impair the mother's ability to conserve calcium, causing rebound bone demineralisation following pregnancy. Although there are limitations to this study (conclusions were based on a sub-set of women from the original trial; the hypothesis was not prespecified; multiple end-point testing), the possibility of adverse effects due to the interruption of high-dose calcium supplementation in women who have previously adapted to low dietary calcium intake is reason for caution.</LI>
</OL>
<P>For these reasons, when updating this review, we considered it important to systematically review the evidence on lower dosages of calcium supplementation in pregnancy. Originally, we had specified that randomised controlled trials of trials with dosages below 1 g daily would be reviewed in subsequent updates of this review. However, in view of the lack of high-quality trials of lower dosages, we revised the review protocol to include lower quality studies (e.g. quasi-randomised trials) of lower dosage studies only.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-05-19 10:10:21 +0100" MODIFIED_BY="[Empty name]">
<P>To determine, from the best available evidence, the effect of calcium supplementation during pregnancy on the risk of high blood pressure and related maternal and fetal or neonatal adverse outcomes. Subgroup analyses tested whether these effects were influenced by whether:</P>
<OL>
<LI>women had low or adequate dietary calcium intake prior to trial entry;</LI>
<LI>women were at low or average risk of hypertensive disorders, or at high risk.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2014-06-19 14:06:29 +0100" MODIFIED_BY="Leanne V Jones">
<SELECTION_CRITERIA MODIFIED="2014-06-12 13:59:06 +0100" MODIFIED_BY="Heather Maxwell">
<CRIT_STUDIES MODIFIED="2013-07-24 15:58:03 +0100" MODIFIED_BY="[Empty name]">
<P>All published, unpublished and ongoing trials with random allocation to calcium supplementation during pregnancy versus placebo. We included trials that were presented only as abstracts if there was sufficient detail (published and unpublished) to confirm that they were methodologically adequate. For the original review we excluded quasi-random designs. However, for this updated review we included trials employing these weaker study designs (e.g. quasi-randomisation by alternation, unstated or other methods), only for the subgroup of trials of calcium supplementation less than 1 g daily, with appropriate caution in the interpretation of the results.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-07-24 15:57:54 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnant women, regardless of the risk of hypertensive disorders of pregnancy. We excluded women with diagnosed hypertensive disorders of pregnancy.</P>
<P>Prespecified subgroups to be compared.</P>
<OL>
<LI>Women at low or average risk of hypertensive disorders of pregnancy (unselected).</LI>
<LI>Women at above average risk of hypertensive disorders of pregnancy. These included women selected by the trial authors on the basis of an increased risk of hypertensive disorders of pregnancy (e.g. teenagers or women older than 40 years, women with previous pre-eclampsia, women with increased sensitivity to angiotensin II, women with pre-existing hypertension). Primiparity alone was not regarded as a high-risk factor.</LI>
<LI>Women or populations with low baseline dietary calcium intake (as defined by trial authors, or if not defined, mean intake less than 900 mg per day).</LI>
<LI>Women or populations with adequate dietary calcium intake (as defined by trial authors, or if not defined, mean intake equal to or greater than 900 mg per day).</LI>
</OL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-06-12 13:59:06 +0100" MODIFIED_BY="Heather Maxwell">
<P>Supplementation with calcium from at the latest 34 weeks of pregnancy compared with placebo treatment. We excluded studies with no placebo. We limited the initial analysis to intended supplementation with at least 1 g of calcium per day. Future updates of this review would include an analysis of effect by dosage, including lower dosage regimens. For the 2012 update of the review, we included trials of calcium less than 1 g daily plus additional supplements (e.g. vitamin D, linoleic acid, or anti-platelet agents).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-07-24 16:02:29 +0100" MODIFIED_BY="[Empty name]">
<P>In the original protocol we prespecified 15 clinical measures of maternal and fetal or neonatal morbidity and mortality. In October 2004 we added seven additional outcomes (marked * below). For this 2013 update we have added two outcome measures, marked ** below, in order to include newly published data. As such, these should be regarded as post-hoc analyses, and interpreted with caution.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-07-24 16:01:36 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">For the woman</HEADING>
<OL>
<LI>High blood pressure as defined by trial authors, with or without proteinuria. Ideally, high blood pressure would be defined as diastolic blood pressure equal to or greater than 90 mmHg, or an increase in systolic blood pressure of 30 mmHg or more, or in diastolic blood pressure of 15 mmHg or more.</LI>
<LI>High blood pressure with significant proteinuria, as defined by trial authors. Ideally, proteinuria would be defined as 2+ by dipstick testing, equal to or greater than 300 mg per 24 hours, or equal to or greater than 500 mg per litre. Although the strict definition of pre-eclampsia includes confirmation of no hypertension or proteinuria outside pregnancy, for convenience the above definition will be referred to in this review as pre-eclampsia.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">For the child</HEADING>
<OL>
<LI>Preterm birth (birth before 37 weeks of estimated gestation).</LI>
<LI>Admission to a neonatal intensive care unit.</LI>
<LI>Stillbirth or death before discharge from hospital.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-07-24 16:02:29 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">For the woman</HEADING>
<OL>
<LI>Maternal death or serious morbidity. Serious morbidity includes eclampsia; renal failure; syndrome of haemolysis, elevated liver enzymes and low platelets (HELLP syndrome); and admission to intensive care. This will be a composite outcome of death or at least one measure of serious morbidity. In addition each individual outcome will be presented.</LI>
<LI>Placental abruption.</LI>
<LI>Caesarean section.</LI>
<LI>*Proteinuria.</LI>
<LI>*Severe pre-eclampsia as defined by trial authors.</LI>
<LI>*Eclampsia.</LI>
<LI>*HELLP syndrome.</LI>
<LI>*Intensive care unit admission.</LI>
<LI>*Maternal death.</LI>
<LI>Mother's hospital stay seven days or more.</LI>
<LI>** Miscarriage.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">For the child</HEADING>
<OL>
<LI>Low birthweight (the first weight obtained after birth less than 2500 g).</LI>
<LI>Neonate small-for-gestational age as defined by trial authors.</LI>
<LI>Neonate in intensive care unit seven days or more.</LI>
<LI>*Death or severe neonatal morbidity.</LI>
<LI>Childhood disability.</LI>
<LI>Systolic blood pressure greater than 95th percentile during childhood.</LI>
<LI>Diastolic blood pressure greater than 95th percentile during childhood.</LI>
<LI>**Dental caries in childhood (one or more decayed, missing or filled teeth, or as defined by trial authors).</LI>
</OL>
<P>Only those outcomes with data appear in the analysis table.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-06-02 11:45:53 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-06-02 11:45:53 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group Trials Register by contacting the Trials Search Co-ordinator (28 March 2013). We updated the search in May 2014 and added the results to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
<P>The Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from: </P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>weekly searches of Embase;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>. </P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.  </P>
<P>For details of searches carried out in the previous version of the review, <I>see</I> <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We did not apply any language restrictions.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-06-19 14:06:29 +0100" MODIFIED_BY="Leanne V Jones">
<P>For the methods used when assessing the trials identified in the 2010 update, <I>see </I>
<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. </P>
<P>For the 2013 update, we have used the following methods when assessing the trials identified by the updated search. </P>
<STUDY_SELECTION MODIFIED="2014-06-12 13:59:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>Two review authors independently assessed for inclusion all the potential studies that we identified as a result of the search strategy. For the 2013 update, this was performed by GJH and MRT. We resolved any disagreement through discussion or, if required, by consulting L Duley (LD).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-06-12 13:59:44 +0100" MODIFIED_BY="Heather Maxwell">
<P>We designed a form to extract data. For eligible studies, GJH and MRT extracted data for the 2013 version . We resolved discrepancies through discussion or, if required, by consulting LD. We entered data into Review Manager software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>) and checked it for accuracy.</P>
<P>When study information and/or data were unclear, we attempted to contact authors of the original reports to provide further details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-06-12 13:59:51 +0100" MODIFIED_BY="Heather Maxwell">
<P>TAL, MRT and GJH independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions (</I>
<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>
<I>). </I>We resolved any disagreement by discussion or by involving a third assessor.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Random sequence generation (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>low risk of bias (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.1) Blinding of participants and personnel (checking for possible performance bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low, high or unclear risk of bias for participants;</LI>
<LI>low, high or unclear risk of bias for personnel.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.2) Blinding of outcome assessment (checking for possible detection bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed methods used to blind outcome assessment as:</P>
<UL>
<LI>low, high or unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)</HEADING>
<P>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We state whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we re-included missing data in the analyses which we undertook.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups; &#8806; 20% participants missing);</LI>
<LI>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; &#8216;as treated&#8217; analysis done with substantial departure of intervention received from that assigned at randomisation; &gt; 20% participants missing);</LI>
<LI>unclear risk of bias.</LI>
</UL>
<P>If it was not possible to enter data based on intention-to-treat or 20% or more participants were excluded from the analysis of that outcome, then the trial was excluded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting (checking for reporting bias)</HEADING>
<P>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk of bias (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</HEADING>
<P>We described for each included study any important concerns we have about other possible sources of bias.</P>
<P>We assessed whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>low risk of other bias;</LI>
<LI>high risk of other bias;</LI>
<LI>unclear whether there is risk of other bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Cochrane Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it is likely to impact on the findings. We explored the impact of the level of bias through undertaking sensitivity analyses - see <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-08-02 13:04:06 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we present results as summary risk ratio with 95% confidence intervals.<I> </I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we used the mean difference for outcomes measured in the same way between trials. In future updates, if appropriate, we plan to use the standardised mean difference to combine trials that measure the same outcome but used different methods. <B> </B>
</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-06-12 14:00:23 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>Cluster-randomised trials would have been included in the analyses along with individually-randomised trials. We would have adjusted their sample sizes using the methods described in the <I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (section 16.3.4) using an estimate of the intra-cluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we had used ICCs from other sources, we would have reported this and conducted sensitivity analyses to investigate the effect of variation in the ICC. If we identified both cluster-randomised trials and individually-randomised trials, we would have synthesised the relevant information. We would consider it reasonable to combine the results from both if there was little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit was considered to be unlikely. We would acknowledge heterogeneity in the randomisation unit and perform sensitivity analyses to investigate the effects of the randomisation unit.<BR/>
</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-06-19 14:06:29 +0100" MODIFIED_BY="Leanne V Jones">
<P>For included studies, we noted levels of attrition. We explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.</P>
<P>For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-06-12 14:00:30 +0100" MODIFIED_BY="Heather Maxwell">
<P>We assessed statistical heterogeneity in each meta-analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if the Tau² was greater than zero and either an I² was greater than 30% or there was a low P value (less than 0.10) in the Chi² test for heterogeneity.<B> </B>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-02-05 21:47:03 +0000" MODIFIED_BY="[Empty name]">
<P>We investigated reporting biases (such as publication bias) by doing a subgroup analysis and funnel plot based on the sample sizes of the trials.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-06-12 14:00:42 +0100" MODIFIED_BY="Heather Maxwell">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials&#8217; populations and methods were judged sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. The random-effects summary was treated as the average of the range of possible treatment effects and we discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we did not combine trials.</P>
<P>When we used random-effects analyses, the results are presented as the average treatment effect with its 95% confidence interval, and the estimates of Tau² and I².</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-06-12 14:00:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>When we identified substantial heterogeneity, we investigated it using subgroup analyses. We considered whether an overall summary was meaningful, and if it was, used random-effects analysis to produce it.</P>
<P>We carried out the following subgroup analyses.</P>
<OL>
<LI>Trials in populations with low versus adequate dietary calcium intake.</LI>
<LI>Trials in participants with low/average versus high hypertensive risk.</LI>
<LI>Trials with small versus larger sample sizes.</LI>
</OL>
<P>We used only primary outcomes in subgroup analyses 2 and 3.</P>
<P>We assessed subgroup differences by interaction tests available within RevMan (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). We reported the results of subgroup analyses quoting the Chi² statistic and P value, and the interaction test I² value.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-08-02 13:10:49 +0100" MODIFIED_BY="[Empty name]">
<P>We undertook sensitivity analysis by considering the results of the larger sample size trials versus the overall results for primary outcomes.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-06-19 14:03:38 +0100" MODIFIED_BY="Leanne V Jones">
<STUDY_DESCRIPTION MODIFIED="2014-06-12 14:01:06 +0100" MODIFIED_BY="Heather Maxwell">
<P>Please see <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK> below.</P>
<P>Compliance, where reported, was generally &gt; 80% (<LINK REF="STD-Belizan-1991" TYPE="STUDY">Belizan 1991</LINK> 84% and 86% for calcium and placebo; <LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK> 84.5% and 86.2%; <LINK REF="STD-S_x002d_Ramos-1994" TYPE="STUDY">S-Ramos 1994</LINK> 79% and 81%). However, in <LINK REF="STD-CPEP-1997" TYPE="STUDY">CPEP 1997</LINK> compliance was 64% and 67% and in <LINK REF="STD-Crowther-1999" TYPE="STUDY">Crowther 1999</LINK> 31% and 24% of women stopped taking the tablets before the end of the trial. In <LINK REF="STD-L_x002d_Jaramillo-1997" TYPE="STUDY">L-Jaramillo 1997</LINK> 2 women were withdrawn for non-compliance.</P>
<SEARCH_RESULTS MODIFIED="2014-06-12 14:00:55 +0100" MODIFIED_BY="Heather Maxwell">
<P>The search strategy identified 49 studies, of which we included 24. (Seven trial reports are awaiting classification. <I>See</I>: <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-06-12 14:01:06 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">High-dose calcium supplementation (&#8805; 1 g/day)</HEADING>
<P>We included 14 studies in the review, however one study (<LINK REF="STD-Jarjou-2004" TYPE="STUDY">Jarjou 2004</LINK>) contributed no data. Of the remaining 13 studies, four were multicentre studies: one in Argentina (<LINK REF="STD-Belizan-1991" TYPE="STUDY">Belizan 1991</LINK>), one in the USA (<LINK REF="STD-CPEP-1997" TYPE="STUDY">CPEP 1997</LINK>), another in Australia (<LINK REF="STD-Crowther-1999" TYPE="STUDY">Crowther 1999</LINK>) and the fourth was international (<LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK>). Most of the 15,730 women recruited to these studies were low risk (15,143 women) and had a low dietary intake of calcium (10,678). Most studies only recruited women who were nulliparous or primiparous. One study did not state the parity of women recruited (<LINK REF="STD-Niromanesh-2001" TYPE="STUDY">Niromanesh 2001</LINK>) and another commented that most women were nulliparous (<LINK REF="STD-Villar-1990" TYPE="STUDY">Villar 1990</LINK>). For most studies the intervention was 1.5 g to 2 g per day of calcium.</P>
<P>Five studies enrolled women considered to be at high risk of pre-eclampsia. The definitions of high risk and the actual risk (rate of pre-eclampsia in the placebo group) were variable: positive 'roll-over' test at 28 to 30 weeks (8/34) (<LINK REF="STD-L_x002d_Jaramillo-1990" TYPE="STUDY">L-Jaramillo 1990</LINK>); teenagers 17 years or younger (3/88) (<LINK REF="STD-Villar-1990" TYPE="STUDY">Villar 1990</LINK>); positive 'roll-over' test at 28 to 32 weeks plus one clinical risk factor (7/15) (<LINK REF="STD-Niromanesh-2001" TYPE="STUDY">Niromanesh 2001</LINK>); positive 'roll-over' and positive angiotensin II infusion test (15/34) (<LINK REF="STD-S_x002d_Ramos-1994" TYPE="STUDY">S-Ramos 1994</LINK>); and nulliparous teenagers 17.5 years or younger (21/135) (<LINK REF="STD-L_x002d_Jaramillo-1997" TYPE="STUDY">L-Jaramillo 1997</LINK>). The clinical usefulness of the pooled results in this subgroup is therefore limited.</P>
<P>Two included studies conducted long-term follow-up of the children whose mothers were recruited to these trials (<LINK REF="STD-Belizan-1991" TYPE="STUDY">Belizan 1991</LINK>; <LINK REF="REF-Hiller-2007" TYPE="REFERENCE">Hiller 2007</LINK>). In <LINK REF="STD-Belizan-1991" TYPE="STUDY">Belizan 1991</LINK>, only the subset of women recruited in private clinics were contacted, and in <LINK REF="REF-Hiller-2007" TYPE="REFERENCE">Hiller 2007</LINK>, the outcomes reported differed from this review (but unpublished data may be made available by the authors at a later date).</P>
<P>Other studies have reported outcomes for small subsets of women (<LINK REF="STD-CPEP-1997" TYPE="STUDY">CPEP 1997</LINK>: <LINK REF="REF-Hatton-2003" TYPE="REFERENCE">Hatton 2003</LINK>; <LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK>: <LINK REF="REF-Zhang-2007" TYPE="REFERENCE">Zhang 2007</LINK>), but these data did not meet the inclusion criteria for this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Low-dose calcium supplementation (less than 1 g/day)</HEADING>
<P>We included 10 studies: four investigated calcium supplementation alone (<LINK REF="STD-Almirante-1998" TYPE="STUDY">Almirante 1998</LINK>; <LINK REF="STD-Bassaw-1998" TYPE="STUDY">Bassaw 1998</LINK>; <LINK REF="STD-Cong-1995" TYPE="STUDY">Cong 1995</LINK>; <LINK REF="STD-Rogers-1999" TYPE="STUDY">Rogers 1999</LINK>); three investigated calcium plus vitamin D (<LINK REF="STD-Li-2000" TYPE="STUDY">Li 2000</LINK>; <LINK REF="STD-Marya-1987" TYPE="STUDY">Marya 1987</LINK>; <LINK REF="STD-Taherian-2002" TYPE="STUDY">Taherian 2002</LINK>); two studies from the same group investigated calcium plus linoleic acid (<LINK REF="STD-Herrera-1998" TYPE="STUDY">Herrera 1998</LINK>; <LINK REF="STD-Herrera-2006" TYPE="STUDY">Herrera 2006</LINK>); and one investigated calcium plus antioxidants (<LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>).</P>
<P>Please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for further details.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-08-02 10:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded 25 studies from the review (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).<BR/>
</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-08-14 16:43:08 +0100" MODIFIED_BY="Denise Atherton">
<P>
<I>See</I> table of <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">High-dose calcium supplementation</HEADING>
<P>All were double-blind, placebo-controlled trials. Pre-specified outcome data were not available from all trials. Not all outcomes were consistently reported therefore there is a possibility of reporting bias in some trials.</P>
<P>In <LINK REF="STD-L_x002d_Jaramillo-1990" TYPE="STUDY">L-Jaramillo 1990</LINK>, a large discrepancy in numbers allocated to each group is not explained. In <LINK REF="STD-Kumar-2009" TYPE="STUDY">Kumar 2009</LINK>, we contacted the authors to clarify the imbalance in group size that occurred in their study. We accept their explanation (<I>see </I>notes in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) but the imbalance does increase the potential for bias.</P>
<P>In some trials, individual denominators were not given for specific outcomes. Where it was clear that the outcomes were not measured in the entire group, we have adjusted the denominators accordingly. In other respects, the methodology of the studies included appears sound.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Low-dose calcium supplementation</HEADING>
<P>We considered four of these studies to be at a low risk of bias (<LINK REF="STD-Bassaw-1998" TYPE="STUDY">Bassaw 1998</LINK>; <LINK REF="STD-Herrera-1998" TYPE="STUDY">Herrera 1998</LINK>; <LINK REF="STD-Herrera-2006" TYPE="STUDY">Herrera 2006</LINK>; <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>) and six to be at a high risk of bias (<LINK REF="STD-Almirante-1998" TYPE="STUDY">Almirante 1998</LINK>; <LINK REF="STD-Cong-1995" TYPE="STUDY">Cong 1995</LINK>; <LINK REF="STD-Li-2000" TYPE="STUDY">Li 2000</LINK>; <LINK REF="STD-Marya-1987" TYPE="STUDY">Marya 1987</LINK>; <LINK REF="STD-Rogers-1999" TYPE="STUDY">Rogers 1999</LINK>; <LINK REF="STD-Taherian-2002" TYPE="STUDY">Taherian 2002</LINK>). We considered the latter studies to be at a high risk because they were either quasi-randomised or not clearly randomised studies.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-06-19 14:03:38 +0100" MODIFIED_BY="Leanne V Jones">
<SUBSECTION>
<HEADING LEVEL="3">High-dose calcium supplementation</HEADING>
<P>In the 13 studies included in the meta-analysis, significant heterogeneity of results occurred for four outcomes: pre-eclampsia; high blood pressure; preterm birth and birthweight less than 2500 g. Factors accounting for the heterogeneity appeared to be maternal risk at trial entry, dietary calcium and trial size. The small trials have more extreme results than large trials, but as all the small trials recruited high-risk women; this could also be related to risk status. In view of the heterogeneity, we used a random-effects model for these four outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(1) High blood pressure with or without proteinuria</HEADING>
<P>The results follow a similar pattern to those for pre-eclampsia (<I>see </I>below). Overall, there were significantly fewer women with high blood pressure with calcium supplementation compared with placebo (12 trials, 15,470 women: average risk ratio (RR) 0.65, 95% confidence interval (CI) 0.53 to 0.81; Heterogeneity: Tau² = 0.06; Chi² = 42.40, df = 11, P &lt; 0.0001; I² = 74%; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The reduction in RR was greatest for the small trials (fewer than 400 women: seven trials, 675 women: average RR 0.38, 95% CI 0.21 to 0.68; Heterogeneity: Tau² = 0.38; Chi² = 18.26, df = 6, P = 0.006; I² = 67%; Test for subgroup differences: Chi² = 6.20, df = 1 (P = 0.01), I² = 83.9%; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>.1), for women at high risk of developing pre-eclampsia (four trials, 327 women: average RR 0.47, 95% CI 0.22 to 0.97; Heterogeneity: Tau² = 0.38; Chi² = 11.01, df = 3 (P = 0.01); I² = 73%; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.2), and for those with low baseline dietary calcium (seven trials, 10,418 women: average RR 0.44, 95% CI 0.28 to 0.70; Heterogeneity: Tau² = 0.26; Chi² = 39.35, df = 6. Test for subgroup differences: Chi² = 8.78, df = 2 (P = 0.01), I² = 77.2%; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.2). Assymetric funnel plots for these analyses (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) suggest that the treatment effect may be overestimated due to small-study effects or publication bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Pre-eclampsia</HEADING>
<P>Overall, there was a significant reduction in the average risk of pre-eclampsia (13 trials, 15,730 women: RR 0.45, 95% CI 0.31 to 0.65 Heterogeneity: Tau² = 0.20; Chi² = 40.31, df = 12 (P &lt; 0.0001; I² = 70%) <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>. This reduction in risk ratio was greatest for women at high risk of pre-eclampsia (five trials, 587 women: average RR 0.22, 95% CI 0.12 to 0.42; Test for subgroup differences: Chi² = 6.81, df = 1, P = 0.009, I² = 85.3%. <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), and for those with low baseline calcium intake (eight trials, 10,678 women: average RR 0.36, 95% CI 0.20 to 0.65; Heterogeneity: Tau² = 0.44; Chi² = 29.35, df = 7, P = 0.0001; I² = 76%; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>. Test for subgroup differences: Chi² = 2.73, df = 2, P = 0.26, I² = 26.8%). Assymetric funnel plots for these analyses (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>, <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>) suggest that the treatment effect may be overestimated due to small-study effects or publication bias. There was also evidence of a subgroup difference between studies with small and larger samples sizes (Test for subgroup differences: Chi² = 15.20, df = 1 (P &lt; 0.0001), I² = 93.4%), <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>.</P>
<P>When subgrouped by both dietary calcium intake and study size, the effect size appeared to be associated most strongly with study size (in the small studies, RR 0.21 for the low calcium trials and 0.26 for the adequate calcium trials, and in the large studies 0.63 and 0.70 respectively; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>, <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>), Test for subgroup differences: Chi² = 10.28, df = 4 (P = 0.04), I² = 61.1%).</P>
<P>Only one study included women with high risk of pre-eclampsia and adequate dietary calcium (<LINK REF="STD-Villar-1990" TYPE="STUDY">Villar 1990</LINK>). The numbers were too small for meaningful statistical analysis (pre-eclampsia in 0/90 with calcium versus 3/88 with placebo).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Preterm birth</HEADING>
<P>Calcium supplementation significantly reduced the average risk of preterm birth overall (11 trials 15,275 women: RR 0.76, 95% CI 0.60 to 0.97; Heterogeneity: Tau² = 0.05; Chi² = 20.04, df = 8 (P = 0.01); I² = 60%; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) and amongst women at high risk of developing pre-eclampsia recruited to four small trials (568 women: average RR 0.45, 95% CI 0.24 to 0.83; Heterogeneity: Tau² = 0.00; Chi² = 1.73, df = 2, P = 0.42; I² = 0%; Test for subgroup differences: Chi² = 3.48, df = 1 (P = 0.06), I² = 71.3%; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). However, this reduction did not translate to a reduction in neonatal high care admissions of babies born &lt; 2500 g. Assymetric funnel plots for these analyses (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>, <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>, <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>) suggest that the treatment effect may be overestimated due to small-study effects or publication bias. There was also evidence of a subgroup difference between studies with small and larger samples sizes (Test for subgroup differences: Chi² = 4.90, df = 1 (P = 0.03), I² = 79.6%), <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Admission to neonatal intensive care unit</HEADING>
<P>There was no overall effect on the RR of admission to a neonatal intensive care unit (four trials, 13,406 women: RR 1.05, 95% CI 0.94 to 1.18; Heterogeneity: Chi² = 2.83, df = 3 (P = 0.42); I² = 0%; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Stillbirth or death before discharge from hospital</HEADING>
<P>There was no overall effect on the RR of a stillbirth or the baby dying before discharge from hospital (11 trials, 15,665 women: RR 0.90, 95% CI 0.74 to 1.09; Heterogeneity: Chi² = 1.46, df = 5 (P = 0.92); I² = 0%; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(6) Maternal death or serious morbidity</HEADING>
<P>The risk of 'maternal death or serious morbidity' was significantly reduced for women allocated calcium supplementation compared with placebo (four trials, 9732 women: RR 0.80, 95% CI 0.65 to 0.97; Heterogeneity: Chi² = 0.20, df = 1 (P = 0.65); I² = 0%; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). It should be noted that virtually all events were restricted to one trial (<LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK>) as the other three trials did not have any events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Placental abruption</HEADING>
<P>In the five trials reporting this outcome, there was no clear difference between the groups (14,336 women: RR 0.86, 95% CI 0.55 to 1.34; Heterogeneity: Chi² = 0.91, df = 2 (P = 0.63); I² = 0%; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(8) Caesarean section</HEADING>
<P>There was a reduction in caesarean section for women in the calcium group, (eight trials, 15,234 women: RR 0.95, 95% CI 0.89 to 1.02; Heterogeneity: Chi² = 5.21, df = 7 (P = 0.63); I² = 0%; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), although the upper confidence limit just crossed the line of no effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(9) *Proteinuria</HEADING>
<P>Only one trial reported proteinuria (<LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK>), and there was no overall difference between the groups (8312 women: RR 1.04, 95% CI 0.86 to 1.26; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(10) *Severe pre-eclampsia as defined by trial authors</HEADING>
<P>Only one trial reported severe pre-eclampsia (<LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK>). Again, there was no clear difference between the groups (one trial, 8302 women: RR 0.74, 95% CI 0.48 to 1.15; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(11) *Eclampsia</HEADING>
<P>The two largest trials reported eclampsia (<LINK REF="STD-CPEP-1997" TYPE="STUDY">CPEP 1997</LINK>; <LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK>) as well as <LINK REF="STD-Kumar-2009" TYPE="STUDY">Kumar 2009</LINK>. There was no clear difference between the groups (three trials, 13,425 women: RR 0.73, 95% CI 0.41 to 1.27; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(12) *HELLP syndrome</HEADING>
<P>Only the two largest studies reported HELLP syndrome (<LINK REF="STD-CPEP-1997" TYPE="STUDY">CPEP 1997</LINK>; <LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK>). The RR was higher for women allocated calcium supplementation, compared with placebo (two trials, 12,901 women: RR 2.67, 95% CI 1.05 to 6.82; Heterogeneity: Chi² = 0.19, df = 1 (P = 0.66); I² = 0%; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(13) *Maternal intensive care unit admission</HEADING>
<P>Only one trial reported admission to intensive care (<LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK>). There was no clear difference between the groups (one trial, 8312 women: RR 0.84, 95% CI 0.66 to 1.07; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(14) *Maternal death</HEADING>
<P>Only one trial reported maternal deaths (<LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK>). One death occurred in the calcium group and six in the placebo group, a difference which was not statistically significant (RR 0.17, 95% CI 0.02 to 1.39; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(15) Mother's hospital stay seven days or more</HEADING>
<P>Data were not available for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(16) Birthweight less than 2500 g</HEADING>
<P>Women in the calcium group were at reduced risk of having a baby with birthweight less than 2500 g (nine trials, 14,883 women: average RR 0.85, 95% CI 0.72 to 1.01; Heterogeneity: Tau² = 0.02; Chi² = 9.93, df = 5 (P = 0.08); I² = 50%; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>), although the overall effect estimate just crossed the line of no effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(17) Neonate small-for-gestational age</HEADING>
<P>There was no overall effect on the risk ratio of the baby being born small-for-gestational age (four trials 13,615 women: RR 1.05, 95% CI 0.86 to 1.29; Heterogeneity: Chi² = 2.74, df = 3 (P = 0.43); I² = 0%; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(18) Neonate in intensive care unit seven days or more</HEADING>
<P>Data were not available for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(19) *Death or severe neonatal morbidity</HEADING>
<P>No data were available for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(20) Childhood disability</HEADING>
<P>Data were not available for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(21) Childhood systolic blood pressure &gt; 95th percentile</HEADING>
<P>One trial assessed during childhood a subset of the children recruited whilst in utero (<LINK REF="STD-Belizan-1991" TYPE="STUDY">Belizan 1991</LINK>). At about seven years of age, diastolic blood pressure greater than 95th percentile was significantly reduced (514 women: RR 0.59, 95% CI 0.39 to 0.91; <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>). While the baseline calcium intake in the original study was low (calcium group mean 646 mg, standard deviation (SD) 396, placebo group 642, SD 448 in a sample assessed during the first four months of the study), the group followed up were only from among the 614 women from the private hospital, not the 580 from the public hospitals. Their dietary calcium intake may have differed from the mean (more likely to be higher in more affluent women). The baseline calcium status of the women in this part of the study therefore cannot be classified.</P>
<P>In the <LINK REF="STD-Crowther-1999" TYPE="STUDY">Crowther 1999</LINK> trial, a follow-up of mothers and offspring was conducted four to seven years later (45% of the original participants) and reported in <LINK REF="REF-Hiller-2007" TYPE="REFERENCE">Hiller 2007</LINK>. Childhood blood pressure was reported as a continuous variable. It was concluded that calcium supplementation during pregnancy may lower the mean blood pressure of the children of women with hypertension in pregnancy. We have sought additional unpublished data from the authors which may be available/suitable for inclusion in the next update.</P>
<P>A limited follow-up of mothers and infants from the <LINK REF="STD-CPEP-1997" TYPE="STUDY">CPEP 1997</LINK> study found reduced systolic blood pressure at two years of age in the calcium supplementation group (mean 95.4 mmHg, SD 7.6, n = 35 versus 100.2, 7.9, n = 18). We have not included the data in this review because the low and unequal follow-up rate (35 and 18 from 497 invited to participate) limit the reliability of the results. In another report of <LINK REF="STD-CPEP-1997" TYPE="STUDY">CPEP 1997</LINK> (<LINK REF="REF-Hatton-2003" TYPE="REFERENCE">Hatton 2003</LINK>), reduced systolic blood pressure was found in the offspring of the calcium supplementation group at two years of age. We have not included these data either because of the high losses to follow-up.</P>
<P>A subsequent report of the Gambian trial (<LINK REF="STD-Jarjou-2004" TYPE="STUDY">Jarjou 2004</LINK>) found no significant difference in systolic blood pressure in 64% of the original trial offspring at between five and 10 years of age. This analysis was restricted to children born at term and the relevant data were not available for our meta-analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(22) Childhood diastolic blood pressure &gt; 95th percentile</HEADING>
<P>Data were available only from the <LINK REF="STD-Belizan-1991" TYPE="STUDY">Belizan 1991</LINK> study. The difference was not statistically significant (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(23) Childhood dental caries</HEADING>
<P>In one study (<LINK REF="STD-Belizan-1991" TYPE="STUDY">Belizan 1991</LINK>), dental caries was assessed at 12 years of age in a subset of those enrolled. It is was not specified how this subset was randomly selected. As this was a post hoc outcome for this review, the data should be interpreted with caution. The study found a significant reduction in dental caries, defined as at least one decayed, filled or missing tooth (one trial, 195 children, RR 0.73, 95% CI 0.62 to 0.87; <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Low-dose calcium supplementation</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(1) High blood pressure with or without proteinuria</HEADING>
<P>High blood pressure was significantly reduced in five studies (665 women, RR 0.53, 95% CI 0.38 to 0.74; Heterogeneity: Chi² = 2.55, df = 4 (P = 0.64); I² = 0%; Test for subgroup differences: Chi² = 2.11, df = 2 (P = 0.35), I² = 5.2%. <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>), including three with calcium supplementation alone (558 women, RR 0.57, 95% CI 0.39 to 0.82; ) and one with calcium plus linoleic acid (48 women, RR 0.20; 95% CI 0.05 to 0.82).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Pre-eclampsia</HEADING>
<P>Pre-eclampsia was reduced but not statistically significantly in one trial of low-dose calcium supplementation alone with low risk of bias (<LINK REF="STD-Bassaw-1998" TYPE="STUDY">Bassaw 1998</LINK>: 171 women, RR 0.30, 95% CI 0.06 to 1.38). The point estimate was consistent with those of all nine trials that reported this outcome (2234 women, RR 0.38, 95% CI 0.28 to 0.52. <LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>). The reduction was also consistent across the subgroups: calcium alone (four studies, one with low risk of bias: 980 women, RR 0.36, 95% CI 0.23 to 0.57; ); calcium plus linoleic acid (two studies with low risk of bias: 134 women, RR 0.23, 95% CI 0.09 to 0.60); calcium plus vitamin D, (two studies with high risk of bias: 1060 women, RR 0.49, 95% CI 0.31 to 0.78) and a trend in one trial of calcium plus antioxidants with low risk of bias (60 women, RR 0.24, 95% CI 0.06 to 1.01). Test for subgroup differences: Chi² = 2.66, df = 3, P = 0.45, I² = 0%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Preterm birth</HEADING>
<P>Preterm birth was significantly reduced in one study of calcium supplementation alone (422 women, average RR 0.40, 95% CI 0.21 to 0.75, <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>), but as it was not reported in the other three studies of calcium supplementation alone, the possibility of publication bias needs to be considered. Overall, there was no effect on preterm birth in four studies (1190 women, average RR 0.67; 95% CI 0.24 to 1.87; Heterogeneity: Tau² = 0.67; Chi² = 12.99, df = 3 (P = 0.005); I² = 77%), <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Admission to neonatal intensive care unit (ICU)</HEADING>
<P>Admission to neonatal ICU was reported in only one trial of calcium supplementation alone, so the reduction may be due to publication bias (422 women, RR 0.44; 95% CI 0.20 to 0.99; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Stillbirth or death before discharge from hospital</HEADING>
<P>There was no overall effect on the RR of a stillbirth or the baby dying before discharge from hospital (five trials, 1025 women: RR 0.48, 95% CI 0.14 to 1.67; Heterogeneity: Chi² = 0.99, df = 4 (P = 0.91); I² = 0%; <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(6) Placental abruption</HEADING>
<P>One study reported this outcome and the numbers were too small for meaningful analysis (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Caesarean section</HEADING>
<P>Caesarean section was significantly reduced in two studies of calcium plus linoleic acid (134 women, average RR 0.55; 95% CI 0.35 to 0.87; Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.86); I² = 0% <LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK>), but not overall (four studies, 521 women, average RR 0.73; 95% CI 0.46 to 1.15; Heterogeneity: Tau² = 0.13; Chi² = 7.48, df = 3 (P = 0.06); I² = 60%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(8) Severe pre-eclampsia</HEADING>
<P>Two trials reported severe pre-eclampsia and there was no clear difference between the groups (146 women: RR 0.34, 95% CI 0.10 to 1.31; Heterogeneity: Chi² = 0.00, df = 1 (P = 0.96); I² = 0%; <LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(9) Eclampsia</HEADING>
<P>One trial of calcium supplementation alone reported eclampsia. There was no clear difference between the groups (168 women: RR 0.17, 95% CI 0.01 to 4.06; <LINK REF="CMP-006.09" TYPE="ANALYSIS">Analysis 6.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(10) Miscarriage (non-prespecified)</HEADING>
<P>An unexpected finding in one small trial of calcium plus antioxidants commencing at eight to 12 weeks of pregnancy was a trend to reduced miscarriage in the calcium plus antioxidant group (60 women, RR 0.06, 95% CI 0.00 to 1.04; <LINK REF="CMP-006.10" TYPE="ANALYSIS">Analysis 6.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(11) Birthweight less than 2500 g</HEADING>
<P>The risk of having a baby with birthweight less than 2500 g was significantly reduced in two studies of calcium supplementation plus linoleic acid (134 women: RR 0.20, 95% CI 0.05 to 0.88; Heterogeneity: Chi² = 0.00, df = 1 (P = 1.00); I² = 0%; <LINK REF="CMP-006.11" TYPE="ANALYSIS">Analysis 6.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(12) Neonate small-for-gestational age</HEADING>
<P>There was no overall effect on the risk of the baby being born small-for-gestational age (four trials 854 women: RR 0.81, 95% CI 0.54 to 1.21; Heterogeneity: Chi² = 2.06, df = 3 (P = 0.56); I² = 0%; <LINK REF="CMP-006.12" TYPE="ANALYSIS">Analysis 6.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-06-12 14:03:44 +0100" MODIFIED_BY="Heather Maxwell">
<SUMMARY_OF_RESULTS MODIFIED="2014-06-12 14:03:19 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">High-dose calcium supplementation</HEADING>
<P>Calcium supplementation with at least 1 g of calcium approximately halves the risk of pre-eclampsia, with the confidence intervals estimating the true effect to be a risk reduction of between 35% and 69%. Women with an adequate dietary intake of calcium were the only subgroup for which this was not statistically significant. Nevertheless, the point estimate for this subgroup of women was a 38% risk reduction. The greatest risk reduction was for women at high risk (variably defined; 78% reduction) and those with low baseline dietary calcium intake (64% reduction).</P>
<P>There was also a 35% reduction in the risk of gestational hypertension, with the greatest effect also amongst women at high risk and those with low calcium diets. These data should be interpreted with caution because of the possibility of small-study effect or publication bias.</P>
<P>The risk of having the composite outcome 'maternal death or severe morbidity' was reduced by 20% with calcium supplementation and there was a 24% reduction in the risk of preterm birth.</P>
<P>The risk of HELLP syndrome was increased; however the absolute number of events was low (2.5/1000 versus 0.9/1000). There are no clear effects on other relevant outcomes at discharge from hospital. There are no clear differences in any other outcomes, although for several outcomes the confidence intervals approach statistical significance, e.g. for caesarean section a small (5%) reduction in risk associated with calcium supplementation is possible. For stillbirth and death before discharge from hospital the point estimate is for a reduction of 10%, although no effect or a small increase in risk has not been excluded (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>, <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Low-dose calcium supplementation</HEADING>
<P>The results with low-dose calcium supplementation alone are similar to those of the smaller studies with high-dose supplementation, showing a large reduction in pre-eclampsia which was consistent between studies with low and high risk of bias. Results for calcium plus other interventions were similar to those for calcium alone, but the possibility that co-interventions contributed to the effect on pre-eclampsia needs to be considered. For antioxidants this is unlikely as antioxidants have not been found to reduce the risk of pre-eclampsia (<LINK REF="REF-Rumbold-2008" TYPE="REFERENCE">Rumbold 2008</LINK>). For vitamin D there is as yet inadequate evidence regarding its effect on pre-eclampsia (<LINK REF="REF-De_x002d_Regil-2012" TYPE="REFERENCE">De-Regil 2012</LINK>). For linoleic acid there is also insufficient evidence.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-06-11 10:54:39 +0100" MODIFIED_BY="Heather Maxwell">
<P>We consider the evidence in favour of high-dose calcium supplementation with respect to reducing the risk of pre-eclampsia to be complete, particularly in women with low calcium diets and those at high risk. Although calcium reduced the risk of pre-eclampsia, it did not translate into significant reductions in the risk of severe pre-eclampsia, eclampsia, or admission to intensive care. Nevertheless, the point estimates for these outcomes favoured calcium supplementation, and so moderate reductions in these outcomes remain possible.</P>
<P>Few side effects were recorded in the included trials. In two trials, the risk of HELLP syndrome was increased with calcium supplementation. A possible explanation for this apparently anomalous finding is that calcium supplementation in the second half of pregnancy may only reduce blood pressure rather than the underlying pre-eclamptic process. Lower blood pressures in the calcium group may have reduced the diagnosis of pre-eclampsia and, thus, medical interventions to curtail pregnancy, allowing more time for the pre-eclampsia to progress to HELLP syndrome (<LINK REF="REF-Hofmeyr-2007" TYPE="REFERENCE">Hofmeyr 2007</LINK>).</P>
<P>There remains little information about the long-term follow-up of children exposed to calcium in utero. One study evaluated childhood systolic hypertension and dental caries. The risk of both of these outcomes was significantly reduced, however, the latter effect was observed in a small subset of the children and the study was not originally designed to assess this outcome. These effects therefore need corroboration.</P>
<P>There is no information about any possible changes in the use of healthcare resources associated with calcium supplementation. It would seem plausible that a reduction in gestational hypertension and pre-eclampsia might lead to fewer antenatal visits, less antepartum hospital admissions and fewer inductions of labour. However, these trials do not provide data on these outcomes.</P>
<P>This 2013 update has included data from trials using less than 1 g calcium daily (mostly 500 to 600 mg). Over half of these studies were at high risk of bias and combined calcium with other supplements. However, the evidence seems to indicate that lower doses of calcium may be effective in reducing hypertensive disorders of pregnancy. The results of the low-dose studies is therefore incomplete and need corroboration by larger high-quality studies.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-06-12 14:03:44 +0100" MODIFIED_BY="Heather Maxwell">
<P>We consider the evidence for the effect of high-dose calcium supplementation on pre-eclampsia, preterm birth and HELLP syndrome to be of a high quality (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>In general, heterogeneity of findings seemed to be largely associated with study size, with the small studies having the most positive results (s<I>ee </I>
<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>0, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>1). These 'small-study effects' may indicate publication bias or other biases, or be caused by differences between small and large studies. As the small studies tended to recruit high-risk women, at least some of the heterogeneity may be explained by calcium having a greater effect for high-risk women. These data on heterogeneity related to sample size should be interpreted with caution however, as the sensitivity analysis was post-hoc, and the cut-off point for sample size (400) was arbitrary.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-05-29 11:04:16 +0100" MODIFIED_BY="[Empty name]">
<P>To our knowledge, there were no biases in the review process.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-06-11 10:54:52 +0100" MODIFIED_BY="Heather Maxwell">
<P>This evidence of a modest risk reduction in gestational hypertension and 'maternal deaths and serious morbidity' contrasts with the large epidemiological differences previously identified between populations with adequate and low dietary calcium intake (<LINK REF="REF-Belizan-1980" TYPE="REFERENCE">Belizan 1980</LINK>; <LINK REF="REF-Hamlin-1952" TYPE="REFERENCE">Hamlin 1952</LINK>; <LINK REF="REF-Hamlin-1962" TYPE="REFERENCE">Hamlin 1962</LINK>). Possible explanations include the following.</P>
<OL>
<LI>Dietary calcium may be a marker for other aetiological factors.</LI>
<LI>Starting supplementation in the middle trimester of pregnancy may be too late to be fully effective.</LI>
</OL>
<P>The finding of reduced childhood hypertension needs replication but, if corroborated, has far-reaching implications for public health. Although based on only a partial follow-up in one study (<LINK REF="STD-Belizan-1991" TYPE="STUDY">Belizan 1991</LINK>), this finding is supported by a very limited follow-up in two other studies (<LINK REF="STD-CPEP-1997" TYPE="STUDY">CPEP 1997</LINK>; <LINK REF="STD-Crowther-1999" TYPE="STUDY">Crowther 1999</LINK>), as well as observational (<LINK REF="REF-McGarvey-1991" TYPE="REFERENCE">McGarvey 1991</LINK>) and animal (<LINK REF="REF-Bergel-2002" TYPE="REFERENCE">Bergel 2002</LINK>) studies.</P>
<P>There are concerns regarding possible adverse effects of calcium supplementation, which may be dose-related. Long-term calcium use in later life has been associated with myocardial infarction, however the association may not be causal (<LINK REF="REF-Li-2012" TYPE="REFERENCE">Li 2012</LINK>). In addition, in a 2010 publication of the Gambia study in which women received calcium supplementation of 1.5 g during pregnancy (<LINK REF="STD-Jarjou-2004" TYPE="STUDY">Jarjou 2004</LINK>), investigators reported reduced bone density in the women postpartum. They suggest that high-dose calcium during pregnancy might reverse metabolic adaptation to long-term low calcium diets resulting in a rebound effect when withdrawn. This finding was based on a selected follow-up and was opposite to the prior hypothesis and therefore needs confirmation in a prospective study.</P>
<P>Finally, epidemiological studies have found a difference in dietary calcium intake between high- and low-income settings of about 500 mg. Doses of 1.5 g/day and higher are well above daily recommended dietary calcium intake. Some women find it difficult to swallow or chew three to four large tablets daily, which may affect adherence. Furthermore, doses in excess of 800 mg daily may inhibit iron absorption. Therefore, further research is necessary to determine the optimal dose of calcium supplements in pregnancy.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-06-12 14:04:03 +0100" MODIFIED_BY="Heather Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2014-06-12 14:04:03 +0100" MODIFIED_BY="Heather Maxwell">
<P>The reduction in hypertension, pre-eclampsia and preterm birth, and in the composite outcome 'maternal death or severe morbidity' with high-dose calcium supplementation support the use of calcium supplementation during pregnancy, particularly for those with low dietary intake or high risk of pre-eclampsia. Implementation may be subject to competing priorities in low-resource settings. The increase in the risk of HELLP syndrome was small in terms of absolute numbers. Therefore, we consider it to be outweighed by the overall reduction in death or severe morbidity.</P>
<P>The one study which enrolled women with high risk of pre-eclampsia and adequate dietary calcium was too small to guide practice.</P>
<P>Based on evidence included in the previous version of this review, which was limited to high-dose calcium supplementation, the World Health Organization recommends a calcium dose of 1.5 to 2 g during pregnancy for women with low dietary calcium intake (<LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>). However, this recommendation may be associated with logistical difficulties in low-income countries: calcium is relatively expensive, and the tablets are bulky and heavy (about 1 kg for a 20 week supply of calcium carbonate and glycine providing 1.5 g elemental calcium daily).</P>
<P>In settings in which the recommended dosage of 1.5 to 2 g daily is not feasible, using a lower dose, rather than nothing, seems to be a reasonable interim approach. Revision of existing guidelines should include consideration of the data on low-dosage supplementation, evidence on potential risk and supplement interactions, and logistic and cost implications.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-01-26 21:50:50 +0000" MODIFIED_BY="[Empty name]">
<P>The increase in the risk of HELLP syndrome identified by this review requires further investigation. Any future trials should also collect information about the use of health service resources, as well as other clinical outcomes. Robust research is needed to confirm the beneficial effects found in the limited evidence on the use of less than one gram of calcium daily. It would also be relevant to assess whether supplementation via dietary modification, for women with low calcium intake, has the same benefits as the tablets administered in these trials.</P>
<P>Further research is needed to determine the effectiveness of calcium supplementation in women with high risk of pre-eclampsia and adequate dietary calcium.</P>
<P>Further research is also needed to provide reassurance that calcium supplementation during pregnancy does not have any adverse effects for the children exposed whilst in utero, and to verify whether it reduces childhood hypertension. Research into the effects of calcium supplementation combined with low-dose aspirin would be of value.</P>
<P>In most of the studies reviewed, supplementation was commenced around 20 weeks of pregnancy. In one small trial of low-dose calcium supplementation commencing at eight to 12 weeks in high-risk women, there was an unanticipated trend to reduced miscarriage. This interesting observation needs to be confirmed by prospective research.</P>
<P>We have hypothesised, based on the finding in this review of no effect of calcium supplementation on proteinuria, that the benefits of calcium supplementation in the second half of pregnancy may be the result of a direct lowering effect on blood pressure, and that supplementation may be needed from before pregnancy to affect the genesis of pre-eclampsia during placental development (<I>Calcium supplementation commencing before pregnancy, or food fortification with calcium, for preventing hypertensive disorders of pregnancy - Cochrane protocol in progress 2013)</I>. We are currently testing this hypothesis in a double-blind randomised trial of supplementation with 500 mg calcium commencing before pregnancy in women with previous pre-eclampsia (<LINK REF="REF-Hofmeyr-2011" TYPE="REFERENCE">Hofmeyr 2011</LINK>). If found to be effective, the next research step will be community supplementation with staple food fortification.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-05-22 14:18:00 +0100" MODIFIED_BY="[Empty name]">
<P>We thank the trial authors who have contributed additional data for this review. We also thank Maria Kalousi and Oliver Boothroyd for their assistance with the translation of certain articles to English, and the Cochrane Pregnancy and Childbirth Group team for administrative support.</P>
<P>As part of the pre-publication editorial process, this review has been commented on by three peers (an editor and two referees who are external to the editorial team), a member of the Pregnancy and Childbirth Group's international panel of consumers and the Group's Statistical Adviser.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Justus Hofmeyr is a collaborator in the WHO Calcium Trial (<LINK REF="STD-WHO-2006" TYPE="STUDY">WHO 2006</LINK>), which was included in this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-05-29 16:00:26 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Lelia Duley prepared the original review in the Oxford Database of Perinatal Trials.<BR/>Álvaro Atallah and Justus Hofmeyr prepared the protocol for the original Cochrane review.<BR/>Justus Hofmeyr prepared the initial data analysis and is primarily responsible for maintaining the review, with input from the other authors. Tess Lawrie prepared the first draft of the 2010 update of the review with input from Justus Hofmeyr, Lelia Duley and Álvaro Atallah.</P>
<P>Justus Hofmeyr prepared the protocol revision and the first draft of the text for the 2013 update. Justus Hofmeyr and Regina Torloni performed the study selection and data extraction for the 2013 update. All authors approved the final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-06-12 14:04:20 +0100" MODIFIED_BY="Heather Maxwell">
<P>Additional outcomes were added in 2004, and clearly identified.</P>
<P>The protocol was updated in 2012 and the updates clearly identified.</P>
<SUBSECTION>
<HEADING LEVEL="3">Protocol amendments September 2012</HEADING>
<P>We have made the following protocol amendments for this review.</P>
<OL>
<LI>We included a separate analysis for trials with less than 1 g of calcium daily.</LI>
<LI>If there were insufficient high-quality randomised placebo-controlled trials of low-dose calcium alone to provide robust evidence of effectiveness, we separately reviewed additional evidence from lower quality studies, with appropriate caution in the interpretation of the results:</LI>
</OL>
<UL>
<LI>quasi-randomised trials (by alternation, unstated method of allocation or other quasi-random methods);</LI>
<LI>trials without placebo control;</LI>
<LI>trials of calcium plus additional supplements (e.g. vitamin D, linoleic acid, or anti-platelet agents).</LI>
</UL>
<P>We included subgroup analysis by trial quality and co-interventions.</P>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-06-10 17:02:40 +0100" MODIFIED_BY="Heather Maxwell">
<STUDIES MODIFIED="2014-06-10 12:04:47 +0100" MODIFIED_BY="Heather Maxwell">
<INCLUDED_STUDIES MODIFIED="2014-06-10 11:52:33 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Almirante-1998" MODIFIED="2012-09-16 15:25:44 +0100" MODIFIED_BY="[Empty name]" NAME="Almirante 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-09-16 15:25:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Almirante CY</AU>
<TI>Calcium supplementation during pregnancy in the prevention of EPH gestosis</TI>
<SO>Prenatal and Neonatal Medicine</SO>
<YR>1998</YR>
<VL>3 Suppl 1</VL>
<PG>24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bassaw-1998" MODIFIED="2013-06-14 09:51:26 +0100" MODIFIED_BY="[Empty name]" NAME="Bassaw 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-06-14 09:51:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bassaw B, Roopnarinesingh S, Roopnarinesingh A, Homer H</AU>
<TI>Prevention of hypertensive disorders of pregnancy</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>123-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Belizan-1991" MODIFIED="2014-06-10 11:49:05 +0100" MODIFIED_BY="Heather Maxwell" NAME="Belizan 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-06-10 11:49:05 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;[9548]&lt;/p&gt;" NOTES_MODIFIED="2014-06-10 11:49:05 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belizan JM, Villar J, Bergel E, del Pino A, Di Fulvio S, Galliano SV, et al</AU>
<TI>Long term effect of calcium supplementation during pregnancy on the blood pressure of offspring: follow up of a randomised controlled trial</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-01 20:13:20 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[6884]&lt;/p&gt;" NOTES_MODIFIED="2010-07-01 20:13:20 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Belizan JM, Villar J, Gonzalez L, Campodonico L, Bergel E</AU>
<TI>Calcium supplementation to prevent hypertensive disorders of pregnancy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>325</VL>
<PG>1399-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[9406]&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Belizan JM</AU>
<TI>Prevention of hypertensive disorders of pregnancy with calcium supplementation</TI>
<SO>8th World Congress on Hypertension in Pregnancy; 1992 November 8-12; Buenos Aires</SO>
<YR>1992</YR>
<PG>93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-14 09:51:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergel E, Gibbons L, Rasines MG, Luetich A, Belizan JM</AU>
<TI>Maternal calcium supplementation during pregnancy and dental caries of children at 12 years of age: follow-up of a randomized controlled trial</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>2010</YR>
<VL>89</VL>
<NO>11</NO>
<PG>1396-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stephens IF</AU>
<TI>Effect of calcium supplementation during pregnancy on blood pressure of offspring. Authors cannot be sure of effect's generalisability to all children aged 5-9 [letter; comment]</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<NO>7126</NO>
<PG>234</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[4213]&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Villar J, Belizan JM, Repke J</AU>
<TI>The effect of calcium supplementation on the incidence of hypertensive disorders of pregnancy and prematurity</TI>
<SO>7th World Congress of Hypertension in Pregnancy; 1990; Perugia, Italy</SO>
<YR>1990</YR>
<PG>54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;6355&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Villar J, Belizan JM, Repke JT</AU>
<TI>Does calcium supplementation reduce pregnancy-induced hypertension and prematurity?</TI>
<SO>Proceedings of the International Symposium on advances in the prevention of low birthweight; 1988 May 8-11; Cape Cod, Massachusetts</SO>
<YR>1988</YR>
<PG>187-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cong-1995" MODIFIED="2012-09-16 14:58:54 +0100" MODIFIED_BY="[Empty name]" NAME="Cong 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-09-16 14:58:54 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[8506]&lt;/p&gt;" NOTES_MODIFIED="2012-09-16 14:58:54 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cong KJ, Chi SL, Liu GR</AU>
<TI>Calcium and pregnancy induced hypertension</TI>
<SO>Chinese Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>28</VL>
<PG>657-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-16 14:58:54 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[8980]&lt;/p&gt;" NOTES_MODIFIED="2012-09-16 14:58:54 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cong KJ, Chi SL, Liu GR</AU>
<TI>Calcium supplementation during pregnancy for reducing pregnancy induced hypertension</TI>
<SO>Chinese Medical Journal</SO>
<YR>1995</YR>
<VL>108</VL>
<PG>57-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-16 14:58:54 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[8505]&lt;/p&gt;" NOTES_MODIFIED="2012-09-16 14:58:54 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cong KJ, Chi SL, Liu GR</AU>
<TI>Calcium supplementation during pregnancy to reduce pregnancy induced hypertension</TI>
<SO>Beijing Medical Journal</SO>
<YR>1992</YR>
<VL>5</VL>
<PG>268</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CPEP-1997" MODIFIED="2014-06-10 11:51:01 +0100" MODIFIED_BY="Heather Maxwell" NAME="CPEP 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-02-23 22:45:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Habli M, Levine RJ, Qian C, Sibai B</AU>
<TI>Neonatal outcomes in pregnancies with preeclampsia or gestational hypertension and in normotensive pregnancies that delivered at 35, 36, or 37 weeks of gestation</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>197</VL>
<NO>4</NO>
<PG>406.e1-406.e7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hatton DC, Harrison-Hohner J, Coste S, Reller M, McCarron D</AU>
<TI>Gestational calcium supplementation and blood pressure in the offspring</TI>
<SO>American Journal of Hypertension</SO>
<YR>2003</YR>
<VL>16</VL>
<PG>801-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[9446]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine RJ for the CPEP Study Group</AU>
<TI>Calcium for preeclampsia prevention (CPEP): a double-blind, placebo-controlled trial in healthy nulliparas</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<PG>S2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Levine RJ for the CPEP Study Group</AU>
<TI>The trial of calcium for preeclampsia prevention (CPEP)</TI>
<SO>8th World Congress on Hypertension in Pregnancy - Protagonists and Presentations; 1992 November 8-12; Buenos Aires, Argentina</SO>
<YR>1992</YR>
<PG>94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-10 11:50:49 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine RJ, Esterlitz JR, Raymond EG, DerSimonian R, Hauth JC, Ben Curet L, et al</AU>
<TI>Trial of calcium for preeclampsia prevention (CPEP): rationale, design, and methods</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>442-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-10 11:51:01 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levine RJ, Hauth JC, Curet LB, Sibai BM, Catalano PM, Morris CD, et al</AU>
<TI>Trial of calcium to prevent preeclampsia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<NO>2</NO>
<PG>69-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crowther-1999" MODIFIED="2014-06-10 11:51:35 +0100" MODIFIED_BY="Heather Maxwell" NAME="Crowther 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-06-10 11:51:21 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Crowther C, Hiller J, Pridmore B, Bryce R, Duggan P, Hague W, et al</AU>
<TI>Calcium supplementation in nulliparous women for the prevention of pregnancy included hypertension, pre-eclampsia and preterm birth: an Australian randomised trial</TI>
<SO>2nd Annual Congress of the Perinatal Society of Australia &amp; New Zealand; 1998 March 30-April 4; Alice Springs, Australia</SO>
<YR>1998</YR>
<PG>101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-10 11:51:35 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Crowther CA, Hiller JE, Pridmore B, Bryce R, Duggan P, Hague WM, et al</AU>
<TI>Calcium supplementation in nulliparous women for the prevention of pregnancy-induced hypertension, preeclampsia and preterm birth: an Australian randomized trial</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1999</YR>
<VL>39</VL>
<NO>1</NO>
<PG>12-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 09:07:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiller JE, Crowther CA, Moore VA, Willson K, Robinson JS</AU>
<TI>Calcium supplementation in pregnancy and its impact on blood pressure in children and women: follow up of a randomised controlled trial</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>2007</YR>
<VL>47</VL>
<NO>2</NO>
<PG>115-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrera-1998" MODIFIED="2012-09-16 16:28:10 +0100" MODIFIED_BY="[Empty name]" NAME="Herrera 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-09-16 16:27:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrera JA, Arevalo-Herrera M, Herrera S</AU>
<TI>Prevention of preeclampsia by linoleic acid and calcium supplementation: a randomized controlled trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1998</YR>
<VL>91</VL>
<NO>4</NO>
<PG>585-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrera-2006" MODIFIED="2013-06-14 14:35:12 +0100" MODIFIED_BY="[Empty name]" NAME="Herrera 2006" YEAR="1998">
<REFERENCE MODIFIED="2013-06-14 14:35:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Herrera JA, Arevalo-Herrera M, Shahabuddin AK, Ersheng G, Herrera S, Garcia RG, et al</AU>
<TI>Calcium and conjugated linoleic acid reduces pregnancy-induced hypertension and decreases intracellular calcium in lymphocytes</TI>
<SO>American Journal of Hypertension</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>4</NO>
<PG>381-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-16 16:10:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrera JA, Shahabuddin AK, Ersheng G, Wei Y, Garcia RG, Lopez-Jaramillo P</AU>
<TI>Calcium plus linoleic acid therapy for pregnancy-induced hypertension</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2005</YR>
<VL>91</VL>
<NO>3</NO>
<PG>221-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-16 16:10:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrera JA, Shahabuddin AKM, Faisal M, Ersheng G, Wei Y, Lixia D, et al</AU>
<TI>Effects of supplementation with oral calcium and linoleic acid in primigravidas at high risk</TI>
<TO>Efectos de la supplementacion oral con calcio y acido linoleico conjugado en primigravidas de alto riesgo</TO>
<SO>Colombia Medica</SO>
<YR>2004</YR>
<VL>35</VL>
<NO>1</NO>
<PG>31-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarjou-2004" MODIFIED="2014-06-10 11:52:33 +0100" MODIFIED_BY="Heather Maxwell" NAME="Jarjou 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-06-10 11:52:33 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawkesworth S, Sawo Y, Fulford AJ, Goldberg GR, Jarjou LM, Prentice A, et al</AU>
<TI>Effect of maternal calcium supplementation on offspring blood pressure in 5- to 10-y-old rural Gambian children</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2010</YR>
<VL>92</VL>
<NO>4</NO>
<PG>741-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-14 14:21:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawkesworth S, Walker CG, Sawo Y, Fulford AJ, Jarjou LM, Goldberg GR, et al</AU>
<TI>Nutritional supplementation during pregnancy and offspring cardiovascular disease risk in The Gambia</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2011</YR>
<VL>94</VL>
<NO>6 Suppl</NO>
<PG>1853S-1860S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-14 14:21:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarjou LM, Laskey MA, Sawo Y, Goldberg GR, Cole TJ, Prentice A</AU>
<TI>Effect of calcium supplementation in pregnancy on maternal bone outcomes in women with a low calcium intake</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2010</YR>
<VL>92</VL>
<NO>2</NO>
<PG>450-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-14 14:21:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jarjou LM, Prentice A, Bennett J</AU>
<TI>Impact of calcium supplementation in the preceding pregnancy on the human milk calcium concentration of Gambian women</TI>
<SO>Advances in Experimental Medicine and Biology</SO>
<YR>2004</YR>
<VL>54</VL>
<PG>347-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-24 14:14:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarjou LM, Prentice A, Sawo Y, Laskey MA, Bennett J, Goldberg GR, Cole TJ</AU>
<TI>Randomized, placebo-controlled, calcium supplementation study in pregnant Gambian women: effects on breast-milk calcium concentrations and infant birth weight, growth, and bone mineral accretion in the first year of life</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>83</VL>
<NO>3</NO>
<PG>657-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-14 12:58:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarjou LMA, Bennett J, Laidlaw A, Goldberg GR, Prentice A</AU>
<TI>Changes in bone turnover and calcitrophic hormones in lactating Gambian women supplemented with calcium during pregnancy</TI>
<SO>Journal of Human Lactation</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>1</NO>
<PG>86-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-04 14:13:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prentice A, Jarjou LM, Goldberg GR, Bennett J, Cole TJ, Schoenmakers I</AU>
<TI>Maternal plasma 25-hydroxyvitamin D concentration and birthweight, growth and bone mineral accretion of Gambian infants</TI>
<SO>Acta Paediatrica</SO>
<YR>2009</YR>
<VL>98</VL>
<NO>8</NO>
<PG>1360-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kumar-2009" MODIFIED="2010-01-28 10:35:43 +0000" MODIFIED_BY="[Empty name]" NAME="Kumar 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-01-07 12:06:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar A, Devi SG, Batra S, Singh C, Shukla DK</AU>
<TI>Calcium supplementation for the prevention of pre-eclampsia</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>1</NO>
<PG>32-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2000" MODIFIED="2012-09-16 16:47:19 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-09-16 16:47:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li X, Gou W</AU>
<TI>Study on prevention of pregnancy induced hypertension and effect of platelet intracellular free ca~(2+) by calcium supplementation</TI>
<SO>Journal of Xi'an Medical University</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>1</NO>
<PG>46-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-L_x002d_Jaramillo-1989" MODIFIED="2010-07-01 20:13:51 +0100" MODIFIED_BY="[Empty name]" NAME="L-Jaramillo 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-07-01 20:13:51 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[5080]&lt;/p&gt;" NOTES_MODIFIED="2010-07-01 20:13:51 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lopez-Jaramillo P, Narvaez M, Weigel RM, Yepez R</AU>
<TI>Calcium supplementation reduces the risk of pregnancy-induced hypertension in an Andes population</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1989</YR>
<VL>96</VL>
<PG>648-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[4526]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez-Jaramillo P, Narvaez M, Yepez R</AU>
<TI>Effect of calcium supplementation on the vascular sensitivity to angiotensin II in pregnant women</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1987</YR>
<VL>156</VL>
<PG>261-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-03 11:37:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Narvaez M, Lopez-Jaramillo P, Weigel M</AU>
<TI>Calcium (Ca++) supplementation reduces the risk for pregnancy induced hypertension (PIH)</TI>
<SO>World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil</SO>
<YR>1988</YR>
<PG>180-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x002d_Jaramillo-1990" MODIFIED="2010-07-01 20:14:06 +0100" MODIFIED_BY="[Empty name]" NAME="L-Jaramillo 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-07-01 20:14:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lopez-Jaramillo P, Narvaez M, Felix C, Lopez A</AU>
<TI>Dietary calcium supplementation and prevention of pregnancy hypertension</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>293</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Narvaez M, Lopez-Jaramillo P, Weigel M</AU>
<TI>Calcium (Ca++) supplementation reduces the risk for pregnancy induced hypertension (PIH)</TI>
<SO>World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil</SO>
<YR>1988</YR>
<PG>180-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x002d_Jaramillo-1997" NAME="L-Jaramillo 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;[9549]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez-Jaramillo P, Delgado F, Jacome P, Teran E, Ruano C, Rivera J</AU>
<TI>Calcium supplementation and the risk of preeclampsia in Ecuadorian pregnant teenagers</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1997</YR>
<VL>90</VL>
<PG>162-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Marya-1987" MODIFIED="2012-09-16 14:32:08 +0100" MODIFIED_BY="[Empty name]" NAME="Marya 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-09-16 14:32:08 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[3749]&lt;/p&gt;" NOTES_MODIFIED="2012-09-16 14:32:08 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marya RK, Rathee S, Manrow M</AU>
<TI>Effect of calcium and vitamin D supplementation on toxaemia of pregnancy</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>1987</YR>
<VL>24</VL>
<PG>38-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niromanesh-2001" NAME="Niromanesh 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niromanesh S, Laghaii S, Mosavi-Jarrahi A</AU>
<TI>Supplementary calcium in prevention of pre-eclampsia</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2001</YR>
<VL>74</VL>
<PG>17-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Purwar-1996" MODIFIED="2010-07-01 20:14:20 +0100" MODIFIED_BY="[Empty name]" NAME="Purwar 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-07-01 20:14:20 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[9960]&lt;/p&gt;" NOTES_MODIFIED="2010-07-01 20:14:20 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Purwar M, Kulkarni H, Motghare V, Dhole S</AU>
<TI>Calcium supplementation and prevention of pregnancy induced hypertension</TI>
<SO>Journal of Obstetrics and Gynaecology Research</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>5</NO>
<PG>425-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Purwar M, Motghare V, Kulkarni H</AU>
<TI>Calcium supplementation and prevention of pregnancy induced hypertension: randomized double blind controlled trial</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1996</YR>
<VL>49</VL>
<NO>Suppl 1</NO>
<PG>28S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rogers-1999" MODIFIED="2012-09-18 09:32:27 +0100" MODIFIED_BY="[Empty name]" NAME="Rogers 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-09-18 09:32:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rogers MS, Fung HYM, Hung CY</AU>
<TI>Calcium and low-dose aspirin prophylaxis in women at high risk of pregnancy-induced hypertension</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>2</NO>
<PG>165-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rumiris-2006" MODIFIED="2013-06-14 14:47:05 +0100" MODIFIED_BY="[Empty name]" NAME="Rumiris 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-06-14 14:47:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rumiris D, Purwosunu Y, Wibowo N, Farina A, Sekizawa A</AU>
<TI>Lower rate of preeclampsia after antioxidant supplementation in pregnant women with low antioxidant status</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2006</YR>
<VL>25</VL>
<PG>241&#8211;53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-S_x002d_Ramos-1994" MODIFIED="2013-06-14 14:35:28 +0100" MODIFIED_BY="[Empty name]" NAME="S-Ramos 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-06-14 14:35:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[8454]&lt;/p&gt;" NOTES_MODIFIED="2013-06-14 14:35:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Ramos L, Briones DK, Kaunitz AM, Delvalle GO, Gaudier FL, Walker KD</AU>
<TI>Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin II-sensitive patients</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1994</YR>
<VL>84</VL>
<PG>349-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[8441]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Ramos L, Delvalle GO, Briones D, Walker C, Delke I, Gaudier F</AU>
<TI>Prevention of preeclampsia by calcium supplementation in angiotensin-sensitive patients</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>170</VL>
<PG>408</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taherian-2002" MODIFIED="2012-09-16 15:49:59 +0100" MODIFIED_BY="[Empty name]" NAME="Taherian 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-09-16 15:49:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taherian AA, Taherian A, Shirvani A</AU>
<TI>Prevention of pre-eclampsia with low-dose aspirin or calcium supplementation</TI>
<SO>Archives of Iranian Medicine</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>3</NO>
<PG>151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Villar-1987" MODIFIED="2010-07-01 20:14:30 +0100" MODIFIED_BY="[Empty name]" NAME="Villar 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;[4731]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Repke JT, Villar J, Anderson C, Pareja G, Dubin N, Belizan JM</AU>
<TI>Biochemical changes associated with blood pressure reduction induced by calcium supplementation during pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>160</VL>
<PG>684-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-01 20:14:30 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[3684]&lt;/p&gt;" NOTES_MODIFIED="2010-07-01 20:14:30 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Repke J, Belizan JM, Pareja G</AU>
<TI>Calcium supplementation reduces blood pressure during pregnancy: results of a randomized controlled clinical trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1987</YR>
<VL>70</VL>
<PG>317-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Villar-1990" MODIFIED="2010-07-01 20:14:43 +0100" MODIFIED_BY="[Empty name]" NAME="Villar 1990" YEAR="05825">
<REFERENCE NOTES="&lt;p&gt;[4213]&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Villar J, Belizan JM, Repke J</AU>
<TI>The effect of calcium supplementation on the incidence of hypertensive disorders of pregnancy and prematurity</TI>
<SO>7th World Congress of Hypertension in Pregnancy; 1990; Perugia, Italy</SO>
<YR>1990</YR>
<PG>54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;6355&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Villar J, Belizan JM, Repke JT</AU>
<TI>Does calcium supplementation reduce pregnancy-induced hypertension and prematurity?</TI>
<SO>Advances in the prevention of low birthweight; 1988 May 8-11; Cape Cod, Massachusetts</SO>
<YR>1998</YR>
<PG>187-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-01 20:14:43 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[5825]&lt;/p&gt;" NOTES_MODIFIED="2010-07-01 20:14:43 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Repke JT</AU>
<TI>Calcium supplementation during pregnancy may reduce preterm delivery in high-risk populations</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>163</VL>
<PG>1124-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-WHO-2006" MODIFIED="2010-07-01 20:21:15 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-07-01 20:21:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abalos E, Merialdi M, Wojdyla D, Carroli G, Campodónico L, Yao SE, et al</AU>
<TI>Effects of calcium supplementation on fetal growth in mothers with deficient calcium intake: a randomised controlled trial</TI>
<SO>Paediatric and Perinatal Epidemiology</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>1</NO>
<PG>53-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 09:02:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdel-Aleem H, Merialdi M, Elsnosy ED, Elsedfy GO, Abdel-Aleem MA, Villar J</AU>
<TI>The effect of calcium supplementation during pregnancy on fetal and infant growth: a nested randomized controlled trial within WHO calcium supplementation trial</TI>
<SO>Journal of Maternal-Fetal &amp; Neonatal Medicine</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>2</NO>
<PG>94-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-23 22:25:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carroli G, Merialdi M, Wojdyla D, Abalos E, Campodonico L, Yao SE, et al</AU>
<TI>Effects of calcium supplementation on uteroplacental and fetoplacental blood flow in low-calcium-intake mothers: a randomized controlled trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2010</YR>
<VL>202</VL>
<NO>1</NO>
<PG>45.e1-45.e9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-04 12:58:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hofmeyr GJ, Mlokoti Z, Nikodem VC, Mangesi L, Ferreira S, Singata M, et al</AU>
<TI>Calcium supplementation during pregnancy for preventing hypertensive disorders is not associated with changes in platelet count, urate, and urinary protein: a randomized control trial</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>3</NO>
<PG>299-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-01 14:55:58 +0100" MODIFIED_BY="Denise Atherton" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Abdel-Aleem H, Merialdi M, Mathai M, Ali M, Zavaleta N, et al</AU>
<TI>World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2006</YR>
<VL>194</VL>
<PG>639-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-01 14:56:03 +0100" MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Aleem HA, Merialdi M, Mathai M, Ali M, Zavaleta N, et al</AU>
<TI>WHO randomized trial of calcium supplementation among low calcium intake pregnant women [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>193</VL>
<NO>6 Suppl</NO>
<PG>S2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-28 09:04:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang J, Villar J, Sun W, Merialdi M, Abdel-Aleem H, Mathai M, et al</AU>
<TI>Blood pressure dynamics during pregnancy and spontaneous preterm birth</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>197</VL>
<NO>2</NO>
<PG>162.e1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-06-10 12:04:47 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Aghamohammady-2010" MODIFIED="2014-06-10 12:00:37 +0100" MODIFIED_BY="Heather Maxwell" NAME="Aghamohammady 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-07-04 14:05:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aghamohammadi A, Rajabi A</AU>
<TI>The effect of calcium supplementation during pregnancy on preterm delivery and preeclampsia in nulliparous beyond age 35</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>2012</YR>
<VL>91 (Suppl 159)</VL>
<PG>60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-10 12:00:37 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Aghamohammady A</AU>
<TI>The effect of calcium supplementation during pregnancy on preterm delivery in primiparous beyond age 35</TI>
<SO>Journal of Maternal-Fetal and Neonatal Medicine</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>S1</NO>
<PG>100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-August-2002" MODIFIED="2010-07-01 20:15:35 +0100" MODIFIED_BY="[Empty name]" NAME="August 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>August P, Sison M, Helseth G</AU>
<TI>Identification of prognostic indices and impact of calcium supplementation in women at high risk for pre-eclampsia: data from a randomized clinical trial [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>Suppl 1</NO>
<PG>44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-01 20:15:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>August P, Sison MC, Helseth G</AU>
<TI>Clinical outcomes of African Americans with chronic hypertension during pregnancy</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>Suppl 1</NO>
<PG>55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belizan-1983" NAME="Belizan 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;[2084]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belizan JM, Villar J, Zalazar A, Rojas L, Chan D, Bryce GF</AU>
<TI>Preliminary evidence of the effect of calcium supplementation on blood pressure in normal pregnant women</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1983</YR>
<VL>146</VL>
<PG>175-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boggess-1997" NAME="Boggess 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;[9550]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boggess KA, Samuel L, Schmuckler BC, Waters J, Easterling TR</AU>
<TI>A randomised controlled trial of the effect of third trimester calcium supplementation on maternal hemodynamic function</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1997</YR>
<VL>90</VL>
<PG>157-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chames-2002" NAME="Chames 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chames M, Bendich A, Bogden J, Sibai B, Prada J</AU>
<TI>A randomized trial of calcium supplementation effects on blood lead levels in pregnancy [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>187</VL>
<NO>6 Pt 2</NO>
<PG>S137</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Souza-2006" MODIFIED="2014-06-10 12:01:56 +0100" MODIFIED_BY="Heather Maxwell" NAME="de Souza 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-06-10 12:01:56 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Souza EV, Sass N, Atallah AN, Kular L Jr</AU>
<TI>Aspirin and calcium to prevent pre eclampsia in chronic hypertension women with abnormal uterine artery doppler ultrasound [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>Suppl 1</NO>
<PG>152</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-01 20:16:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>de Souza EV</AU>
<TI>Aspirin and calcium to prevent preeclampsia in chronic hypertensive women with abnormal uterine artery Doppler ultrasound [abstract]</TI>
<TO>Acido acetilalicilico associado ao calcio na prevencao da pre-eclampsia em gestantes hipertensas cronicas selecionadas pela dopplervelocimetria das arterias uterinas</TO>
<SO>Revista Brasileira de Ginecologia y Obstetricia</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>2</NO>
<PG>136</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diogenes-2011" MODIFIED="2013-06-14 09:50:15 +0100" MODIFIED_BY="[Empty name]" NAME="Diogenes 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-06-14 09:50:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diogenes MEL, Bezerra FF, Rezende EP, Taveira MF, Pinhal I, Donangelo CM</AU>
<TI>Maternal vitamin D status of adolescent mothers at mid-pregnancy influence bone mineral content of their newborns</TI>
<SO>FASEB Journal</SO>
<YR>2011</YR>
<VL>25</VL>
<PG>603.19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dizavandy-1998" MODIFIED="2010-01-04 10:35:30 +0000" MODIFIED_BY="[Empty name]" NAME="Dizavandy 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-01-04 10:35:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dizavandy EB, Alavi GS, Cordi M</AU>
<TI>The effect of calcium supplementation in the prevention of hypertensive disorders of pregnancy in nulliparous women</TI>
<SO>Medical Journal of the Islamic Republic of Iran</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>1</NO>
<PG>11-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ettinger-2011" MODIFIED="2013-07-04 14:06:14 +0100" MODIFIED_BY="[Empty name]" NAME="Ettinger 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-07-04 14:06:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ettinger AS, Lamadrid H, Mercado A, Kordas K, Peterson K, Hu H, et al</AU>
<TI>Effect of calcium on bone resorption and bone mineral density in pregnancy: A randomized control trial</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2011</YR>
<VL>173</VL>
<NO>Suppl</NO>
<PG>S236</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Felix-1991" NAME="Felix 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;10202&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Felix C, Jacome P, Lopez A, Moya W, Narvaez M, Lopez-Jaramillo P</AU>
<TI>The hypotensive effect of calcium supplementation during normal pregnancy in Andean women is not related to vascular production of prostacyclin by umbilical arteries</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>2</NO>
<PG>93-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karandish-2003" MODIFIED="2010-01-09 12:33:32 +0000" MODIFIED_BY="[Empty name]" NAME="Karandish 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-09 12:33:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karandish M, Djazayery A, Mahmoudi M, Behrooz A</AU>
<TI>The effect of calcium supplementation during pregnancy on birth weight</TI>
<SO>Medical Journal of Reproduction and Infertility</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>3</NO>
<PG>184</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawasaki-1985" MODIFIED="2010-07-01 14:56:47 +0100" MODIFIED_BY="Denise Atherton" NAME="Kawasaki 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-07-01 14:56:47 +0100" MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawasaki N, Matsui K, Ito M, Nakamura T, Yoshimura T, Ushijima H, et al</AU>
<TI>Effect of calcium supplementation on the vascular sensitivity to angiotensin II in pregnant women</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1985</YR>
<VL>153</VL>
<PG>576-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knight-1992" NAME="Knight 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;[7217]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knight KB, Keith RE</AU>
<TI>Calcium supplementation on normotensive and hypertensive pregnant women</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1992</YR>
<VL>55</VL>
<PG>891-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Lavin-1986" NAME="Lavin 1986" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Normotensive women with a positive 'roll-over' test at 28 to 32 weeks of pregnancy, to recieve calcium or placebo. Main outcome: presence or absence of pregnancy induced hypertension. Study apparently cancelled.&lt;/p&gt;" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Lavin JP</AU>
<TI>The effect of calcium supplementation on pregnancy induced hypertension</TI>
<SO>Personal communication</SO>
<YR>1986</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-MacDonald-1986" MODIFIED="2010-01-05 10:09:51 +0000" MODIFIED_BY="[Empty name]" NAME="MacDonald 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-01-05 10:09:51 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Single cebtre study (Leeds). Follow-up completed 1979 (55 subjects). Random allocation by sealed, numbered envelopes. Outcomes: Maternal and cord blood levels of calcium, 25 hydroxy Vit D, vit D binding protein, parathyroid hormone.&lt;/p&gt;" NOTES_MODIFIED="2010-01-05 10:09:51 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>MacDonald HN</AU>
<TI>Fetal and maternal benefits from calcium and vitamin D supplementation of pregnant Asians</TI>
<SO>Personal communication</SO>
<YR>1986</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montanaro-1990" MODIFIED="2010-07-01 20:17:17 +0100" MODIFIED_BY="[Empty name]" NAME="Montanaro 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-07-01 14:56:58 +0100" MODIFIED_BY="Denise Atherton" NOTES="&lt;p&gt;[5804]&lt;/p&gt;" NOTES_MODIFIED="2010-07-01 14:56:58 +0100" NOTES_MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Montanaro D, Boscutti G, Antonucci F, Messa P, Mioni G, Driul P, et al</AU>
<TI>Prevention of pregnancy-induced hypertension (PIH) and pre-eclampsia (PE) by oral calcium supplementation</TI>
<SO>Proceedings of the 10th International Congress of Nephrology; 1987 July 26-31; London, UK</SO>
<YR>1987</YR>
<PG>281</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-01 20:17:17 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[5804]&lt;/p&gt;" NOTES_MODIFIED="2010-07-01 20:17:17 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Montanaro D, Boscutti G, Mioni G, Driul P, Tosolini G</AU>
<TI>Calcium supplementation decreases the incidence of pregnancy-induced hypertension (PIH) and pre-eclampsia (PE)</TI>
<SO>7th World Congress of Hypertension in Pregnancy; 1990; Perugia, Italy</SO>
<YR>1990</YR>
<PG>267</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prada-2001" NAME="Prada 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Prada J, Tsang R, Guo S. Reduction of blood pressure from calcium supplementation in adolescent pregnancy: a randomized trial [abstract]. American Journal of Hypertension 2001;14(4 Pt 2):179A&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prada J, Tsang R, Guo S</AU>
<TI>Reduction of blood pressure from calcium supplementation in adolescent pregnancy: a randomized trial [abstract]</TI>
<SO>American Journal of Hypertension</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>4 Pt 2</NO>
<PG>179A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prada-2002" NAME="Prada 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prada JA, Sibai BM, Guo S</AU>
<TI>Effect of calcium supplementation on the maternal blood pressure of adolescents and twins [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>187</VL>
<NO>6 Pt 2</NO>
<PG>S217</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raman-1978" NAME="Raman 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;[1462]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raman L, Rajalakshmi K, Krishnamachari K, Gowrinath Sastry J</AU>
<TI>Effect of calcium supplementation to undernourished mothers during pregnancy on the bone density of neonates</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1978</YR>
<VL>31</VL>
<PG>466-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Repke-1989" NAME="Repke 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;[4900]&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Repke J, Villar J, Bergel E, Belizan JM</AU>
<TI>The effect of iron absorption in patients receiving calcium supplementation</TI>
<SO>9th Annual Meeting of the Society of Perinatal Obstetricians; 1989 February 1-4; New Orleans, Louisiana, USA</SO>
<YR>1989</YR>
<PG>512</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salzano-2001" MODIFIED="2014-06-10 12:04:15 +0100" MODIFIED_BY="Heather Maxwell" NAME="Salzano 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-06-10 12:04:15 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salzano P, Felicetti M, Laboccetta A, Borrelli P, Di Domenico A, Borrelli A</AU>
<TI>Prevention of gestational hypertension with calcium, linoleic acid, mono and polyunsaturated fatty acid supplements</TI>
<SO>Minerva Ginecologica</SO>
<YR>2001</YR>
<VL>53</VL>
<NO>4</NO>
<PG>235-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-S_x002d_Ramos-1995" MODIFIED="2010-07-01 20:18:21 +0100" MODIFIED_BY="[Empty name]" NAME="S-Ramos 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;[7490]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Ramos L, Adair CD, Delvalle GO, Gaudier F, Delke I</AU>
<TI>Calcium supplementation in mild preeclampsia remote from term: a prospective randomized double-blind clinical trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<PG>385</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-01 20:18:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[7490]&lt;/p&gt;" NOTES_MODIFIED="2010-07-01 20:18:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Ramos L, Adair D, Kaunitz AM, Briones DK, Delvalle GO, Delke I</AU>
<TI>Calcium supplementation in mild pre-eclampsia remote from term: a randomized double-blind clinical trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1995</YR>
<VL>85</VL>
<PG>915-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suzuki-1996" MODIFIED="2014-06-10 12:04:47 +0100" MODIFIED_BY="Heather Maxwell" NAME="Suzuki 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-06-10 12:04:47 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;. [9404]&lt;/p&gt;" NOTES_MODIFIED="2014-06-10 12:04:47 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Suzuki Y, Itoh Y, Hayashi Y, Murakami I, Yamaguchi K, Ohshima T, et al</AU>
<TI>Calcium supplementation to prevent gestational hypertension</TI>
<SO>10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4-8; Seattle, Washington</SO>
<YR>1996</YR>
<PG>113</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamas-1997" MODIFIED="2010-07-01 14:57:14 +0100" MODIFIED_BY="Denise Atherton" NAME="Tamas 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-07-01 14:57:14 +0100" MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tamas P, Szabo I, Szekely J, Csermely T, Prievara FT, Nemeth L, et al</AU>
<TI>Effects of Doxium 500 (R) in gestational hypertension</TI>
<TO>A doxium 500 (R) Hatasanak vizsgalata terhessegi Hypertoniaban (kettos vak, placebo-kontrollalt tanulmany)</TO>
<SO>Magyar Noorvosok Lapja</SO>
<YR>1997</YR>
<VL>60</VL>
<NO>3</NO>
<PG>181-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wanchu-2001" NAME="Wanchu 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wanchu M, Malhotra S, Khullar M</AU>
<TI>Calcium supplementation in pre-eclampsia</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>2001</YR>
<VL>49</VL>
<PG>795-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-02-11 14:43:25 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Asemi-2012" MODIFIED="2014-02-11 14:42:46 +0000" MODIFIED_BY="[Empty name]" NAME="Asemi 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-02-11 14:42:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asemi Z, Tabassi Z, Heidarzadeh Z, Khorammian H, Sabihi SS, Samimi M</AU>
<TI>Effect of calcium-vitamin D supplementation on metabolic profiles in pregnant women at risk for pre-eclampsia: a randomized placebo-controlled trial</TI>
<SO>Pakistan Journal of Biological Sciences</SO>
<YR>2012</YR>
<VL>15</VL>
<NO>7</NO>
<PG>316-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diogenes-2013" MODIFIED="2014-02-11 14:42:46 +0000" MODIFIED_BY="[Empty name]" NAME="Diogenes 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-02-11 14:42:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diogenes ME, Bezerra FF, Rezende EP, Taveira MF, Pinhal I, Donangelo CM</AU>
<TI>Effect of calcium plus vitamin D supplementation during pregnancy in Brazilian adolescent mothers: a randomized, placebo-controlled trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2013</YR>
<VL>98</VL>
<NO>1</NO>
<PG>82-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-2013" MODIFIED="2014-02-11 14:43:25 +0000" MODIFIED_BY="[Empty name]" NAME="Goldberg 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-02-11 14:43:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg GR, Jarjou LM, Cole TJ, Prentice A</AU>
<TI>Randomized, placebo-controlled, calcium supplementation trial in pregnant Gambian women accustomed to a low calcium intake: effects on maternal blood pressure and infant growth</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2013</YR>
<VL>98</VL>
<NO>4</NO>
<PG>972-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-02-11 14:43:25 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-11 14:43:25 +0000" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN96502494"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrera-2006a" MODIFIED="2014-02-11 14:42:46 +0000" MODIFIED_BY="[Empty name]" NAME="Herrera 2006a" YEAR="2006">
<REFERENCE MODIFIED="2014-02-11 14:42:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrera JA, Arevalo-Herrera M, Villegas A, Herrera S, Villalba M, Bromet A</AU>
<TI>Calcium oral supplementation in adolescent pregnant women</TI>
<SO>Colombia Medica</SO>
<YR>2006</YR>
<VL>37</VL>
<NO>2 Suppl 1</NO>
<PG>15-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarjou-2013" MODIFIED="2014-02-11 14:42:46 +0000" MODIFIED_BY="[Empty name]" NAME="Jarjou 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-02-11 14:42:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarjou MA, Yankuba S, Goldberg R, Laskey MA, Cole J, Prentice A</AU>
<TI>Unexpected long-term effects of calcium supplementation in pregnancy on maternal bone outcomes in women with a low calcium intake: a follow-up study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2013</YR>
<VL>98</VL>
<NO>3</NO>
<PG>723-30</PG>
<EN>ISRCTN96502494</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sulovic-2013" MODIFIED="2014-02-11 14:42:46 +0000" MODIFIED_BY="[Empty name]" NAME="Sulovic 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-02-11 14:42:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sulovic N, Kontic-Vucinic O, Sulovic L, Relic G, Nebojsa R</AU>
<TI>Did calcium management prevent preeclampsia?</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>2013</YR>
<VL>41</VL>
<NO>Suppl 1</NO>
<PG>Abstract no:454</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2000" MODIFIED="2012-06-11 21:44:37 +0100" MODIFIED_BY="[Empty name]" NAME="Zheng 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-06-11 21:44:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng QS, Zhang YP</AU>
<TI>Clinical experience with calcium supplementation in pregnancy</TI>
<SO>Journal of Practical Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>2</NO>
<PG>102-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-09-22 15:13:12 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Mahomed-1998" NAME="Mahomed 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Randomised trial. Twin gestation at or before 28 weeks of pregnancy. Treated with calcium 1g in solution or placebo daily. Sample size 400 per group.&lt;/p&gt;" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Mahomed K, Marume A, Hammond N, Madzima M</AU>
<TI>Calcium supplementation for the prevention of pregnancy induced hypertension and preterm labour in twin pregnancies: a randomised controlled trial</TI>
<SO>Personal communication</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-06-10 17:02:40 +0100" MODIFIED_BY="Heather Maxwell">
<ADDITIONAL_REFERENCES MODIFIED="2014-06-10 16:51:57 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Belizan-1980" NAME="Belizan 1980" TYPE="JOURNAL_ARTICLE">
<AU>Belizan JM, Villar J</AU>
<TI>The relationship between calcium intake and edema, proteinuria, and hypertension-gestosis: an hypothesis</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1980</YR>
<VL>33</VL>
<PG>2202-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Belizan-1988" NAME="Belizan 1988" TYPE="JOURNAL_ARTICLE">
<AU>Belizan JM, Villar J, Repke J</AU>
<TI>The relationship between calcium intake and pregnancy-induced hypertension: up-to-date evidence</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1988</YR>
<VL>158</VL>
<PG>898-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Belizan-1997" MODIFIED="2014-06-10 16:43:18 +0100" MODIFIED_BY="Heather Maxwell" NAME="Belizan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Belizan JM, Villar J, Bergel E, del Pino A, Di Fulvio S, Galliano SV, et al</AU>
<TI>Long term effect of calcium supplementation during pregnancy on the blood pressure of offspring: follow up of a randomised controlled trial</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergel-2002" MODIFIED="2010-02-23 22:33:55 +0000" MODIFIED_BY="[Empty name]" NAME="Bergel 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bergel E, Belizan JM</AU>
<TI>A deficient maternal calcium intake during pregnancy increases blood pressure of the offspring in adult rats</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2002</YR>
<VL>109</VL>
<PG>540-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Betr_x00e1_n-2005" MODIFIED="2014-06-10 16:44:54 +0100" MODIFIED_BY="Heather Maxwell" NAME="Betrán 2005" TYPE="JOURNAL_ARTICLE">
<AU>Betrán AP, Wojdyla D, Posner SF, Gülmezoglu AM</AU>
<TI>National estimates for maternal mortality: an analysis based on the WHO systematic review of maternal mortality and morbidity</TI>
<SO>BMC Public Health</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>131</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bucher-1996" NAME="Bucher 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bucher HC, Guyatt GH, Cook RJ</AU>
<TI>Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>275</VL>
<PG>1113-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carroli-1994" NAME="Carroli 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carroli G, Duley L, Belizan JM, Villar J</AU>
<TI>Calcium supplementation during pregnancy: a systematic review of randomised controlled trials</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1994</YR>
<VL>101</VL>
<NO>9</NO>
<PG>753-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carroli-2010" MODIFIED="2014-06-10 16:47:52 +0100" MODIFIED_BY="Heather Maxwell" NAME="Carroli 2010" TYPE="OTHER">
<AU>Carroli G, Merialdi M, Wojdyla D, Abalos E, Campodonico L, Yao SE, et al</AU>
<TI>Effects of calcium supplementation on uteroplacental and fetoplacental blood flow in low-calcium-intake mothers: a randomized controlled trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2010</YR>
<VL>202</VL>
<PG>45.e1-45.e9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clark-2008" MODIFIED="2014-06-10 16:47:15 +0100" MODIFIED_BY="Heather Maxwell" NAME="Clark 2008" TYPE="JOURNAL_ARTICLE">
<AU>Clark SL, Belfort MA, Dildy GA, Herbst MA, Meyers JA, Hankins GD</AU>
<TI>Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2008</YR>
<VL>199</VL>
<NO>1</NO>
<PG>36.e1-e5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CLASP-1994" NAME="CLASP 1994" TYPE="JOURNAL_ARTICLE">
<AU>CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group</AU>
<TI>CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant woman</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<PG>619-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De_x002d_Regil-2012" MODIFIED="2013-06-14 13:56:11 +0100" MODIFIED_BY="[Empty name]" NAME="De-Regil 2012" TYPE="COCHRANE_REVIEW">
<AU>De-Regil LM, Palacios C, Ansary A, Kulier R, Peña-Rosas JP</AU>
<TI>Vitamin D supplementation for women during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-06-14 13:56:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-14 13:56:08 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008873.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duvekot-2002" NAME="Duvekot 2002" TYPE="JOURNAL_ARTICLE">
<AU>Duvekot EJ, de Groot CJ, Bloemenkamp KW, Oei SG</AU>
<TI>Pregnant women with a low milk intake have an increased risk of developing preeclampsia</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2002</YR>
<VL>105</VL>
<PG>11-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Early-Breast-Cancer-Trialists_x0027_--Group-1990" MODIFIED="2014-06-10 16:48:56 +0100" MODIFIED_BY="Heather Maxwell" NAME="Early Breast Cancer Trialists'  Group 1990" TYPE="BOOK_SECTION">
<AU>Early Breast Cancer Trialists' Collaborative Group</AU>
<TI>Statistical methods</TI>
<SO>Treatment of Early Breast Cancer: Vol 1. Worldwide Evidence 1985-1990</SO>
<YR>1990</YR>
<PG>13-8</PG>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ECCPA-1996" NAME="ECCPA 1996" TYPE="JOURNAL_ARTICLE">
<AU>ECPPA (Estudo Collaborativo para Prevenção da Pre-eclampsia com Aspirina) Collaborative Group</AU>
<TI>ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant woman</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1996</YR>
<VL>103</VL>
<PG>39-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamlin-1952" NAME="Hamlin 1952" TYPE="JOURNAL_ARTICLE">
<AU>Hamlin RHJ</AU>
<TI>The prevention of eclampsia and pre-eclampsia</TI>
<SO>Lancet</SO>
<YR>1952</YR>
<VL>i</VL>
<PG>64-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamlin-1962" NAME="Hamlin 1962" TYPE="JOURNAL_ARTICLE">
<AU>Hamlin RHJ</AU>
<TI>Prevention of pre-eclampsia</TI>
<SO>Lancet</SO>
<YR>1962</YR>
<VL>1</VL>
<PG>864-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hatton-2003" NAME="Hatton 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hatton DC, Harrison-Hohner J, Coste S, Reller M, McCarron D</AU>
<TI>Gestational calcium supplementation and blood pressure in the offspring</TI>
<SO>American Journal of Hypertension</SO>
<YR>2003</YR>
<VL>16</VL>
<PG>801-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-08-21 09:16:57 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hiller-2007" MODIFIED="2010-02-04 10:29:54 +0000" MODIFIED_BY="[Empty name]" NAME="Hiller 2007" TYPE="JOURNAL_ARTICLE">
<AU>Hiller JE, Crowther CA, Moore VA, Willson K, Robinson JS</AU>
<TI>Calcium supplementation in pregnancy and its impact on blood pressure in children and women: follow up of a randomised controlled trial</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>2007</YR>
<VL>47</VL>
<NO>2</NO>
<PG>115-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-HMSO-1994" NAME="HMSO 1994" TYPE="BOOK">
<AU>HMSO</AU>
<SO>Report on confidential enquiries into maternal deaths in the United Kingdom 1988-1990. Department of Health Welsh Office, Scottish Office Home and Health Department, Department of Health and Social Security, Northern Ireland</SO>
<YR>1994</YR>
<PB>HMSO</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2007" MODIFIED="2010-07-01 14:57:31 +0100" MODIFIED_BY="Denise Atherton" NAME="Hofmeyr 2007" TYPE="JOURNAL_ARTICLE">
<AU>Hofmeyr G, Duley L, Atallah A</AU>
<TI>Dietary calcium supplementation for prevention of pre-eclampsia and related problems: a systematic review and commentary</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2007</YR>
<VL>114</VL>
<NO>8</NO>
<PG>933-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2008" MODIFIED="2010-02-23 22:41:57 +0000" MODIFIED_BY="[Empty name]" NAME="Hofmeyr 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hofmeyr GJ, Mlokoti Z, Nikodem VC, Mangesi L, Ferreira S, Singata M, et al</AU>
<TI>Calcium supplementation during pregnancy for preventing hypertensive disorders is not associated with changes in platelet count, urate, and urinary protein: a randomized control trial</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>3</NO>
<PG>299-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2011" MODIFIED="2013-07-25 10:16:26 +0100" MODIFIED_BY="[Empty name]" NAME="Hofmeyr 2011" TYPE="OTHER">
<AU>Hofmeyr GJ, Novikova N, Singata M, Fawcus S, Oyebajo A, Munjanja S, et al </AU>
<TI>Protocol 11PRT/4028: Long term calcium supplementation in women at high risk of pre-eclampsia: a randomised, placebo-controlled trial (PACTR201105000267371)</TI>
<SO>Lancet http://www.thelancet.com/protocol-reviews/11PRT-4028</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Isezuo-2004" NAME="Isezuo 2004" TYPE="JOURNAL_ARTICLE">
<AU>Isezuo SA, Ekele BA</AU>
<TI>Eclampsia and abnormal QTc</TI>
<SO>West African Journal of Medicine</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>123-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1993" NAME="Johnson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Johnson A, Townshend P, Yudkin P, Bull D, Wilkinson AR</AU>
<TI>Functional abilities at age 4 years of children born before 29 weeks gestation</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<PG>1715-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kazerooni-2003" NAME="Kazerooni 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kazerooni T, Hamze-Nejadi S, Kazerooni T, Hamze-Nejadi S</AU>
<TI>Calcium to creatinine ratio in a spot sample of urine for early prediction of pre-eclampsia</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2003</YR>
<VL>80</VL>
<PG>279-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khan-2006" MODIFIED="2013-06-14 14:18:27 +0100" MODIFIED_BY="[Empty name]" NAME="Khan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF</AU>
<TI>WHO analysis of causes of maternal death: a systematic review</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<PG>1066&#8211;74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kisters-2000" NAME="Kisters 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kisters K, Barenbrock M, Louwen F, Hausberg M, Rahn KH, Kosch M</AU>
<TI>Membrane, intracellular, and plasma magnesium and calcium concentrations in preeclampsia</TI>
<SO>American Journal of Hypertension</SO>
<YR>2000</YR>
<VL>13</VL>
<PG>765-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumru-2003" NAME="Kumru 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kumru S, Aydin S, Simsek M, Sahin K, Yaman M, Ay G</AU>
<TI>Comparison of serum copper, zinc, calcium, and magnesium levels in preeclamptic and healthy pregnant women</TI>
<SO>Biological Trace Element Research</SO>
<YR>2003</YR>
<VL>94</VL>
<PG>105-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Langenveld-2011" MODIFIED="2013-07-25 10:16:52 +0100" MODIFIED_BY="[Empty name]" NAME="Langenveld 2011" TYPE="JOURNAL_ARTICLE">
<AU>Langenveld J, Ravelli AC, van Kaam AH, van der Ham DP, van Pampus MG, Porath M, et al</AU>
<TI>Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: a 7 year retrospective analysis of a national registry</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2011</YR>
<VL>205</VL>
<NO>6</NO>
<PG>540.e1-540.e7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2012" MODIFIED="2013-07-25 10:17:03 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2012" TYPE="JOURNAL_ARTICLE">
<AU>Li K, Kaaks R, Linseisen J, Rohrmann S</AU>
<TI>Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg)</TI>
<SO>Heart</SO>
<YR>2012</YR>
<VL>98</VL>
<NO>12</NO>
<PG>920-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGarvey-1991" NAME="McGarvey 1991" TYPE="JOURNAL_ARTICLE">
<AU>McGarvey ST, Zinner SH, Willett WC, Rosner B</AU>
<TI>Maternal prenatal dietary potassium, calcium, magnesium and infant blood pressure</TI>
<SO>Hypertension</SO>
<YR>1991</YR>
<VL>17</VL>
<PG>218-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHBPEP-2000" MODIFIED="2014-06-10 16:51:32 +0100" MODIFIED_BY="Heather Maxwell" NAME="NHBPEP 2000" TYPE="JOURNAL_ARTICLE">
<AU>National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy</AU>
<TI>Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>183</VL>
<PG>S1-S22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHMRC-1993" MODIFIED="2014-06-10 16:51:57 +0100" MODIFIED_BY="Heather Maxwell" NAME="NHMRC 1993" TYPE="BOOK">
<AU>NHMRC</AU>
<SO>NHMRC Report on Maternal Deaths in Australia 1988-1990</SO>
<YR>1993</YR>
<PB>Government Publishing Service</PB>
<CY>Canberra</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ozkan-2011" MODIFIED="2013-07-25 10:18:22 +0100" MODIFIED_BY="[Empty name]" NAME="Ozkan 2011" TYPE="JOURNAL_ARTICLE">
<AU>Ozkan H, Cetinkaya M, Koksal N, Ozmen A, Y&#305;ld&#305;z M</AU>
<TI>Maternal preeclampsia is associated with an increased risk of retinopathy of prematurity</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>2011</YR>
<VL>39</VL>
<NO>5</NO>
<PG>523-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Repke-1991" NAME="Repke 1991" TYPE="JOURNAL_ARTICLE">
<AU>Repke JT, Villar J</AU>
<TI>Pregnancy-induced hypertension and low birth weight: the role of calcium</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1991</YR>
<VL>54</VL>
<PG>237S-241S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-08-02 12:31:35 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rumbold-2008" MODIFIED="2013-07-11 11:21:26 +0100" MODIFIED_BY="[Empty name]" NAME="Rumbold 2008" TYPE="COCHRANE_REVIEW">
<AU>Rumbold A, Duley L, Crowther CA, Haslam RR</AU>
<TI>Antioxidants for preventing pre-eclampsia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-06-14 14:13:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-14 14:13:32 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004227.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Segovia-2004" NAME="Segovia 2004" TYPE="JOURNAL_ARTICLE">
<AU>Segovia BL, Vega IT, Villarreal EC, Licona NA</AU>
<TI>Hypocalciuria during pregnancy as a risk factor of preeclampsia</TI>
<SO>Ginecologia y Obstetricia de Mexico</SO>
<YR>2004</YR>
<VL>72</VL>
<PG>570-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-1983" NAME="Villar 1983" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Belizan JM, Fischer PJ</AU>
<TI>Epidemiologic observations on the relationship between calcium intake and eclampsia</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1983</YR>
<VL>21</VL>
<PG>271-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-1989" NAME="Villar 1989" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Repke J, Markush L, Calvert W, Rhoads G</AU>
<TI>The measuring of blood pressure during pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>161</VL>
<PG>1019-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-1993" NAME="Villar 1993" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Belizan JM, Fisher PJ</AU>
<TI>Epidemiologic observation on the relationship between calcium intake and eclampsia</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1993</YR>
<VL>21</VL>
<PG>271-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-1994" NAME="Villar 1994" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Ezcurra EJ, Gurtner de la Fuente V, Campodonico L</AU>
<TI>Preterm delivery syndrome: the unmet need</TI>
<SO>Research and Clinical Forums</SO>
<YR>1994</YR>
<VL>16</VL>
<PG>9-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-1998" NAME="Villar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Gulmezoglu AM, de Onis M</AU>
<TI>Nutritional and antimicrobial interventions to prevent preterm birth: an overview of randomized controlled trials</TI>
<SO>Obstetrical and Gynecological Survey</SO>
<YR>1998</YR>
<VL>53</VL>
<NO>9</NO>
<PG>575-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-2000" NAME="Villar 2000" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Belizan JM</AU>
<TI>Same nutrient, different hypotheses: disparities in trials of calcium supplementation during pregnancy</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2000</YR>
<VL>71 Suppl</VL>
<PG>1375S-1379S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-2004" MODIFIED="2010-07-01 14:57:55 +0100" MODIFIED_BY="Denise Atherton" NAME="Villar 2004" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Say L, Shennan A, Lindheimer M, Duley L, Conde-Agudelo A, et al</AU>
<TI>Methodological and technical issues related to the diagnosis, screening, prevention and treatment of pre-eclampsia and eclampsia</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2004</YR>
<VL>85</VL>
<NO>Suppl 1</NO>
<PG>S28-S41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-von-Dadelszen-2004" MODIFIED="2010-07-01 14:58:04 +0100" MODIFIED_BY="Denise Atherton" NAME="von Dadelszen 2004" TYPE="JOURNAL_ARTICLE">
<AU>von Dadelszen P, Magee LA, Devarakonda RM, Hamilton T, Ainsworth LM, Yin R, et al</AU>
<TI>The prediction of adverse maternal outcomes in pre-eclampsia</TI>
<SO>Journal of Obstetrics and Gynaecology Canada: JOGC</SO>
<YR>2004</YR>
<VL>26</VL>
<PG>871-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2011" MODIFIED="2013-07-25 10:19:06 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2011" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia</TI>
<SO>whqlibdoc.who.int/publications/2011/9789241548335_eng.pdf</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yamasmit-2004" NAME="Yamasmit 2004" TYPE="JOURNAL_ARTICLE">
<AU>Yamasmit W, Chaithongwongwatthana S, Charoenvidhya D, Uerpairojkit B, Tolosa J</AU>
<TI>Random urinary protein-to-creatinine ratio for prediction of significant proteinuria in women with preeclampsia</TI>
<SO>Journal of Maternal-Fetal &amp; Neonatal Medicine</SO>
<YR>2004</YR>
<VL>16</VL>
<PG>275-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2007" MODIFIED="2010-02-23 22:47:59 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zhang J, Villar J, Sun W, Merialdi M, Abdel-Aleem H, Mathai M, et al</AU>
<TI>Blood pressure dynamics during pregnancy and spontaneous preterm birth</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>197</VL>
<NO>2</NO>
<PG>162.e1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-06-10 17:02:40 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Duley-1995" NAME="Duley 1995" NOTES="&lt;p&gt;Routine calcium supplementation in pregnancy. [revised 23 June 1993] In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration; Issue 2, Oxford: Update Software; 1995&lt;/p&gt;" TYPE="OTHER">
<AU>Duley L</AU>
<TI>Routine calcium supplementation in pregnancy</TI>
<SO>[revised 23 June 1993] In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration; Issue 2, Oxford: Update Software; 1995</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2002" MODIFIED="2014-06-10 17:02:40 +0100" MODIFIED_BY="Heather Maxwell" NAME="Hofmeyr 2002" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ, Atallah AN, Duley L</AU>
<TI>Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-06-10 17:01:41 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2014-06-10 17:01:41 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD001059"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2006" MODIFIED="2014-06-10 16:59:22 +0100" MODIFIED_BY="Heather Maxwell" NAME="Hofmeyr 2006" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ, Atallah ÁN, Duley L.</AU>
<TI>Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-06-10 16:58:04 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2014-06-10 16:58:04 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD001059.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2010" MODIFIED="2014-06-10 16:55:18 +0100" MODIFIED_BY="Heather Maxwell" NAME="Hofmeyr 2010" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ, Lawrie TA, Atallah ÁN, Duley L</AU>
<TI>Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2014-03-06 13:19:33 +0000" MODIFIED_BY="Leanne V Jones">
<IDENTIFIER MODIFIED="2014-03-06 13:19:33 +0000" MODIFIED_BY="Leanne V Jones" TYPE="DOI" VALUE="10.1002/14651858.CD001059.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-11-17 11:12:34 +0000" MODIFIED_BY="Jill V Hampson"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-06-13 15:05:44 +0100" MODIFIED_BY="Leanne V Jones">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-06-13 15:05:44 +0100" MODIFIED_BY="Leanne V Jones" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-07-24 16:30:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Almirante-1998">
<CHAR_METHODS MODIFIED="2013-07-24 16:28:11 +0100" MODIFIED_BY="[Empty name]">
<P>&#8220;divided into two groups and followed up until delivery.&#8221;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 16:30:11 +0100" MODIFIED_BY="[Empty name]">
<P>430 pregnant women who were nulliparas, adolescents and elderly.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-16 15:36:37 +0100" MODIFIED_BY="[Empty name]">
<P>Group B 212 women received 500 mg elemental calcium from 16-20 weeks till delivery; Group A 210 women served as controls.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-24 16:30:17 +0100" MODIFIED_BY="[Empty name]">
<P>Pre-eclampsia, preterm birth, admission to NICU.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-24 16:30:18 +0100" MODIFIED_BY="[Empty name]">
<P>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:56:08 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Bassaw-1998">
<CHAR_METHODS MODIFIED="2014-06-11 10:55:38 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomised clinical trial. Participants were alternately allocated to either the supplemented or to the control groups in order to match for age, parity, ethnic group and body mass index. Data from the 'control' group were not used in this analysis. Randomisation was conducted by the pharmacist using a table of random numbers, and supplements were distributed to the participants in sealed envelopes. Clinicians were unaware whether the participants were in the supplemented or control groups, and which supplementation was administered.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-11 10:15:57 +0100" MODIFIED_BY="Heather Maxwell">
<P>Pregnant women recruited into the study before 20 weeks&#8217; gestation primigravidae, or multigravidae with obstetric history of pre-eclampsia. Participants were normotensive and urinalysis was negative for albuminuria. None had any underlying medical disorders such as chronic hypertension, renal disease, diabetes mellitus and collagen vascular disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-11 10:55:51 +0100" MODIFIED_BY="Heather Maxwell">
<P>2 calcium tablets (1200 mg elemental calcium), a combination of 1 calcium tablet and 1 baby Cafenol (80 mg aspirin) or 1 baby Cafenol daily. All participants including the controls received the routine haematinics which were ferrous sulphate (200 mg) and folic acid (5 mg) daily.</P>
<P>There were 114 primigravidae amongst the controls. Of the supplemented groups, 45 primigravidae received aspirin, 36 had calcium and aspirin, and calcium tablets were administered to 42 primigravidae. All of these women were less than 24 years of age.</P>
<P>For this review we have used only data for calcium (600 mg) and Cafenol (80 mg aspirin) vs Cafenol daily (80 mg aspirin).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-11 10:55:57 +0100" MODIFIED_BY="Heather Maxwell">
<P>DBP (measured by the same observer with the participants in a sitting position, recorded at the onset of muffing -phase 4 Korotkoff sound), PIH (BP &#8805; 140/90 mmHg), pre-eclampsia (hypertension plus proteinuria).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-11 10:56:08 +0100" MODIFIED_BY="Heather Maxwell">
<P>8 participants were unavailable for analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:54:58 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Belizan-1991">
<CHAR_METHODS MODIFIED="2014-06-11 10:17:56 +0100" MODIFIED_BY="Heather Maxwell">
<P>Multicentre trial. Numbered, sealed opaque envelopes, containing randomisation codes. Of 593 (calcium) vs 601 (placebo) enrolled, 14 vs 13 were lost before starting treatment and excluded from analysis; 577 vs 588 had at least partial follow-up. Follow-up was incomplete for 52 vs 46, but delivery data were available in 17 vs 12 of these, giving delivery data for 544 vs 554.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-25 10:08:04 +0100" MODIFIED_BY="[Empty name]">
<P>Nulliparous women, &lt; 20 weeks' pregnant; BP &lt; 140/90 mmHg (mean of 5 measurements); no present or past disease; not taking medication; normal oral glucose tolerance tests.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 g calcium as 500 mg calcium carbonate tablets, vs identical looking placebo tablets. Compliance was 84% (calcium) and 86% (placebo).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-11 10:18:36 +0100" MODIFIED_BY="Heather Maxwell">
<P>Gestational hypertension (DBP 90 or more; SBP 140 or more mmHg, on 2 occasions 6 hours apart); pre-eclampsia (gestational hypertension + proteinuria &gt; 0.3 g/L on 2 random urine samples 6 hours apart); BP measured with random-zero sphygmomanometers, Korotkoff sound 5. Perinatal death.<BR/>Follow-up: BP &gt; 95th percentile for sex, age and height for children 5-9 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-11 10:54:58 +0100" MODIFIED_BY="Heather Maxwell">
<P>3 hospitals in Rosario, Argentina. Data for preterm birth given as percentages, not clear what the denominators were. Assumed to be the numbers with complete follow-up (527 vs 542) as these were the numbers which were divisible by the percentages to give whole numbers. Unpublished placental abruption data obtained from authors.</P>
<P>Babies born in the private hospitals followed up at 7 years. Of 614 randomised (calcium 309/placebo 305), 301/299 completed the first study, 2/6 infant deaths and 1/0 maternal deaths had occurred, leaving 298/293 eligible for follow-up. 289/285 were contacted, 10/5 refused to participate, 22/19 lived outside the country, and 257/261 were assessed (88% of those eligible).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-24 16:35:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cong-1995">
<CHAR_METHODS MODIFIED="2013-07-24 16:34:32 +0100" MODIFIED_BY="[Empty name]">
<P>&#8220;Healthy antepartum cases were randomized and divided into 3 groups.&#8221;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 16:34:34 +0100" MODIFIED_BY="[Empty name]">
<P>Healthy primipara.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 16:34:52 +0100" MODIFIED_BY="[Empty name]">
<P>A: 120 mg calcium daily; B: 240 mg calcium daily; C: no calcium (D: 1 g calcium; E: 2 g calcium; E: no calcium not included as trials with high risk of bias not included in high calcium dose review).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-24 16:34:58 +0100" MODIFIED_BY="[Empty name]">
<P>Biochemical studies; hypertension, pre-eclampsia, birthweight, gestational age, method of delivery.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-24 16:35:11 +0100" MODIFIED_BY="[Empty name]">
<P>1<SUP>st</SUP> period (low dose) April 1987 to June 1988 (groups A, B, C); 2nd<SUP>t</SUP> period (high dose) April 1989 to June 1990 (groups C, D, F).</P>
<P>Similar results for groups A and B, which were combined in this meta-analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:51:09 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-CPEP-1997">
<CHAR_METHODS MODIFIED="2014-06-11 10:20:00 +0100" MODIFIED_BY="Heather Maxwell">
<P>Numbered treatment packs in computer-generated simple randomisation sequence. Loss to follow-up: calcium 132/2295 vs placebo 121/2294.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-11 10:51:09 +0100" MODIFIED_BY="Heather Maxwell">
<P>Pregnant nulliparas (45% black, 35% non-Hispanic white, 17% Hispanic white). Passed compliance test (took 75% of placebo over 6-14 days); BP 134/84 mmHg or less; urine protein dipstick negative or trace; 13-21 weeks' pregnant.</P>
<P>Exclusion criteria: taking medications; obstetric or pre-existing diseases or personal characteristics which could influence study end-points, absorption or metabolism of calcium; any risk associated with calcium supplementation, or compliance; elevated serum creatinine (1.0 mg per dL or more) or calcium (10.6 mg per dL or more); renal disease; haematuria; history or family history of urolithiasis; frequent use of calcium supplements or antacids.</P>
<P>Of 11,959 women screened, 5703 excluded initially and a further 1667 after the compliance test. The remaining 4589 women were enrolled.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 g/day elemental calcium as calcium carbonate, or placebo. Taken until delivery, development of pre-eclampsia or suspicion of urolithiasis. All women took 50 mg calcium per day as normal supplementation and were asked to drink 6 glasses of water per day.</P>
<P>Compliance was 64% in the calcium group and 67% in the placebo group. 20% of women took &gt; 90% of the allocated treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-11 10:22:07 +0100" MODIFIED_BY="Heather Maxwell">
<P>Gestational hypertension (DBP sitting, fifth Korotkoff sound unless zero, 90 mmHg or more on 2 occasions, 4 hours-1 week apart); severe gestational hypertension (DBP 110 mmHg twice or treated, or complications); proteinuria (300 mg/24 hours or more, 1+ on 2 occasions 4 hours-1 week apart, 2+ or more, or protein/creatinine ratio 0.35 or more); pre-eclampsia (gestational hypertension + proteinuria within 7 days of each other); severe pre-eclampsia (50/2163 vs 59/2173); renal insufficiency (21/2163 vs 23/2173); urolithiasis (1/2163 vs 3/2173); prematurity (&lt; 37 weeks); baby small-for-gestational age (124/2163 vs 105/2173); perinatal death.<BR/>A limited follow-up of mothers and infants found to have reduced SBP at 2 years of age in the calcium supplementation group (mean 95.4 mmHg, SD 7.6, n = 35 vs 100.2, 7.9, n = 18). The data have not been included in this review because of the low and unequal follow-up rate (35 and 18 from 497 invited to participate) limit the reliability of the results.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-15 15:42:45 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre trial, 5 US university centres. Maternal outcomes reported as percentages of the whole number enrolled. In this review, denominators of 2163 (calcium) and 2173 (placebo) have been used. Neonatal outcomes in the report are based on live births (2134 and 2139). Addition of abortions and fetal deaths brings these numbers to 2156 and 2166. It is not clear why a discrepancy in numbers remains.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:23:52 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Crowther-1999">
<CHAR_METHODS MODIFIED="2010-03-04 12:54:41 +0000" MODIFIED_BY="[Empty name]">
<P>Central telephone randomisation, stratified by centre using variable blocks. Double-blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-15 15:43:18 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: nulliparous women; singleton pregnancy; &lt; 24 weeks' gestation; BP &lt; 140/90 mmHg; expected to give birth at a collaborating centre.<BR/>Exclusion criteria: antihypertensive therapy; medical contraindication to calcium supplementation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-04 13:19:41 +0000" MODIFIED_BY="[Empty name]">
<P>Calcium carbonate 1.8 g daily or lactose placebo tablets, from 20-24 weeks until birth.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-24 16:38:07 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: PIH (DBP 90 mmHg or more on 2 consecutive occasions 4 hours apart, or 110 mmHg once; pre-eclampsia (as above plus proteinuria 0.3 g or more per 24 hours or 2+ protein or more on 2 random clean-catch urine samples); preterm birth (&lt; 37 weeks).<BR/>Secondary: severe PIH (DBP 110 or more on 2 occasions 4 hours apart, or 120 or more once); severe pre-eclampsia (as above plus proteinuria); very preterm birth (&lt; 32 weeks; extremely preterm birth (&lt; 28 weeks); maternal fetal and infant events after trial entry.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-11 10:23:52 +0100" MODIFIED_BY="Heather Maxwell">
<P>5 hospitals in Australia. August 1992 to December 1996.<BR/>Estimated sample size 948. Trial stopped prematurely for financial reasons.<BR/>31% in the calcium group and 24% in the placebo group stopped taking the tablets during the trial. Analysis was by Intention-to-treat.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:58:56 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Herrera-1998">
<CHAR_METHODS MODIFIED="2013-06-01 10:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation sequence was generated using random number tables, and prepared by an administrative staff member.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 16:38:28 +0100" MODIFIED_BY="[Empty name]">
<P>1676 healthy primigravid women screened. Primigravidas with risk factors for pre-eclampsia (high biopsychosocial risk, positive roll-over test and high mean BP (&gt; 85 mmHg) selected.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 16:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>450 mg linoleic acid plus 600 mg calcium (n = 44) vs identical looking placebos (n = 45) in the third trimester.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-24 16:38:37 +0100" MODIFIED_BY="[Empty name]">
<P>Biochemical studies; maternal and neonatal clinical outcomes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-11 10:58:56 +0100" MODIFIED_BY="Heather Maxwell">
<P>May 1995 to May 1996, 3 hospital outpatient clinics in Cali, Columbia.</P>
<P>1 study group excluded for taking ASA;  2 from control group lost to follow-up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-13 15:05:44 +0100" MODIFIED_BY="Leanne V Jones" STUDY_ID="STD-Herrera-2006">
<CHAR_METHODS MODIFIED="2013-07-24 16:39:00 +0100" MODIFIED_BY="[Empty name]">
<P>"The participants were allocated in two random groups."</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-13 15:05:44 +0100" MODIFIED_BY="Leanne V Jones">
<P>220 primigravid women screened for abnormal Doppler ultrasound in uterine or arcuate arteries (diastolic notch) from week 18 to 22 of gestation. Primigravidas &lt; 19 years or &gt; 35 years, 18 to 22 weeks with risk factors for pre-eclampsia including reliable family history of PE were included. Those with DBP of 85 mm Hg or more at the first antenatal visit, cardiovascular or renal disease, or hypertensive or taking any medication at the time were excluded. Mean daily calcium intake was also similar at study entry (601.5 mg [range, 310&#8212;1101 mg] vs 576.0 mg [314&#8212;936 mg]; P = 0.94)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-11 10:29:57 +0100" MODIFIED_BY="Heather Maxwell">
<P>450 mg conjugated linoleic acid plus 600 mg calcium (n = 25)  vs placebo (n = 25) from 18 to 22 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-24 16:39:49 +0100" MODIFIED_BY="[Empty name]">
<P>Biochemical studies.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-13 15:05:27 +0100" MODIFIED_BY="Leanne V Jones">
<P>March 2001 to March 2003; 4 outpatient clinics in Bangladesh and Colombia.</P>
<P>220 women screened; eco-Doppler ultrasound positive in 53 women; three eligible women refused to participate.</P>
<P>1 woman from the control group was lost during the follow-up (change of residence) and 1 woman from the supplemented group withdrew.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:30:40 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Jarjou-2004">
<CHAR_METHODS MODIFIED="2014-06-11 10:30:40 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomised double-blind placebo-controlled trial conducted in The Gambia between 1995 and 2000.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-24 14:30:26 +0100" MODIFIED_BY="[Empty name]">
<P>662 pregnant women were randomised; 452 of 546 live born children were followed up.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 16:40:28 +0100" MODIFIED_BY="[Empty name]">
<P>1500 mg calcium (Ca) orally per day or placebo from 20 weeks' gestation until delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-25 10:22:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Maternal BP at 36 - 38 weeks' gestation.<BR/>2. Breast-milk calcium concentration during lactation.<BR/>3. Postpartum bone mineral content of mother and baby.</P>
<P>4. Cardiovascular risk in offspring.</P>
<P>5. BP in offspring (Hawkesworth 2011). Follow-up of 350 children (64%). There were no differences in mean BP measurements.</P>
<P>6. Maternal plasma 25 hydroxyvitamin D, birthweight and infant growth and bone mineral accretion (Prentice 2009).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-25 10:08:15 +0100" MODIFIED_BY="[Empty name]">
<P>To our knowledge, maternal BP outcomes have not yet been reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:52:15 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Kumar-2009">
<CHAR_METHODS MODIFIED="2010-03-05 10:00:42 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-25 10:08:16 +0100" MODIFIED_BY="[Empty name]">
<P>Healthy normotensive primigravid women with uncomplicated single pregnancy; pregnancy 12 to 25 weeks' gestation, known date of the last menstrual period, and intention to deliver at Lok Nayak Hospital, New Delhi. Study population had a low dietary calcium.</P>
<P>Exclusions:  multiple pregnancy, polyhydramnios, fetal malformations, diabetes, chronic hypertension, renal disease, cardiovascular disease, urolithiasis, or BP of 140/90 mmHg or higher at first visit or at enrolment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-15 15:44:29 +0000" MODIFIED_BY="[Empty name]">
<P>4 tablets (2 g calcium or placebo) were taken daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-11 10:52:15 +0100" MODIFIED_BY="Heather Maxwell">
<P>Pre-eclampsia (SBP &gt; 140 mmHg and DBP &gt; 90 mmHg on 2 occasions 4 hours apart after 20 weeks' pregnancy in women normotensive previously, together with proteinuria &gt; 300 mg/24 h or 1+ on a clean-catch dipstick in the absence of urinary infection); eclampsia; preterm delivery; caesarean section.</P>
<P>Baseline characteristics comparable.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-11 10:32:37 +0100" MODIFIED_BY="Heather Maxwell">
<P>Imbalanced groups: 290 allocated to calcium, 262 to placebo group.  17 and 11 lost to follow-up so 273 and 251 analysed respectively. <I>See</I> below.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-15 15:45:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-L_x002d_Jaramillo-1989">
<CHAR_METHODS>
<P>Assigned independently in sequence using a table of random numbers. All 106 women enrolled completed the study (calcium 55, placebo 51), 14 women who delivered at 36-38 weeks excluded (calcium 6, placebo 8), none developed gestational hypertension. These women are included in this review.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-15 15:45:29 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: nulliparity; age 25 years or less; certain menstrual dates; clinic attendance before 24 weeks' gestation; residence in Quito; normotensive; no medical disorders; not taking medication or vitamin/mineral preparations.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-15 15:45:39 +0000" MODIFIED_BY="[Empty name]">
<P>Calcium supplementation with 4 calcium gluconate tablets daily, each containing 500 mg elemental calcium, from after 23 weeks' gestation till delivery, vs identical placebo tablets.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Gestational hypertension (BP 140/90 mmHg or more, or rise of 30 mmHg systolic or 15 mmHg diastolic, on 2 occasions 6 hours apart); weekly weight gain, mean (SEM) (calcium 412 (26) vs placebo 452 (28) g); birthweight (3097 (40) vs 2832 (50) g); length of gestation (39.3 (0.08) vs 38.7 (0.07) weeks).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quito, Ecuador (altitude 2800 m). 1984 to 1986. An earlier report of apparently the same study gave an incidence of gestational hypertension of calcium 3/46 vs placebo 13/46 (Lopez-Jaramillo 1987).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-15 15:46:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-L_x002d_Jaramillo-1990">
<CHAR_METHODS>
<P>Randomised, double-blind trial. Stated "Each patient was assigned independently in sequence", and "All women completed the study".</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Healthy nulliparous women with positive roll-over test at 28-30 weeks' gestational age - judged at high risk for gestational hypertension.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-15 15:46:08 +0000" MODIFIED_BY="[Empty name]">
<P>2000 mg elemental calcium daily, from 28-32 weeks to delivery, vs placebo starch tablets.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Gestational hypertension (BP &gt; 140/90 mmHg on 2 occasions 6 hours apart); proteinuria (300 mg/L); duration of pregnancy (calcium mean 39.2 (SD 1.2) vs placebo 37.4 (2.3) weeks); birthweight (2936 (396) vs 2685 (427) g).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-05 10:34:12 +0000" MODIFIED_BY="[Empty name]">
<P>Quito, Ecuador (altitude 2800 m). 22 in calcium group, 34 in placebo group. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:34:04 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-L_x002d_Jaramillo-1997">
<CHAR_METHODS MODIFIED="2014-06-11 10:34:04 +0100" MODIFIED_BY="Heather Maxwell">
<P>Prospective, randomised, double-blind, placebo-controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: age &lt; 17.5 years; nulliparous; first prenatal visit before 20 weeks' gestation; certain menstrual dates; residency in Quito for at least 1 year; BP =/&lt; 120/80 mmHg; no underlying medical disorders; no drug, mineral or vitamin therapy. Average daily calcium intake in this population is 51% of the recommended dietary allowance.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-25 10:11:45 +0100" MODIFIED_BY="[Empty name]">
<P>Elemental calcium 2 g daily as calcium carbonate from 20 weeks (n = 134), vs placebo tablets (n = 140).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-25 10:11:47 +0100" MODIFIED_BY="[Empty name]">
<P>Pre-eclampsia (BP &gt; 140/90 mmHg on 2 occasions &gt; 6 hours apart, and proteinuria &gt; 300 mg/L (&gt; 1+ on dipstick on 2 occasions 4-24 hours apart). BP recorded as mean of 2 measurements, 2 minutes apart, in the right arm, in the sitting position (1st and 5th Korotkoff sounds).</P>
<P>Maternal serum ionised calcium at 38 weeks was calcium group mean 1.23, SD 0.02 mM vs placebo 1.16, 0.02; umbilical cord serum ionised calcium levels were calcium 1.44, 0.04 vs placebo 1,37, 0.03; gestational length was calcium 39.6, 0.4 vs placebo 38.7, 0.3.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quito, Ecuador (altitude 2800 m). 1990 to 1995.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:56:48 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Li-2000">
<CHAR_METHODS MODIFIED="2013-07-24 16:42:43 +0100" MODIFIED_BY="[Empty name]">
<P>"Patients were divided into 3 groups."</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-11 10:56:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>High-risk women with a predisposition to PIH.  Participants were required to be at 20-24 weeks' gestation when entering the study, with a BMI index of &lt; 24,  and an arterial pressure of &lt; 11.3 kPa. Study states only that participants were &#8216;selected from our hospital outpatient clinic and labour ward&#8217;.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 16:43:06 +0100" MODIFIED_BY="[Empty name]">
<P>The first group (n = 29) received a daily dose of 600 mg of Calictrate-D, the second group(n = 29) received 1200 mg if Calcitrate-D daily, and the third group (n = 30) the control group, received nothing. From 20-24 weeks till birth.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-24 16:43:10 +0100" MODIFIED_BY="[Empty name]">
<P>Hypertension; biochemical studies.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-24 16:43:16 +0100" MODIFIED_BY="[Empty name]">
<P>The outpatient clinic and labour ward of the First Afifliated Hospital of Xi&#8217;an Medical University.</P>
<P>Aug 1996 to Dec 1998. No information on consent or ethical approval.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-25 10:11:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marya-1987">
<CHAR_METHODS MODIFIED="2013-07-24 16:43:23 +0100" MODIFIED_BY="[Empty name]">
<P>"Randomly selected."</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 16:43:30 +0100" MODIFIED_BY="[Empty name]">
<P>400 pregnant women 20 to 35 years old attending antenatal clinic.  Dietary intake about 500 mg calcium and 40 IU vit D daily.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-25 10:11:48 +0100" MODIFIED_BY="[Empty name]">
<P>200 women daily supplement calcium 375 mg plus vitamin D 1200 IU from 20 to 24 weeks of pregnancy onwards, vs 200 women no supplement.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-24 16:43:45 +0100" MODIFIED_BY="[Empty name]">
<P>"Toxaemia", biochemical studies, mean BP.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-24 16:43:46 +0100" MODIFIED_BY="[Empty name]">
<P>Medical College Hospital, Rohtak, India.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:55:03 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Niromanesh-2001">
<CHAR_METHODS MODIFIED="2014-06-11 10:36:39 +0100" MODIFIED_BY="Heather Maxwell">
<P>Double-blind, placebo-controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-11 10:36:55 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women at high risk for pre-eclampsia: positive 'roll-over' test and at least 1 risk factor for pre-eclampsia; 28-32 weeks' pregnant; BP &lt; 140/90 mmHg. Exclusion criteria: chronic medical conditions.<BR/>Not defined as low- or adequate calcium intake (from table 1 dairy intake appears to be about 200 mL + 400 g per day).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Elemental calcium 2 g daily (500 mg 6-hourly) or placebo, coded by the pharmacy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-15 15:47:36 +0000" MODIFIED_BY="[Empty name]">
<P>Pre-eclampsia: an increase (30 mmHg) of SBP above 14 mmHg and an increase (15 mmHg) of DBP above 90 mmHg, twice 4-6 hours apart, with proteinuria 1+; duration of pregnancy (39.5 SD 0.8 vs 37.7 SD 2.5 weeks); birthweight (3316 SD 308 vs 2764 SD 761 g); weekly maternal weight increase (no difference).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-11 10:55:03 +0100" MODIFIED_BY="Heather Maxwell">
<P>No loss to follow-up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:37:37 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Purwar-1996">
<CHAR_METHODS MODIFIED="2014-06-11 10:37:37 +0100" MODIFIED_BY="Heather Maxwell">
<P>Prospective, randomised, double-blind, placebo-controlled trial. Allocated by means of a computer-generated randomisation list. After randomisation, 11/201 (5.5%) women lost to follow-up (calcium 6, placebo 5).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Calcium intake mean 336 mg (calcium) and 352 mg (placebo group) per day.<BR/>Inclusion criteria: nulliparity; normal single viable pregnancy; known dates; antenatal clinic before 20 weeks; intending to deliver in the same institute; normal glucose tolerance test; no hypertension; no underlying medical disorders.</P>
<P>Exclusion criteria: renal disease; collagen vascular disease; chronic hypertension; endocrinological disease; taking medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral calcium containing 2 g elemental calcium daily (n = 103), compared with identical placebo tablets (n = 98), taken from 20 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Gestational hypertension (SBP &gt; 140 mmHg and DBP &gt; 90 mmHg, twice 6 hours apart) and pre-eclampsia (hypertension + proteinuria =/&gt; 0.3 g/24 hours).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nagpur, India.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:57:04 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Rogers-1999">
<CHAR_METHODS MODIFIED="2014-06-11 10:57:04 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomised to control vs aspirin vs calcium in ratio 1 ;2 ;2 using 5 unsealed envelopes, selected by participants.  Imbalance suggested that &#8216;something went wrong&#8217;, perhaps tendency for participants to select from a certain part of the pile of envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 16:44:45 +0100" MODIFIED_BY="[Empty name]">
<P>500 primiparous Chinese women in 2<SUP>nd</SUP> trimester with sitting MAP 80 to 106 mmHg screened at 22-24 weeks with rested left lateral automated BP (cut-off MAP 60 mmHg). 369 selected: calcium 154, aspirin 132, control 83.  32 delivered elsewhere and excluded. Leaving 337.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 16:44:51 +0100" MODIFIED_BY="[Empty name]">
<P>Aspirin 80 mg daily from 22 weeks vs calcium 600 mg daily from 22 to 32 weeks, then 1200 mg daily vs control.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-24 16:44:52 +0100" MODIFIED_BY="[Empty name]">
<P>Hypertension, pre-eclampsia, mean BP.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-24 16:44:53 +0100" MODIFIED_BY="[Empty name]">
<P>July 1992 to Dec 1994.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:40:39 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Rumiris-2006">
<CHAR_METHODS MODIFIED="2013-07-24 16:45:05 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled trial. Participants randomised according to a computer-generated random number sequence by an independent third party who had no conflict of interest in the study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 16:46:11 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnant women with low antioxidant status at 8 to 12 weeks of gestation. <I>Exclusion criteria: </I>
</P>
<P>1) history or current use of anti-hypertensive medication or diuretics; </P>
<P>2) use of vitamins C &gt; 150 mg and/ or E &gt; 75 IU per day;</P>
<P>3) known placental abnormalities;</P>
<P>4) current pregnancy as a result of in vitro fertilization; </P>
<P>5) regular use of platelet active drugs or non-steroidal anti-inflammatory drugs (NSAIDs); </P>
<P>6) known fetal abnormalities;</P>
<P>7) documented uterine bleeding within a week of screening;</P>
<P>8) uterine malformations;  </P>
<P>9) history of medical complications. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-11 10:40:39 +0100" MODIFIED_BY="Heather Maxwell">
<P>Supplementation  with  calcium (800 mg), N-acetylcysteine (200 mg), Cu (2 mg), Zn (15 mg), Mn (0.5 mg), and selenium (100 mcg) and vitamins A (1000 IU), B6 (2.2 mg), B12 (2.2 mcg), C (200 mg), and E (400 IU), from 8 to 12 weeks of gestation throughout pregnancy.</P>
<P>Both groups received Fe (30 mg) and folic acid (400 mcg).</P>
<P>Placebo supplement&#8217;s size and appearance were matched with those of antioxidants.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-24 16:46:38 +0100" MODIFIED_BY="[Empty name]">
<P>Maternal - pre-eclampsia, hypertension, proteinuria and abortion.</P>
<P>Perinatal - intrauterine growth restriction, intrauterine fetal death, preterm delivery (before 37 weeks).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:40:56 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-S_x002d_Ramos-1994">
<CHAR_METHODS MODIFIED="2014-06-11 10:40:56 +0100" MODIFIED_BY="Heather Maxwell">
<P>Double-blind placebo-controlled trial. 4/33 allocated calcium lost to follow-up.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-08 11:09:41 +0000" MODIFIED_BY="[Empty name]">
<P>Normotensive nulliparas; positive roll-over test (281/1065) and positive angiotensin II infusion test at 20-24 weeks' gestation (67/281). 67 allocated to calcium (33) or placebo (34).<BR/>Exclusion criteria: factors increasing the risk of gestational hypertension, including renal disease, collagen vascular disease, diabetes mellitus, chronic hypertension, multifetal pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-25 10:11:50 +0100" MODIFIED_BY="[Empty name]">
<P>Calcium supplementation with 2 g per day elemental calcium as 500 mg calcium carbonate tablets, vs identical placebo tablets. Compliance checked with electronic pillboxes. Compliance was 79% vs 81%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-24 16:28:25 +0100" MODIFIED_BY="[Empty name]">
<P>Gestational hypertension (BP at least 140/90 mmHg on 2 occasions 4-6 hours apart, on bedrest in hospital); pre-eclampsia (gestational hypertension + proteinuria: 1+ or 300 mg/24 hours); severe pre-eclampsia (pre-eclampsia plus 1 of BP at least 160 mmHg systolic or 110 mmHg diastolic; proteinuria at least 5 g/24 hours; oliguria &lt; 400 ml per day; elevated liver enzymes; thrombocytopenia &lt; 100,000/microlitre; pulmonary oedema; severe epigastric pain).</P>
<P>Birthweight (calcium 3245 (SD 414) vs placebo 3035 (542) g); mean gestational ages (35.6 vs 34.4 weeks); 5 minute Apgar &lt; 7 (1/29 vs 1/34); cord arterial pH (7.25 (0.07) vs 7.20 (0.07)); fetal growth impairment (2/29 vs 4/34).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jacksonville, Florida, USA. University hospital serving low-income population.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:57:15 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Taherian-2002">
<CHAR_METHODS MODIFIED="2013-07-24 16:51:29 +0100" MODIFIED_BY="[Empty name]">
<P>&#8220;Healthy antepartum cases were randomized and divided into 3 groups.&#8221;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-11 10:42:07 +0100" MODIFIED_BY="Heather Maxwell">
<P>990 nulliparous women, single pregnancy, first prenatal visit before 20 weeks of gestation, SDP/DBP lower than 130/80 mmHg, and no proteinuria detectable by a dipstick. Participants were excluded if they had a history of cardiovascular, renal or endocrinologic problems, medical or obstetric complications and those with known hazardous condition (multifetal gestation, hydatidiform mole).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-25 10:03:12 +0100" MODIFIED_BY="[Empty name]">
<P>Group 1 received 75 mg aspirin each day from 20<SUP>th</SUP> week of pregnancy till delivery; group 2 were treated with 500 mg oral calcium-D daily (calcium<B>-</B>D = 500 mg calcium carbonate + 200 IU vitamin D); and the control group 3 received no medication at all.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-11 10:57:15 +0100" MODIFIED_BY="Heather Maxwell">
<P>Participants were considered to have mild pre-eclampsia if they demonstrated an increase of 30 mmHg in systolic or 15 mmHg in DBP above the standard pressure. In addition, they should have demonstrated equal or greater than 300 mg/24 hours in urine collection, or in 2 random urine specimens obtained 4 hours apart and containing at least 1+ protein by the dipstick method. Severe pre-eclampsia was defined as BP equal or greater than 160/110 mmHg and 4+ protein by dipstick</P>
<P>on 2 occasions 4 hours apart.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-24 16:52:53 +0100" MODIFIED_BY="[Empty name]">
<P>April 1998 to March 2001. Antenatal outpatient clinics of Isfahan Health Centers.</P>
<P>Data presented as percentages with no individual n values. Have extrapolated n values from numbers and percentages given for main outcome PE (Aspirin 326, calcium 325, control 327) and calculated other numbers from percentages reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-08 11:32:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Villar-1987">
<CHAR_METHODS MODIFIED="2010-03-08 11:32:17 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised controlled trial. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: nulliparous or primiparous; known menstrual dates; age 18-30 years; singleton pregnancy; negative roll-over test.</P>
<P>Exclusion criteria: underlying medical disorders.</P>
<P>Mean calcium intake at 26 weeks was; calcium group: 1129 (SD 736) and placebo group 914 (478).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Calcium carbonate 1.5 g (500 mg tablets) from 26 weeks' gestation vs placebo tablets. Women at John Hopkins Hospital also received vitamin preparations containing 200 mg calcium and 100 mg magnesium per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Weight gain in last trimester of pregnancy; BP increase; gestational hypertension.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Recruitment 1983-1985. 34 black women from John Hopkins Hospital, Baltimore, USA, 18 white women from Rosario, Argentina.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-09 10:21:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Villar-1990">
<CHAR_METHODS MODIFIED="2010-03-08 12:03:42 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised trial. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Pregnant women 17 years or younger; no underlying medical disorders; most were nulliparous with known last menstrual period and singleton pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 g elemental calcium as 500 mg calcium carbonate tablets, vs placebo tablets. All women were prescribed prenatal vitamin tablets containing 200 mg calcium and 100 mg magnesium per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-09 10:21:52 +0000" MODIFIED_BY="[Empty name]">
<P>Preterm labour; preterm delivery &lt; 37 weeks (calcium 7.4 vs placebo 21.1%); delivery 30-37 weeks; idiopathic prematurity; spontaneous prematurity; low birthweight (&lt; 2500 g) (calcium 9.6% vs placebo 21.1%); postdates &gt; 42 weeks (calcium 7.4 vs placebo 5.3%); impaired fetal growth (3.2 vs 3.2%); premature rupture of membranes (2.1 vs 1.0%); Apgar score &lt; 8 at 5 minutes (4.4 vs 10.5%).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>John Hopkins Hospital, Baltimore, 1985-1988.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 10:44:26 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-WHO-2006">
<CHAR_METHODS MODIFIED="2010-03-15 15:50:07 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised trial. Randomisation stratified by centre, with computer-generated blocks of 6-8. Allocation by consecutively numbered treatment packs containing calcium tablets or identical placebo. Treatment packs were prepared centrally.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-25 10:08:24 +0100" MODIFIED_BY="[Empty name]">
<P>Populations with median daily calcium intake &lt; 600 mg; Primiparous women less than 20 weeks' pregnant. Exclusion criteria: renal disease or urolithiasis; parathyroid disease; BP &gt; 140 mmHg systolic or &gt; 90 mmHg diastolic; history of hypertension; antihypertensive therapy; diuretic, digoxin, phenytoin or tetracycline treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Chewable calcium carbonate tablets with 500 mg elemental calcium, 3 daily, or identical placebo, from enrolment till delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-25 10:10:15 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: pre-eclampsia (BP diastolic 90 mmHg or more, or systolic 140 mmHg or more, plus proteinuria 2+ on dipsticks or 300 mg per day; preterm birth (&lt; 37 weeks). Secondary outcomes: severe pre-eclampsia (diastolic 110 mmHg or more or systolic 160 mmHg or more); early onset pre-eclampsia (&lt; 32 weeks), PIH; eclampsia; placental abruption; birthweight &lt; 2500 g; spontaneous preterm delivery; medically indicated preterm delivery; admission to neonatal ICU for &gt; 2 days; fetal, neonatal and perinatal mortality (before discharge from hospital).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-11 10:44:26 +0100" MODIFIED_BY="Heather Maxwell">
<P>Multicentre trial in Argentina, Egypt, India, Peru, South Africa and Vietnam. Enrolment from 2001-2003.<BR/>14,362 women screened, 8325 randomised. Exclusions: 6 calcium (4 not pregnant, 2 lost before treatment started) and 7 placebo (5 not pregnant, 2 lost before treatment started). Loss to follow-up: 143 and 155 in calcium and placebo group respectively (some data available on women not followed up to delivery). Treatment compliance 84.5% and 86.2% respectively. Baseline characteristics well matched.</P>
<P>An ancillary study in Argentina assessed 510 of the participants by Doppler ultrasound for RI, PI in uterine and umbilical arteries, and for bilateral uterine artery notching (<LINK REF="REF-Carroli-2010" TYPE="REFERENCE">Carroli 2010</LINK>). Similarly, a group of 708 participants in South Africa were assessed for serum and urine parameters of endothelial damage (<LINK REF="REF-Hofmeyr-2008" TYPE="REFERENCE">Hofmeyr 2008</LINK>).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ASA: acetylsalicylic acid<BR/>BMI: body mass index<BR/>BP: blood pressure<BR/>DBP: diastolic blood pressure<BR/>dl: decilitre<BR/>ICU: intensive care unit<BR/>IU: international units<BR/>mcg: microgram<BR/>mg: milligram<BR/>NICU: neonatal intensive care unit<BR/>PE: pulmonary embolism<BR/>PI: pulsatility index<BR/>PIH: pregnancy-induced hypertension<BR/>RI: resistance index<BR/>SBP: systolic blood pressure<BR/>SD: standard deviation<BR/>SEM: standard error of the mean<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-06-11 10:12:27 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-06-11 10:06:51 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Aghamohammady-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-11 10:06:51 +0100" MODIFIED_BY="Heather Maxwell">
<P>No data given in abstract. 100 nulliparous women 35 years old or more randomly allocated to receive calcium 2000 g or placebo from 15-20 weeks until term.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-August-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Excluded pending full report of results. Inadequate data in abstracts for inclusion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Belizan-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>N = 36. No clinically important outcomes presented in format suitable for inclusion in this review. </P>
<P>Participants: healthy, 20-35 years, singleton pregnancy.<BR/>Intervention: calcium 1 g (n = 11), calcium 2 g (n = 11) or placebo (n = 14). <BR/>Outcomes: DBP 20-24 weeks, and in the third trimester. <BR/>Study design: randomised, no further information.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-11 10:07:37 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Boggess-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-11 10:07:37 +0100" MODIFIED_BY="Heather Maxwell">
<P>N = 23. After randomisation, 5/23 (22%) were excluded.</P>
<P>Participants: 18-35 years. Excluded if BP &gt; 140/90 mmHg at 24 weeks; smokers; illicit drug use; multiple pregnancy; cardiovascular renal or endocrine disease; hypertension in previous pregnancy; calcium supplementation &gt; 200-250 mg elemental calcium.<BR/>Intervention: oral calcium carbonate 1.5 g/day for 6 weeks from 28-31 weeks, or placebo tablets. All had 200 to 250 mg calcium in standard prenatal vitamin-mineral preparations.<BR/>Outcomes: gestational hypertension (BP at least 140.90 mmHg on 2 occasions, 6 hours apart); pre-eclampsia (gestational hypertension plus at least 1+ proteinuria).<BR/>Study design: randomised trial. Randomisation schedule in balanced blocks of 10.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chames-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Excluded pending publication of full report. No relevant clinical outcomes reported in the abstract. No difference found in blood lead levels between women receiving calcium 1000 mg daily from 13-19 weeks (n = 24) or placebo (n = 26).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-25 10:12:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Souza-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-25 10:12:21 +0100" MODIFIED_BY="[Empty name]">
<P>Participants randomised to calcium 2 g/day AND aspirin (ASA).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-25 10:12:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diogenes-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-25 10:12:29 +0100" MODIFIED_BY="[Empty name]">
<P>Supplementation with calcium (600 mg) (n = 17) plus vitamin D vs placebo (n = 9). Biochemical outcomes only. Abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-11 10:08:17 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Dizavandy-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-11 10:08:17 +0100" MODIFIED_BY="Heather Maxwell">
<P>Excluded due to the unexplained large and imbalanced loss to follow-up (6/58 in calcium group and 24/85 in placebo group). Hypocalciuric women in Iran randomised to receive calcium (2 g) or identical placebo but method of randomisation is unclear. Attempts to contact authors for more details failed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-25 10:12:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ettinger-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-25 10:12:40 +0100" MODIFIED_BY="[Empty name]">
<P>670 women randomised to calcium 1.2 g vs placebo in first trimester of pregnancy (Mexico City, 2001-2003). Calcium was associated with reduction in bone resorption during pregnancy. No outcomes specified for this review were reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-25 10:12:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Felix-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-25 10:12:45 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as allocation was by alternation, not random. 14 women received calcium supplementation 2 g/day and 11 received placebo. No women developed hypertension or pre-eclampsia. The production of 6-keto-prostaglandin F1alpha by umbilical arteries was similar between groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-11 10:09:08 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Karandish-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-11 10:09:08 +0100" MODIFIED_BY="Heather Maxwell">
<P>No details of randomisation available (attempts were made to contact the author) and outcome assessed (birthweight) is not a review outcome. Study compared 1 g calcium vs placebo in 68 women from 28-30 weeks' gestation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kawasaki-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>N = 94. Not a randomised trial. </P>
<P>Interventions: calcium L-aspartate 600 mg/day from 20 weeks to delivery (n = 22) vs no supplementation (n = 72). <BR/>Outcomes: pregnancy-induced hypertension.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-11 10:09:52 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Knight-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-11 10:09:52 +0100" MODIFIED_BY="Heather Maxwell">
<P>Excluded because no clinically relevant outcomes reported, placebo not used, and participants not followed till delivery. Normotensive (n = 30 and hypertensive (BP 140/85 mmHg or more, n = 20) nulliparous women "randomly allocated" to receive calcium 1 g from about 12 weeks to 32 weeks, or a control group. Follow-up continued to 36 weeks. Mean DBP reduced in the hypertensive group receiving calcium.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lavin-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Planned trial of calcium versus placebo in women with a positive roll-over test at 28-32 weeks. Trial apparently cancelled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-11 10:10:06 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-MacDonald-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-11 10:10:06 +0100" MODIFIED_BY="Heather Maxwell">
<P>RCT of calcium AND vitamin D versus placebo in 55 Asian women with no method or results provided in this personal communication from 1986. Attempts to contact the author for more details were unsuccessful.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-15 15:54:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montanaro-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-15 15:54:55 +0000" MODIFIED_BY="[Empty name]">
<P>N = 170. No placebo.</P>
<P>Participants: normotensive at 24 weeks' pregnancy.<BR/>Interventions: calcium 2 g/day from 24 weeks to delivery.<BR/>Outcomes: pregnancy-induced hypertension, pre-eclampsia.<BR/>Study design: "randomised, single-blinded trial".</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-15 15:55:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prada-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-15 15:55:18 +0000" MODIFIED_BY="[Empty name]">
<P>Excluded pending publication of full report. Abstract does not include outcomes specified for this review. Mean BP was reduced in adolescents receiving calcium supplementation 1000 mg daily (n = 62) compared with placebo (n = 62). Not clear whether participants in this report include participants from <LINK REF="STD-Prada-2002" TYPE="STUDY">Prada 2002</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-15 15:55:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prada-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-15 15:55:28 +0000" MODIFIED_BY="[Empty name]">
<P>Excluded pending publication of full report. Abstract does not include outcomes specified for this review. Mean blood pressure was similar in adolescents and women with twin pregnancy receiving calcium supplementation 1000 mg daily (n = 94) compared with placebo (n = 93). Not clear whether participants in this report include participants from <LINK REF="STD-Prada-2001" TYPE="STUDY">Prada 2001</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-16 11:53:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raman-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-16 11:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>N = 273. Allocation was by strict rotation, a quasi-randomised trial. Supplementation with 300 mg vs 600 mg vs placebo. No data given on pre-eclampsia. Biochemical data on only 87 women.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Repke-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>N = 255. Presented as abstract only. No clinical data available. </P>
<P>Interventions: calcium 2 g/day vs placebo, after 20 weeks of pregnancy. <BR/>Study design: 'randomised clinical trial'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-24 16:29:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-S_x002d_Ramos-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-24 16:29:17 +0100" MODIFIED_BY="[Empty name]">
<P>N = 75. Excluded because calcium used for treatment of women with pre-eclampsia rather than prevention.</P>
<P>Participants: nulliparous, gestation 24-36 weeks; mild pre-eclampsia (BP 140/90-160/100, proteinuria at least 300 mg/day).<BR/>Interventions: calcium 2 g/day elemental calcium (4 tablets of calcium carbonate 1250 mg), versus matching placebo.<BR/>Outcomes: initial and last BP and biochemical markers; preterm delivery; caesarean section; severe pre-eclampsia; gestation at delivery; birthweight; Apgar &lt; 7 at 1 minute and 5 minutes; cord arterial pH &lt; 7.16; fetal growth restriction; perinatal death.<BR/>Study design: double-blind, placebo-controlled study using a computer-generated random number list.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-24 16:32:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salzano-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-24 16:32:12 +0100" MODIFIED_BY="[Empty name]">
<P>Method of 'randomisation' not described and no explanation given for discrepancy in group sizes (25 vs 40).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Suzuki-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>N = 152. Not a randomised trial. </P>
<P>Interventions: calcium 1 g/day from 20 weeks vs no calcium. <BR/>Outcomes: pre-eclampsia, gestational hypertension.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tamas-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study of treatment of gestational hypertension, not prevention, using the drug dobesilate calcium, not calcium supplementation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-15 15:56:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wanchu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-15 15:56:18 +0000" MODIFIED_BY="[Empty name]">
<P>No placebo used. 120 consecutive nulliparous women less than 20 weeks' pregnant "randomly assigned" to receive 2 g elemental calcium daily, or no treatment. Analysis restricted to 100 women who "completed the protocol". Mild pre-eclampsia occurred in 9/50 vs 6/50 and severe pre-eclampsia in 0/50 vs 2/50 study vs control groups respectively.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ASA: acetylsalicylic acid<BR/>BP: blood pressure<BR/>DBP: diastolic blood pressure<BR/>RCT: randomised controlled trial<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-02-11 14:42:46 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Asemi-2012">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Diogenes-2013">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Goldberg-2013">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Herrera-2006a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Jarjou-2013">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Sulovic-2013">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-25 10:13:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-07-25 10:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Awaiting translation.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-06-11 10:05:00 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-06-11 10:05:00 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Mahomed-1998">
<CHAR_STUDY_NAME MODIFIED="2013-07-25 10:14:00 +0100" MODIFIED_BY="[Empty name]">
<P>Calcium supplementation for the prevention of pregnancy-induced hypertension and preterm labour in twin pregnancies.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-05-24 15:15:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Women with twin pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-11 10:05:00 +0100" MODIFIED_BY="Heather Maxwell">
<P>Calcium solution (1 g elemental calcium per 5 mL).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pregnancy-induced hypertension, preterm labour, perinatal mortality and short-term morbidity, maternal morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Not stated.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Prof K Mahomed.<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sample size 400 per group.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-06-11 10:56:32 +0100" MODIFIED_BY="Heather Maxwell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-06-11 10:56:32 +0100" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Almirante-1998">
<DESCRIPTION>
<P>Not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-01 10:13:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bassaw-1998">
<DESCRIPTION>
<P>The supplement vs control group were allocated by alternation, but clear that various supplemented groups were randomised by the pharmacist using random number tables.  In this review we use only data for calcium plus aspirin vs aspirin, which were randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-04 11:52:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belizan-1991">
<DESCRIPTION>
<P>Computer-generated random number sequence - Epistats Statistical Package.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 15:42:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CPEP-1997">
<DESCRIPTION>
<P>Packages of study tablets prepared and numbered by pharmaceutical manufacturer according to a computer-generated simple randomisation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:35:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cong-1995">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-05 09:50:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crowther-1999">
<DESCRIPTION>
<P>Stratified randomisation centrally co-ordinated using variable blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:38:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrera-1998">
<DESCRIPTION>
<P>&#8220; allocated randomly.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:40:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrera-2006">
<DESCRIPTION>
<P>&#8220;random cards were prepared and sealed by an independent administrative staff member using a random number table prepared with the True Epistat statistical package version 5.0.&#8221; </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:20:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jarjou-2004">
<DESCRIPTION>
<P>Random permuted blocks of 4.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 15:45:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-2009">
<DESCRIPTION>
<P>Simple randomisation sequence developed manually.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-05 10:48:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1989">
<DESCRIPTION>
<P>Assigned using a random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-05 10:32:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1990">
<DESCRIPTION>
<P>Authors state that this was a randomised controlled trial but no details of sequence generation are provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 10:56:32 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-L_x002d_Jaramillo-1997">
<DESCRIPTION>
<P>Random number table used to assign each participant independently in sequence to calcium or placebo regimen.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:43:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2000">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:43:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marya-1987">
<DESCRIPTION>
<P>Not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-08 09:58:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niromanesh-2001">
<DESCRIPTION>
<P>Women were "randomly assigned".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-08 10:35:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Purwar-1996">
<DESCRIPTION>
<P>Computer-generated random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:44:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rogers-1999">
<DESCRIPTION>
<P>5 open envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:48:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>Participants randomised according to a computer-generated random number sequence by an independent third party who had no conflict of interest in the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-08 10:52:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-S_x002d_Ramos-1994">
<DESCRIPTION>
<P>Randomisation by computer-generated list. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:53:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taherian-2002">
<DESCRIPTION>
<P>"We used a table of random number to assign each case independently to one of three groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 15:49:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Villar-1987">
<DESCRIPTION>
<P>'Randomly assigned' - no other details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-08 12:04:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-1990">
<DESCRIPTION>
<P>Computer-generated list of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-09 09:50:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHO-2006">
<DESCRIPTION>
<P>Computer-generated randomisation lists for each site with random blocks of 6 to 8 women.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-07-24 16:48:34 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Almirante-1998">
<DESCRIPTION>
<P>Not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-16 11:23:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bassaw-1998">
<DESCRIPTION>
<P>Supplements were distributed in sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 15:40:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belizan-1991">
<DESCRIPTION>
<P>Complete set of numbered sealed opaque envelopes was sent to each of 3 hospitals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:28:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CPEP-1997">
<DESCRIPTION>
<P>On enrolment, each woman was assigned the next numbered package of medication at 1 of 5 centres. The blister-packed tablets were identical in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:35:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cong-1995">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-05 09:50:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crowther-1999">
<DESCRIPTION>
<P>Identical sealed treatment packs prepared by drug company.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:38:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrera-1998">
<DESCRIPTION>
<P>&#8220; allocated randomly.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-16 16:14:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrera-2006">
<DESCRIPTION>
<P>&#8220;allocated in two random groups&#8230;.sequentially numbered, sealed, opaque envelope containing a card that indicated the study allocation.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:40:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jarjou-2004">
<DESCRIPTION>
<P>Sealed opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-05 10:06:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-2009">
<DESCRIPTION>
<P>Coded numbers assigned to treatment packets and distributed to participants using the random number sequence. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-05 10:57:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1989">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-05 10:32:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1990">
<DESCRIPTION>
<P>No details given about how concealment was achieved or whether tablets looked identical.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-08 09:47:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L_x002d_Jaramillo-1997">
<DESCRIPTION>
<P>Adequate. Tablets similar in weight, colour, size. Containers and tablets prepared by the Department of Chemistry and Pharmacy, Central University of Ecuador.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:43:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2000">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:43:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marya-1987">
<DESCRIPTION>
<P>Not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-08 10:15:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niromanesh-2001">
<DESCRIPTION>
<P>Adequate. Manufacturer coded the tablets which had same packaging and physical characteristics. Pharmacy dispensed the tablets.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-08 11:11:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Purwar-1996">
<DESCRIPTION>
<P>Adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:44:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rogers-1999">
<DESCRIPTION>
<P>Unsealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:48:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>Participants randomised according to a computer-generated random number sequence by an independent third party who had no conflict of interest in the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:48:34 +0100" MODIFIED_BY="Jill V Hampson" RESULT="YES" STUDY_ID="STD-S_x002d_Ramos-1994">
<DESCRIPTION>
<P>Adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-16 15:57:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taherian-2002">
<DESCRIPTION>
<P>"randomly allocated to three equivalent groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-08 11:53:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-1987">
<DESCRIPTION>
<P>Random numbers in closed envelopes. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-08 12:49:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-1990">
<DESCRIPTION>
<P>Opaque envelopes with bottle numbers; project co-ordinator responsible for assigning treatment. Identical tablets and containers prepared at The John Hopkins Hospital pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 15:51:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHO-2006">
<DESCRIPTION>
<P>Consecutively numbered identical treatment boxes were allocated for each woman enrolled. Randomisation codes remained at the WHO Clinical Trial Unit until analysis.<BR/>Boxes and tablet bottles were prepared and numbered by Magistra SA, Geneva and shipped to trial centres. Placebo and calcium tablets identical.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-06-11 10:56:12 +0100" MODIFIED_BY="Heather Maxwell" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 16:30:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Almirante-1998">
<DESCRIPTION>
<P>No placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-11 10:56:12 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Bassaw-1998">
<DESCRIPTION>
<P>Clinicians were unaware whether the participants were in the supplemented or control groups, and which supplementation was administered. Participants were not blinded as placebos were not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 16:34:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belizan-1991">
<DESCRIPTION>
<P>Randomisation code was held centrally such that the woman and her healthcare providers were blind to her trial group. Tablets were identical in appearance, weight, colour, taste.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-04 12:53:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CPEP-1997">
<DESCRIPTION>
<P>Double-blind. The code was held centrally.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 16:35:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cong-1995">
<DESCRIPTION>
<P>No placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-05 09:50:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crowther-1999">
<DESCRIPTION>
<P>Double-blind. Tablets identical in size, colour and consistency. Code held centrally and only broken after trial closure and exploratory data analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 16:38:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrera-1998">
<DESCRIPTION>
<P>&#8220;Double blind, placebo controlled trial.&#8221; </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-11 10:52:52 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Herrera-2006">
<DESCRIPTION>
<P>&#8220;allocated in two random groups&#8230;.sequentially numbered, sealed, opaque envelope containing a card that indicated the study allocation.&#8221; - It appears the study was not double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-11 10:52:59 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Jarjou-2004">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-11 10:53:05 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Kumar-2009">
<DESCRIPTION>
<P>Double-blind. Calcium and placebo tablets were identical. Randomisation code broken after completion of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-08 09:37:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L_x002d_Jaramillo-1989">
<DESCRIPTION>
<P>Double-blind. Identical containers and tablets prepared by the Faculty of Chemistry and Pharmacy, Central University of Ecuador.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-05 10:32:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1990">
<DESCRIPTION>
<P>Stated double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-08 09:49:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L_x002d_Jaramillo-1997">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 16:43:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2000">
<DESCRIPTION>
<P>No placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 16:43:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marya-1987">
<DESCRIPTION>
<P>No placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-24 15:04:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niromanesh-2001">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-08 10:38:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Purwar-1996">
<DESCRIPTION>
<P>Double-blind. Containers and tablets prepared by a pharmaceutical firm in Nagpur. Tablets same size, weight and colour.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-24 16:44:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rogers-1999">
<DESCRIPTION>
<P>No placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-16 10:55:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-08 11:08:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-S_x002d_Ramos-1994">
<DESCRIPTION>
<P>Double-blind. Tablets prepared by pharmaceutical company and were identical with respect to weight, size, flavour and appearance. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-25 10:03:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Taherian-2002">
<DESCRIPTION>
<P>No placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-08 11:55:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-1987">
<DESCRIPTION>
<P>Tablets same weight, size and colour, prepared by The John Hopkins pharmacy and distributed to the 2 hospitals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-08 12:48:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-1990">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-09 09:51:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHO-2006">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-06-11 10:56:19 +0100" MODIFIED_BY="Heather Maxwell" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:30:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Almirante-1998">
<DESCRIPTION>
<P>No record of loss to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-11 10:56:19 +0100" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Bassaw-1998">
<DESCRIPTION>
<P>8 participants were unavailable for analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-04 11:52:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belizan-1991">
<DESCRIPTION>
<P>All or partial data available for 579/593 (Ca) and 588/601 (Pl) respectively. Delivery data available for 544 and 554 respectively.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-24 15:08:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CPEP-1997">
<DESCRIPTION>
<P>Attrition &lt; 10%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-11 10:19:40 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Cong-1995">
<DESCRIPTION>
<P>Loss to follow-up not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-24 15:08:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crowther-1999">
<DESCRIPTION>
<P>Attrition &lt; 10%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-11 10:26:54 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Herrera-1998">
<DESCRIPTION>
<P>1 from study group excluded for taking ASA;  2 from control group lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:40:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrera-2006">
<DESCRIPTION>
<P>1 loss to follow-up in each group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-24 14:22:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jarjou-2004">
<DESCRIPTION>
<P>&gt; 20% missing data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-24 15:08:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-2009">
<DESCRIPTION>
<P>Attrition &lt; 10%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-24 15:07:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1989">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-24 15:07:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1990">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-08 09:51:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1997">
<DESCRIPTION>
<P>274 recruited, 260 analysed. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:43:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2000">
<DESCRIPTION>
<P>Loss to follow-up not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:43:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marya-1987">
<DESCRIPTION>
<P>No record of losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-08 10:18:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niromanesh-2001">
<DESCRIPTION>
<P>No incomplete outcome data (sample size = 30).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-24 15:04:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Purwar-1996">
<DESCRIPTION>
<P>Attrition &lt; 10%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:44:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rogers-1999">
<DESCRIPTION>
<P>10% loss to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:48:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>No loss to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:48:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-S_x002d_Ramos-1994">
<DESCRIPTION>
<P>&lt; 10% attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-25 10:03:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taherian-2002">
<DESCRIPTION>
<P>No record of losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-25 10:04:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-1987">
<DESCRIPTION>
<P>&lt; 10% attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-25 10:04:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-1990">
<DESCRIPTION>
<P>&lt; 10% attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-09 10:00:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHO-2006">
<DESCRIPTION>
<P>143/4151 and 155/4161 women in calcium and placebo groups respectively were missing delivery data but were included in other analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-06-11 10:22:25 +0100" MODIFIED_BY="Heather Maxwell" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Almirante-1998">
<DESCRIPTION>
<P>No information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:09:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bassaw-1998">
<DESCRIPTION>
<P>Expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-04 11:56:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belizan-1991">
<DESCRIPTION>
<P>All primary outcomes addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 10:22:25 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-CPEP-1997">
<DESCRIPTION>
<P>Authors used total number of women enrolled to each group as denominator instead of total number minus those lost to follow-up. Also small discrepancy in overall numbers but unlikely to affect results substantially.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-21 11:55:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cong-1995">
<DESCRIPTION>
<P>Limited information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-05 09:57:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crowther-1999">
<DESCRIPTION>
<P>Intention-to-treat analysis. 227 in calcium group and 229 in placebo group. Baseline characteristics similar.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:38:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrera-1998">
<DESCRIPTION>
<P>Main outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:40:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Herrera-2006">
<DESCRIPTION>
<P>No information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:31:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jarjou-2004">
<DESCRIPTION>
<P>Maternal hypertension outcomes have not yet been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:08:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-2009">
<DESCRIPTION>
<P>Expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-05 11:05:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-L_x002d_Jaramillo-1989">
<DESCRIPTION>
<P>14 women excluded from the report because they delivered before 38 weeks leaving 43/49 women in the calcium and placebo groups respectively. Data from the 14 excluded women are included in this review.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:07:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1990">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 14:55:08 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1997">
<DESCRIPTION>
<P>Only participants with no missing values were included in the analyses (125 in calcium group and 135 in placebo group).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:43:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2000">
<DESCRIPTION>
<P>No information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:43:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marya-1987">
<DESCRIPTION>
<P>No report of registered protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:04:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niromanesh-2001">
<DESCRIPTION>
<P>Expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:04:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Purwar-1996">
<DESCRIPTION>
<P>Expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:44:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rogers-1999">
<DESCRIPTION>
<P>No information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:48:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>Unable to comment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:05:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-S_x002d_Ramos-1994">
<DESCRIPTION>
<P> Expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-25 10:03:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taherian-2002">
<DESCRIPTION>
<P>No information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:05:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-1987">
<DESCRIPTION>
<P> Expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:05:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-1990">
<DESCRIPTION>
<P>Expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:06:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHO-2006">
<DESCRIPTION>
<P>Expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-06-11 10:41:41 +0100" MODIFIED_BY="Heather Maxwell" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Almirante-1998">
<DESCRIPTION>
<P>Abstract only, no details, no placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:08:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bassaw-1998">
<DESCRIPTION>
<P>None noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 15:41:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belizan-1991">
<DESCRIPTION>
<P>Balanced group sizes, baseline characteristics including dietary calcium similar in both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-04 13:09:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CPEP-1997">
<DESCRIPTION>
<P> Baseline characteristics similar.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:35:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cong-1995">
<DESCRIPTION>
<P>Very limited description of methods.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-05 09:50:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Crowther-1999">
<DESCRIPTION>
<P>Only achieved 48% of recruitment target (456 instead of 948) due to lack of funds.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:38:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herrera-1998">
<DESCRIPTION>
<P>&#8220;Double blind, placebo controlled trial.&#8221; </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 10:30:22 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Herrera-2006">
<DESCRIPTION>
<P>Low to moderate (appears not double-blind).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:31:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jarjou-2004">
<DESCRIPTION>
<P>Of 155 women randomised, 125 who had normal pregnancy were selected for the sub-studies. It's not clear whether bias could have been introduced by this selection.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-05 10:17:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-2009">
<DESCRIPTION>
<P>Imbalance in size of groups. The authors were contacted regarding the imbalance and they explained that a random sequence was generated for 600 participants (unblocked) but recruiting was stopped at 552 participants and so 48 numbers remained unallocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:07:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1989">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-05 10:34:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1990">
<DESCRIPTION>
<P>Large discrepancy in size of groups not accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-08 09:38:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_Jaramillo-1997">
<DESCRIPTION>
<P>14 withdrawals after randomisation: 12 by change to another hospital or private medical doctor, 2 by non-compliance. 9/134 (6.7%) were from the calcium group and 5/140 (3.6%) from the placebo group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:43:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2000">
<DESCRIPTION>
<P>Methods not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:43:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marya-1987">
<DESCRIPTION>
<P>Very limited reporting of methods.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 10:37:26 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Niromanesh-2001">
<DESCRIPTION>
<P>No incomplete data or loss to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 10:38:06 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Purwar-1996">
<DESCRIPTION>
<P>Apart from 11 women lost to follow-up, there are no missing data. Otherwise baseline characteristics and compliance similar; balanced loss to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:44:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rogers-1999">
<DESCRIPTION>
<P>See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 15:04:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>None noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 10:41:41 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-S_x002d_Ramos-1994">
<DESCRIPTION>
<P>Data entered before breaking the code. Intention-to-treat analysis. 4/33 in the calcium group lost to follow-up so 29 in calcium and 34 in placebo, however even if the 4 lost to follow-up had PIH, results would still have significantly favoured the calcium group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-18 09:52:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Taherian-2002">
<DESCRIPTION>
<P>High &#8211; limited information on methods. No mention of loss to follow-up.  </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 15:49:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Villar-1987">
<DESCRIPTION>
<P>Women at John Hopkins Hospital only also received vitamin preparations containing 200 mg calcium/day.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 14:55:08 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Villar-1990">
<DESCRIPTION>
<P>Baseline characteristics similar except for maternal weight (higher in placebo group - P &lt; 0.01).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 15:52:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHO-2006">
<DESCRIPTION>
<P>Intention-to-treat principle. Baseline characteristics, compliance and drop-out rates similar.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-06-11 11:06:56 +0100" MODIFIED_BY="Heather Maxwell">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-06-11 11:06:56 +0100" MODIFIED_BY="Heather Maxwell" NO="1">
<TITLE MODIFIED="2013-05-24 12:45:23 +0100" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Calcium supplementation compared with placebo for preventing hypertensive disorders and related problems in pregnancy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: pregnant women</B>
</P>
<P>
<B>Settings: outpatient</B>
</P>
<P>
<B>Intervention: high-dose calcium (&#8805; 1 g/day)</B>
</P>
<P>
<B>Comparison: placebo</B>
</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>No calcium</P>
</TH>
<TH VALIGN="TOP">
<P>Calcium</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="6" VALIGN="TOP">
<P>
<B>Pre-eclampsia</B>
</P>
<P/>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Overall</B>
</P>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.45</B> (0.31 to 0.65)</P>
<P/>
<P/>
<P/>
<P>
<B>RR 0.36 </B>(0.20 to 0.65)</P>
<P/>
<P/>
<P/>
<P>
<B>RR 0.22 </B>(0.12 to 0.42)</P>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P>15,730<BR/>(13)</P>
<P/>
<P/>
<P>10,678</P>
<P>(8)</P>
<P/>
<P/>
<P>587</P>
<P>(5)</P>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
<P/>
<P/>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
<P/>
<P/>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P>P &lt; 0.0001</P>
<P/>
<P/>
<P/>
<P>P = 0.0007</P>
<P/>
<P/>
<P/>
<P/>
<P>P &lt; 0.00001</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>65 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>29 per 1000</B>
<BR/>(20 to 42)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Low calcium diet</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>57 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>21 per 1000</B>
<BR/>(11 to 37)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>High-risk women</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>176 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>38 per 1000</B>
<BR/>(21 to 74)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Preterm birth</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Overall</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.76</B> (0.60 to 0.97)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>15,275<BR/>(11)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>P = 0.03</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>104 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>79 per 1000</B>
<BR/>(62 to 101)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>HELLP Syndrome</B>
</P>
</TD>
<TD>
<P>
<B>1 per 1000</B>
<BR/>
</P>
</TD>
<TD>
<P>
<B>3 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>RR 2.67 </B>(1.05 to 6.82)</P>
</TD>
<TD>
<P>12,904</P>
<P>(2)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>P = 0.04</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
CI: confidence interval
<BR/>
HELLP: 
haemolysis, elevated liver enzymes and low platelets
<BR/>
RR: risk ratio
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-06-12 14:07:53 +0100" MODIFIED_BY="Heather Maxwell">
<COMPARISON ID="CMP-001" MODIFIED="2014-03-05 13:44:53 +0000" MODIFIED_BY="Leanne V Jones" NO="1">
<NAME>Routine high-dose calcium supplementation in pregnancy by baseline dietary calcium</NAME>
<DICH_OUTCOME CHI2="42.40450014282654" CI_END="0.8066632530561233" CI_START="0.5279806534607001" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6526121294239834" ESTIMABLE="YES" EVENTS_1="1260" EVENTS_2="1472" I2="74.05935699524844" I2_Q="77.22325980755981" ID="CMP-001.01" LOG_CI_END="-0.09330772656818881" LOG_CI_START="-0.27738199081693954" LOG_EFFECT_SIZE="-0.18534485869256417" METHOD="MH" MODIFIED="2014-03-05 13:44:53 +0000" MODIFIED_BY="Leanne V Jones" NO="1" P_CHI2="1.3783092274621822E-5" P_Q="0.012395271262901741" P_Z="7.914126964739085E-5" Q="8.78088779650663" RANDOM="YES" SCALE="14.286214874370337" SORT_BY="USER" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.060288443674069214" TOTALS="YES" TOTAL_1="7726" TOTAL_2="7744" WEIGHT="100.0" Z="3.9469857368674157">
<NAME>High blood pressure (with or without proteinuria)</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.5324403176068566" CI_END="0.9932644433946872" CI_START="0.8123321370851764" DF="3" EFFECT_SIZE="0.8982542112306096" ESTIMABLE="YES" EVENTS_1="547" EVENTS_2="614" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.002935111003527538" LOG_CI_START="-0.09026636508071911" LOG_EFFECT_SIZE="-0.04660073804212331" NO="1" P_CHI2="0.46945722548026236" P_Z="0.03646458947464462" STUDIES="4" TAU2="0.0" TOTAL_1="2505" TOTAL_2="2517" WEIGHT="32.67397920392394" Z="2.091708614073403">
<NAME>Adequate calcium diet</NAME>
<DICH_DATA CI_END="3.2386838149791783" CI_START="0.04001625580138121" EFFECT_SIZE="0.36" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5103685509392996" LOG_CI_START="-1.3977635494047251" LOG_EFFECT_SIZE="-0.44369749923271273" ORDER="1" O_E="0.0" SE="1.1208462411483104" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="1.2562962962962962" WEIGHT="0.8879991161439289"/>
<DICH_DATA CI_END="1.3373071704026946" CI_START="0.10053370491086208" EFFECT_SIZE="0.36666666666666664" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.12623117322227295" LOG_CI_START="-0.9976883123451477" LOG_EFFECT_SIZE="-0.4357285695614374" ORDER="2" O_E="0.0" SE="0.6601958693134833" STUDY_ID="STD-Villar-1990" TOTAL_1="90" TOTAL_2="88" VAR="0.43585858585858583" WEIGHT="2.3564105312159693"/>
<DICH_DATA CI_END="1.380236711853532" CI_START="0.5902776185343098" EFFECT_SIZE="0.9026199860885694" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.1399535746881291" LOG_CI_START="-0.22894368354370867" LOG_EFFECT_SIZE="-0.044495054427789775" ORDER="3" O_E="0.0" SE="0.21669207555626024" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="0.046955455608879995" WEIGHT="10.901562636562481"/>
<DICH_DATA CI_END="1.004177715946483" CI_START="0.815707589773221" EFFECT_SIZE="0.9050499347432074" ESTIMABLE="YES" EVENTS_1="509" EVENTS_2="565" LOG_CI_END="0.0018105795668501195" LOG_CI_START="-0.08846549676934357" LOG_EFFECT_SIZE="-0.043327458601246704" ORDER="5" O_E="0.0" SE="0.05302861411366513" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.002812033914816004" WEIGHT="18.528006920001562"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="39.35196444389638" CI_END="0.6988248367201592" CI_START="0.2779207701296725" DF="6" EFFECT_SIZE="0.44070164148435986" ESTIMABLE="YES" EVENTS_1="703" EVENTS_2="847" I2="84.75298480065938" ID="CMP-001.01.02" LOG_CI_END="-0.15563166828722852" LOG_CI_START="-0.5560789954477693" LOG_EFFECT_SIZE="-0.3558553318674989" MODIFIED="2010-01-07 12:44:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="6.105875656192694E-7" P_Z="4.950462490880977E-4" STUDIES="7" TAU2="0.2647321632403627" TOTAL_1="5206" TOTAL_2="5212" WEIGHT="57.40675716025697" Z="3.4834225969860495">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="0.5653174689130992" CI_START="0.06601461466914227" EFFECT_SIZE="0.19318181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="24" LOG_CI_END="-0.24770759416955618" LOG_CI_START="-1.1803599073742332" LOG_EFFECT_SIZE="-0.7140337507718947" ORDER="1" O_E="0.0" SE="0.547844585479835" STUDY_ID="STD-L_x002d_Jaramillo-1990" TOTAL_1="22" TOTAL_2="34" VAR="0.30013368983957217" WEIGHT="3.243768838569453"/>
<DICH_DATA CI_END="0.8710096324971176" CI_START="0.26410616415560584" EFFECT_SIZE="0.47962382445141066" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.0599770421023101" LOG_CI_START="-0.5782214623768545" LOG_EFFECT_SIZE="-0.3190992522395823" ORDER="2" O_E="0.0" SE="0.30441933782052116" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="0.09267113323908457" WEIGHT="7.643366365259145"/>
<DICH_DATA CI_END="0.6572969199542048" CI_START="0.03633715113456673" EFFECT_SIZE="0.15454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.1822384027873744" LOG_CI_START="-1.439649124772528" LOG_EFFECT_SIZE="-0.8109437637799511" ORDER="3" O_E="0.0" SE="0.738609282377537" STUDY_ID="STD-L_x002d_Jaramillo-1989" TOTAL_1="55" TOTAL_2="51" VAR="0.5455436720142602" WEIGHT="1.929785587701868"/>
<DICH_DATA CI_END="0.5929732148002642" CI_START="0.13609425669450542" EFFECT_SIZE="0.284077892325315" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.22696492371359167" LOG_CI_START="-0.8661602020451153" LOG_EFFECT_SIZE="-0.5465625628793535" ORDER="4" O_E="0.0" SE="0.37546647055959415" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.14097507051447858" WEIGHT="5.808932086552994"/>
<DICH_DATA CI_END="0.910487633755234" CI_START="0.48622208265306216" EFFECT_SIZE="0.6653564409505092" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="87" LOG_CI_END="-0.040725948417479924" LOG_CI_START="-0.3131653207773698" LOG_EFFECT_SIZE="-0.17694563459742485" ORDER="5" O_E="0.0" SE="0.1600322359208424" STUDY_ID="STD-Belizan-1991" TOTAL_1="579" TOTAL_2="588" VAR="0.02561031653382416" WEIGHT="13.610511753519303"/>
<DICH_DATA CI_END="1.0548224711363225" CI_START="0.8604231990759956" EFFECT_SIZE="0.9526771357980425" ESTIMABLE="YES" EVENTS_1="613" EVENTS_2="645" LOG_CI_END="0.023179373099550035" LOG_CI_START="-0.06528788850439987" LOG_EFFECT_SIZE="-0.02105425770242488" ORDER="6" O_E="0.0" SE="0.0519661073861678" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.0027004763168707235" WEIGHT="18.560821261746213"/>
<DICH_DATA CI_END="0.658315853479314" CI_START="0.1726357341153547" EFFECT_SIZE="0.33711843711843714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" LOG_CI_END="-0.18156568615707572" LOG_CI_START="-0.7628693040852348" LOG_EFFECT_SIZE="-0.47221749512115524" MODIFIED="2010-01-07 12:44:59 +0000" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.34146062267031707" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.11659535683440066" WEIGHT="6.609571266907999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4549654839743185" CI_START="0.5680177915521761" DF="0" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.16285269071210204" LOG_CI_START="-0.24563806102855215" LOG_EFFECT_SIZE="-0.04139268515822506" NO="3" P_CHI2="1.0" P_Z="0.6912130919082727" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.919263635819082" Z="0.39720934580684963">
<NAME>Dietary calcium not specified</NAME>
<DICH_DATA CI_END="1.4549654839743185" CI_START="0.5680177915521761" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.16285269071210204" LOG_CI_START="-0.24563806102855215" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="48313" O_E="0.0" SE="0.2399494896342928" STUDY_ID="STD-Niromanesh-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.057575757575757586" WEIGHT="9.919263635819082"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="40.309494956985176" CI_END="0.647050621117564" CI_START="0.3107089176343305" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.44837974769391575" ESTIMABLE="YES" EVENTS_1="379" EVENTS_2="510" I2="70.23033899877593" I2_Q="26.76069989997467" ID="CMP-001.02" LOG_CI_END="-0.1890617415692581" LOG_CI_START="-0.5076462819114136" LOG_EFFECT_SIZE="-0.34835401174033587" METHOD="MH" MODIFIED="2014-02-05 20:35:25 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="6.387881802949469E-5" P_Q="0.2552820434366232" P_Z="1.8174105353508817E-5" Q="2.7307743209841355" RANDOM="YES" SCALE="1000.0" SORT_BY="USER" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1957339649071223" TOTALS="YES" TOTAL_1="7851" TOTAL_2="7879" WEIGHT="100.0" Z="4.286217505393231">
<NAME>Pre-eclampsia</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.196157822130676" CI_END="1.1974061754762029" CI_START="0.319578575122647" DF="3" EFFECT_SIZE="0.6185995145501999" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="197" I2="51.582898852495845" ID="CMP-001.02.01" LOG_CI_END="0.07824149363622529" LOG_CI_START="-0.4954223439322059" LOG_EFFECT_SIZE="-0.2085904251479904" NO="1" P_CHI2="0.10244718358093641" P_Z="0.154062253144137" STUDIES="4" TAU2="0.20015510265298644" TOTAL_1="2505" TOTAL_2="2517" WEIGHT="31.344700631966617" Z="1.4253285427328006">
<NAME>Adequate calcium diet</NAME>
<DICH_DATA CI_END="3.2386838149791783" CI_START="0.04001625580138121" EFFECT_SIZE="0.36" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5103685509392996" LOG_CI_START="-1.3977635494047251" LOG_EFFECT_SIZE="-0.44369749923271273" ORDER="1" O_E="0.0" SE="1.1208462411483104" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="1.2562962962962962" WEIGHT="2.4118424310577007"/>
<DICH_DATA CI_END="2.6660884062158257" CI_START="0.007321947360692846" EFFECT_SIZE="0.13971742543171115" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4258745463138206" LOG_CI_START="-2.135373397694696" LOG_EFFECT_SIZE="-0.8547494256904377" ORDER="2" O_E="0.0" SE="1.5044897206923997" STUDY_ID="STD-Villar-1990" TOTAL_1="90" TOTAL_2="88" VAR="2.263489319669095" WEIGHT="1.4240545854923012"/>
<DICH_DATA CI_END="0.9005185378929982" CI_START="0.21363426985509443" EFFECT_SIZE="0.43861329247270636" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" LOG_CI_END="-0.045507342453812105" LOG_CI_START="-0.6703290792878431" LOG_EFFECT_SIZE="-0.35791821087082765" ORDER="3" O_E="0.0" SE="0.36702338113378913" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="0.13470616229887863" WEIGHT="10.598192854970558"/>
<DICH_DATA CI_END="1.164315856627379" CI_START="0.7667101490907422" EFFECT_SIZE="0.9448242080003523" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="168" LOG_CI_END="0.06607081208552928" LOG_CI_START="-0.11536878786554355" LOG_EFFECT_SIZE="-0.024648987890007152" ORDER="4" O_E="0.0" SE="0.10657851915176493" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.011358980744583125" WEIGHT="16.91061076044606"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="29.353194912935194" CI_END="0.6472457341261135" CI_START="0.19859477147087976" DF="7" EFFECT_SIZE="0.3585242232461809" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="306" I2="76.15251075474826" ID="CMP-001.02.02" LOG_CI_END="-0.18893080323622607" LOG_CI_START="-0.7020321896333692" LOG_EFFECT_SIZE="-0.44548149643479756" MODIFIED="2010-01-07 12:47:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.247261496513108E-4" P_Z="6.656885795972745E-4" STUDIES="8" TAU2="0.44406894142989517" TOTAL_1="5331" TOTAL_2="5347" WEIGHT="65.74964028875159" Z="3.403333968446566">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="1.4767841726119282" CI_START="0.005425822032279613" EFFECT_SIZE="0.08951406649616368" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.1693170291692847" LOG_CI_START="-2.265534455260467" LOG_EFFECT_SIZE="-1.0481087130455913" ORDER="1" O_E="0.0" SE="1.4302438146632677" STUDY_ID="STD-L_x002d_Jaramillo-1990" TOTAL_1="22" TOTAL_2="34" VAR="2.0455973693825356" WEIGHT="1.5624946394907322"/>
<DICH_DATA CI_END="0.8375361676745214" CI_START="0.11670668475773119" EFFECT_SIZE="0.31264367816091954" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.07699642956596733" LOG_CI_START="-0.9329042676028722" LOG_EFFECT_SIZE="-0.5049503485844198" ORDER="2" O_E="0.0" SE="0.5027645008750067" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="0.2527721433400946" WEIGHT="7.808295429545985"/>
<DICH_DATA CI_END="0.6572969199542048" CI_START="0.03633715113456673" EFFECT_SIZE="0.15454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.1822384027873744" LOG_CI_START="-1.439649124772528" LOG_EFFECT_SIZE="-0.8109437637799511" ORDER="3" O_E="0.0" SE="0.738609282377537" STUDY_ID="STD-L_x002d_Jaramillo-1989" TOTAL_1="55" TOTAL_2="51" VAR="0.5455436720142602" WEIGHT="4.724367795168788"/>
<DICH_DATA CI_END="0.7654298803110793" CI_START="0.039700103380788714" EFFECT_SIZE="0.17432052483598875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.11609458809933586" LOG_CI_START="-1.4012083623137712" LOG_EFFECT_SIZE="-0.7586514752065536" ORDER="4" O_E="0.0" SE="0.7548821923893373" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.5698471243865325" WEIGHT="4.57439224156033"/>
<DICH_DATA CI_END="0.5827111349564926" CI_START="0.07262323440944443" EFFECT_SIZE="0.2057142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="21" LOG_CI_END="-0.23454668294991027" LOG_CI_START="-1.1389244128881042" LOG_EFFECT_SIZE="-0.6867355479190071" ORDER="5" O_E="0.0" SE="0.5312359553076582" STUDY_ID="STD-L_x002d_Jaramillo-1997" TOTAL_1="125" TOTAL_2="135" VAR="0.2822116402116402" WEIGHT="7.3273363279069965"/>
<DICH_DATA CI_END="1.2564036801956278" CI_START="0.34913643328973276" EFFECT_SIZE="0.6623113313809417" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.0991291998422843" LOG_CI_START="-0.457004829068703" LOG_EFFECT_SIZE="-0.17893781461320935" ORDER="6" O_E="0.0" SE="0.32667588149015536" STUDY_ID="STD-Belizan-1991" TOTAL_1="579" TOTAL_2="588" VAR="0.10671713154737002" WEIGHT="11.578956850226305"/>
<DICH_DATA CI_END="1.1291564763039879" CI_START="0.7521460297532139" EFFECT_SIZE="0.9215696178923073" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="186" LOG_CI_END="0.052754129778371656" LOG_CI_START="-0.12369783260104086" LOG_EFFECT_SIZE="-0.03547185141133463" ORDER="7" O_E="0.0" SE="0.10364875615296752" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.010743064652057323" WEIGHT="16.961054712124536"/>
<DICH_DATA CI_END="0.658315853479314" CI_START="0.1726357341153547" EFFECT_SIZE="0.33711843711843714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" LOG_CI_END="-0.18156568615707572" LOG_CI_START="-0.7628693040852348" LOG_EFFECT_SIZE="-0.47221749512115524" MODIFIED="2010-01-07 12:47:42 +0000" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.34146062267031707" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.11659535683440066" WEIGHT="11.212742292727922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0236399778788619" CI_START="0.019936856420550257" DF="0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.01014723875593224" LOG_CI_START="-1.7003433187844461" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2014-02-05 20:35:25 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.05278085445299506" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.90565907928179" Z="1.936709576713618">
<NAME>Dietary calcium not specified</NAME>
<DICH_DATA CI_END="1.0236399778788619" CI_START="0.019936856420550257" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.01014723875593224" LOG_CI_START="-1.7003433187844461" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="48325" O_E="0.0" SE="1.004750620564033" STUDY_ID="STD-Niromanesh-2001" TOTAL_1="15" TOTAL_2="15" VAR="1.0095238095238095" WEIGHT="2.90565907928179"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.03552375208524" CI_END="0.9684314128748296" CI_START="0.6037502692114263" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7646507217259265" ESTIMABLE="YES" EVENTS_1="722" EVENTS_2="795" I2="60.07092153422052" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.013931131852219374" LOG_CI_START="-0.21914266258906775" LOG_EFFECT_SIZE="-0.11653689722064355" METHOD="MH" MODIFIED="2014-02-05 14:56:41 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.010202510577607682" P_Q="0.46683945943805616" P_Z="0.02600916321604849" Q="0.5294471444821096" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04953406741631938" TOTALS="YES" TOTAL_1="7620" TOTAL_2="7655" WEIGHT="100.00000000000001" Z="2.2260749247604896">
<NAME>Preterm birth</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.310374986974882" CI_END="1.333555164555573" CI_START="0.2641418834181628" DF="2" EFFECT_SIZE="0.5935046527262672" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="272" I2="83.75354120312241" ID="CMP-001.03.01" LOG_CI_END="0.1250109856551056" LOG_CI_START="-0.5781627298222486" LOG_EFFECT_SIZE="-0.22657587208357152" NO="1" P_CHI2="0.0021224526215913864" P_Z="0.20656227421033913" STUDIES="4" TAU2="0.41748730439370574" TOTAL_1="2509" TOTAL_2="2524" WEIGHT="39.94205260832432" Z="1.2630749394495993">
<NAME>Adequate calcium diet</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7968304860933008" CI_START="0.1570224143047178" EFFECT_SIZE="0.3537234042553192" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.09863405850903476" LOG_CI_START="-0.8040383494121157" LOG_EFFECT_SIZE="-0.4513362039605752" ORDER="2" O_E="0.0" SE="0.4143579722840249" STUDY_ID="STD-Villar-1990" TOTAL_1="94" TOTAL_2="95" VAR="0.17169252919532874" WEIGHT="6.568124642594275"/>
<DICH_DATA CI_END="0.9005185378929982" CI_START="0.21363426985509443" EFFECT_SIZE="0.43861329247270636" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" LOG_CI_END="-0.045507342453812105" LOG_CI_START="-0.6703290792878431" LOG_EFFECT_SIZE="-0.35791821087082765" ORDER="3" O_E="0.0" SE="0.36702338113378913" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="0.13470616229887863" WEIGHT="7.886680683411932"/>
<DICH_DATA CI_END="1.2889032490745085" CI_START="0.9183716999471098" EFFECT_SIZE="1.0879762258063865" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="229" LOG_CI_END="0.11022031846273883" LOG_CI_START="-0.03698150772721611" LOG_EFFECT_SIZE="0.03661940536776136" ORDER="4" O_E="0.0" SE="0.08646708136477087" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.007476556159741905" WEIGHT="25.487247282318116"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.341949290232437" CI_END="1.0235665392554565" CI_START="0.6431621131851072" DF="5" EFFECT_SIZE="0.8113687314489673" ESTIMABLE="YES" EVENTS_1="457" EVENTS_2="523" I2="21.159886792208226" ID="CMP-001.03.02" LOG_CI_END="0.010116080210225921" LOG_CI_START="-0.1916795465345819" LOG_EFFECT_SIZE="-0.090781733162178" MODIFIED="2010-02-04 10:45:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2743530488955991" P_Z="0.07782348998080364" STUDIES="7" TAU2="0.019734522074649496" TOTAL_1="5111" TOTAL_2="5131" WEIGHT="60.0579473916757" Z="1.7634567242332218">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="2.994016851312268" CI_START="0.009548632027969623" EFFECT_SIZE="0.16908212560386474" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.47625424036619707" LOG_CI_START="-2.0200588425794814" LOG_EFFECT_SIZE="-0.7719023011066422" ORDER="1" O_E="0.0" SE="1.4663466618713423" STUDY_ID="STD-L_x002d_Jaramillo-1990" TOTAL_1="22" TOTAL_2="34" VAR="2.1501725327812284" WEIGHT="0.6605625771508512"/>
<DICH_DATA CI_END="1.9948580418152504" CI_START="0.26915960180625875" EFFECT_SIZE="0.7327586206896551" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2999119958373661" LOG_CI_START="-0.5699901228626176" LOG_EFFECT_SIZE="-0.13503906351262576" ORDER="2" O_E="0.0" SE="0.5109848106093057" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="0.261105476673428" WEIGHT="4.677588183629409"/>
<DICH_DATA CI_END="1.5435702531595743" CI_START="0.06616883962042779" EFFECT_SIZE="0.31958762886597936" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18852640049463437" LOG_CI_START="-1.1793464813585786" LOG_EFFECT_SIZE="-0.49541004043197223" ORDER="3" O_E="0.0" SE="0.8034953018805451" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.6456047001441082" WEIGHT="2.0902932315250533"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="0.0" STUDY_ID="STD-L_x002d_Jaramillo-1997" TOTAL_1="125" TOTAL_2="135" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4439272814417574" CI_START="0.5827153416347585" EFFECT_SIZE="0.9172778091184163" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="37" LOG_CI_END="0.15954532199829777" LOG_CI_START="-0.23454354772483224" LOG_EFFECT_SIZE="-0.03749911286326723" ORDER="5" O_E="0.0" SE="0.23148975284673337" STUDY_ID="STD-Belizan-1991" TOTAL_1="527" TOTAL_2="542" VAR="0.053587505673041706" WEIGHT="14.090590526029684"/>
<DICH_DATA CI_END="1.0392392349245045" CI_START="0.803410716235685" EFFECT_SIZE="0.9137482903244862" ESTIMABLE="YES" EVENTS_1="398" EVENTS_2="436" LOG_CI_END="0.01671553451373544" LOG_CI_START="-0.09506237976020236" LOG_EFFECT_SIZE="-0.03917342262323345" ORDER="6" O_E="0.0" SE="0.06565890015411037" STUDY_ID="STD-WHO-2006" TOTAL_1="4038" TOTAL_2="4042" VAR="0.004311091169447435" WEIGHT="26.985599057856987"/>
<DICH_DATA CI_END="0.937856801490909" CI_START="0.3177553429557519" EFFECT_SIZE="0.5459020146520146" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="32" LOG_CI_END="-0.02786346766560416" LOG_CI_START="-0.49790713818798576" LOG_EFFECT_SIZE="-0.26288530292679496" MODIFIED="2010-01-07 12:51:24 +0000" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.27610597881854143" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.07623451153934484" WEIGHT="11.553313815483708"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8296365279461755" CI_END="1.1792834271009878" CI_START="0.9383680223124948" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0519514519380897" ESTIMABLE="YES" EVENTS_1="530" EVENTS_2="507" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.0716181952842911" LOG_CI_START="-0.027626800519400346" LOG_EFFECT_SIZE="0.021995697382445376" METHOD="MH" MODIFIED="2014-02-05 15:00:39 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4186445337176242" P_Q="0.38306702869797393" P_Z="0.3849703393502747" Q="0.7608361046676078" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6689" TOTAL_2="6717" WEIGHT="100.0" Z="0.8687747797321457">
<NAME>Admission to neonatal intensive care unit</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2594354555703755" CI_START="0.9501619415395876" DF="0" EFFECT_SIZE="1.093923049262855" ESTIMABLE="YES" EVENTS_1="343" EVENTS_2="315" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.10017591537689102" LOG_CI_START="-0.022202369107684895" LOG_EFFECT_SIZE="0.03898677313460305" NO="1" P_CHI2="1.0" P_Z="0.2117402289321696" STUDIES="1" TAU2="0.0" TOTAL_1="2163" TOTAL_2="2173" WEIGHT="62.19328880668738" Z="1.2487946131797016">
<NAME>Adequate calcium diet</NAME>
<DICH_DATA CI_END="1.2594354555703755" CI_START="0.9501619415395876" EFFECT_SIZE="1.093923049262855" ESTIMABLE="YES" EVENTS_1="343" EVENTS_2="315" LOG_CI_END="0.10017591537689102" LOG_CI_START="-0.022202369107684895" LOG_EFFECT_SIZE="0.03898677313460305" ORDER="48371" O_E="0.0" SE="0.07188561008851804" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.0051675409377984465" WEIGHT="62.19328880668738"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.179605894710943" CI_END="1.1943607237010765" CI_START="0.8088894204716577" DF="2" EFFECT_SIZE="0.9829067878637696" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="192" I2="8.240292208182078" ID="CMP-001.04.02" LOG_CI_END="0.07713551326992044" LOG_CI_START="-0.09211084471825394" LOG_EFFECT_SIZE="-0.007487665724166754" MODIFIED="2010-02-04 10:45:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.33628299541773254" P_Z="0.8623194160223548" STUDIES="3" TAU2="0.0" TOTAL_1="4526" TOTAL_2="4544" WEIGHT="37.806711193312616" Z="0.17342240414611784">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="2.47771586905389" CI_START="0.034672914866548166" EFFECT_SIZE="0.29310344827586204" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.39405150237217457" LOG_CI_START="-1.4600096467415014" LOG_EFFECT_SIZE="-0.5329790721846633" ORDER="1" O_E="0.0" SE="1.0890846967400782" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="1.186105476673428" WEIGHT="0.72875771116193"/>
<DICH_DATA CI_END="1.5438411039912607" CI_START="0.8242470662272912" EFFECT_SIZE="1.128054298642534" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="65" LOG_CI_END="0.18860259961960657" LOG_CI_START="-0.08394258998228117" LOG_EFFECT_SIZE="0.05233000481866273" ORDER="2" O_E="0.0" SE="0.16009439349259572" STUDY_ID="STD-Belizan-1991" TOTAL_1="544" TOTAL_2="554" VAR="0.025630214827762076" WEIGHT="12.746050640672761"/>
<DICH_DATA CI_END="1.1921303830254861" CI_START="0.7216633670377222" EFFECT_SIZE="0.9275326550381618" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="123" LOG_CI_END="0.07632375668935042" LOG_CI_START="-0.14166533973085874" LOG_EFFECT_SIZE="-0.03267079152075415" ORDER="3" O_E="0.0" SE="0.12804787430066103" STUDY_ID="STD-WHO-2006" TOTAL_1="3953" TOTAL_2="3956" VAR="0.016396258112917887" WEIGHT="24.331902841477927"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4572920661848912" CI_END="1.0890860238459352" CI_START="0.7359751889475501" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8952878264447408" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="205" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.03706218481187666" LOG_CI_START="-0.13313682626684167" LOG_EFFECT_SIZE="-0.04803732072748247" METHOD="MH" MODIFIED="2014-02-05 14:57:28 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9179450759159951" P_Q="0.3656118063985758" P_Z="0.2685670397303688" Q="0.818525099463699" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7821" TOTAL_2="7844" WEIGHT="100.00000000000001" Z="1.106368573388706">
<NAME>Stillbirth or death before discharge from hospital</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2456047286844193" CI_END="1.8970107258787723" CI_START="0.6621857809968441" DF="1" EFFECT_SIZE="1.1207914743945124" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="26" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.2780697864378431" LOG_CI_START="-0.17902014901570543" LOG_EFFECT_SIZE="0.04952481871106882" NO="1" P_CHI2="0.6201871002587418" P_Z="0.6710432205234496" STUDIES="4" TAU2="0.0" TOTAL_1="2509" TOTAL_2="2524" WEIGHT="12.642826828616858" Z="0.42471668477344826">
<NAME>Adequate calcium diet</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Villar-1990" TOTAL_1="94" TOTAL_2="95" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="22.094875438874084" CI_START="0.18424159473195686" EFFECT_SIZE="2.0176211453744495" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3442915575451948" LOG_CI_START="-0.7346123159237016" LOG_EFFECT_SIZE="0.3048396208107465" ORDER="3" O_E="0.0" SE="1.2211584260157702" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="1.4912279014293135" WEIGHT="0.4852878633642019"/>
<DICH_DATA CI_END="1.8632184221114894" CI_START="0.6318153242443422" EFFECT_SIZE="1.08499306518724" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="25" LOG_CI_END="0.27026376952716774" LOG_CI_START="-0.19940984479040225" LOG_EFFECT_SIZE="0.03542696236838276" ORDER="4" O_E="0.0" SE="0.27588860597202736" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.07611452290518858" WEIGHT="12.157538965252657"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4142944198405107" CI_END="1.065703271067092" CI_START="0.6982880697246074" DF="3" EFFECT_SIZE="0.862651656262619" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="179" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.027636298802042235" LOG_CI_START="-0.15596537783157585" LOG_EFFECT_SIZE="-0.06416453951476682" MODIFIED="2010-02-04 10:46:05 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9372740437719345" P_Z="0.17071057631672132" STUDIES="7" TAU2="0.0" TOTAL_1="5312" TOTAL_2="5320" WEIGHT="87.35717317138315" Z="1.3699241623430032">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="9.196087501391645" CI_START="0.01644553380754024" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9636030949581328" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.41017446508904926" ORDER="1" O_E="0.0" SE="1.6139274781606219" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="2.604761904761905" WEIGHT="0.6748971166542476"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-L_x002d_Jaramillo-1989" TOTAL_1="49" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="0.0" STUDY_ID="STD-L_x002d_Jaramillo-1997" TOTAL_1="125" TOTAL_2="135" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.575365645010253" CI_START="0.29455421561670153" EFFECT_SIZE="0.8709677419354839" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.41083889797405604" LOG_CI_START="-0.5308347573246267" LOG_EFFECT_SIZE="-0.05999792967528537" ORDER="5" O_E="0.0" SE="0.5531437664822174" STUDY_ID="STD-Belizan-1991" TOTAL_1="558" TOTAL_2="567" VAR="0.3059680263981339" WEIGHT="3.3846840285895685"/>
<DICH_DATA CI_END="1.0699023125806273" CI_START="0.689182101101549" EFFECT_SIZE="0.8586952449837619" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="166" LOG_CI_END="0.029344126242276954" LOG_CI_START="-0.16166601023412344" LOG_EFFECT_SIZE="-0.06616094199592325" ORDER="6" O_E="0.0" SE="0.11220029968166223" STUDY_ID="STD-WHO-2006" TOTAL_1="4181" TOTAL_2="4197" VAR="0.012588907248654814" WEIGHT="80.75814136137478"/>
<DICH_DATA CI_END="3.5704038333440558" CI_START="0.340931634717992" EFFECT_SIZE="1.1032967032967034" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5527173401105586" LOG_CI_START="-0.46733269913474473" LOG_EFFECT_SIZE="0.04269232048790696" MODIFIED="2010-01-07 12:54:38 +0000" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.5991824423818201" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.35901959925864313" WEIGHT="2.539450664764551"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19966076157657983" CI_END="0.97342152487206" CI_START="0.6546058298800623" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7982527200780406" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="210" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.011699054610076745" LOG_CI_START="-0.18402013121031394" LOG_EFFECT_SIZE="-0.09785959291019532" METHOD="MH" MODIFIED="2014-02-05 14:51:53 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6549948189319149" P_Q="1.0" P_Z="0.026008025428547743" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4856" TOTAL_2="4876" WEIGHT="100.0" Z="2.2260919143476388">
<NAME>Maternal death/serious morbidity</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.19966076157657983" CI_END="0.97342152487206" CI_START="0.6546058298800623" DF="1" EFFECT_SIZE="0.7982527200780406" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="210" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-0.011699054610076745" LOG_CI_START="-0.18402013121031394" LOG_EFFECT_SIZE="-0.09785959291019532" MODIFIED="2010-02-04 10:43:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6549948189319149" P_Z="0.026008025428547743" STUDIES="4" TAU2="0.0" TOTAL_1="4856" TOTAL_2="4876" WEIGHT="100.0" Z="2.2260919143476388">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="9.196087501391645" CI_START="0.01644553380754024" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9636030949581328" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.41017446508904926" ORDER="1" O_E="0.0" SE="1.6139274781606219" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="2.604761904761905" WEIGHT="0.6589228028529716"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-Belizan-1991" TOTAL_1="579" TOTAL_2="588" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.977162863972039" CI_START="0.6565433112642425" EFFECT_SIZE="0.8009680033288802" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="209" LOG_CI_END="-0.010033046281575234" LOG_CI_START="-0.18273661881651052" LOG_EFFECT_SIZE="-0.09638483254904288" ORDER="7" O_E="0.0" SE="0.10144693340349262" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.010291480296972667" WEIGHT="99.34107719714703"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-04 10:44:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adequate calcium diet</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9142487836135851" CI_END="1.3397017232756445" CI_START="0.5514706215713737" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8595383307654524" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.12700811601029213" LOG_CI_START="-0.2584776187256668" LOG_EFFECT_SIZE="-0.06573475135768733" METHOD="MH" MODIFIED="2014-02-05 15:01:00 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6331016140462257" P_Q="0.8475754925828523" P_Z="0.5038504465809209" Q="0.03694580952536527" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7158" TOTAL_2="7178" WEIGHT="100.00000000000001" Z="0.6684436469848148">
<NAME>Placental abruption</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6845059955641122" CI_START="0.3915575708903566" DF="0" EFFECT_SIZE="0.8121459694989107" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.2264725610789532" LOG_CI_START="-0.40720437439319157" LOG_EFFECT_SIZE="-0.09036590665711916" NO="1" P_CHI2="1.0" P_Z="0.5761590969953607" STUDIES="3" TAU2="0.0" TOTAL_1="2414" TOTAL_2="2416" WEIGHT="38.148756540876136" Z="0.5590038474299102">
<NAME>Adequate calcium diet</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Villar-1990" TOTAL_1="94" TOTAL_2="95" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6845059955641122" CI_START="0.3915575708903566" EFFECT_SIZE="0.8121459694989107" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.2264725610789532" LOG_CI_START="-0.40720437439319157" LOG_EFFECT_SIZE="-0.09036590665711916" ORDER="3" O_E="0.0" SE="0.3722249686477573" STUDY_ID="STD-CPEP-1997" TOTAL_1="2295" TOTAL_2="2294" VAR="0.1385514272848239" WEIGHT="38.148756540876136"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.879293175082108" CI_END="1.5549849082461948" CI_START="0.5079859717364347" DF="1" EFFECT_SIZE="0.8887691036770653" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.19172617838073053" LOG_CI_START="-0.2941482807900542" LOG_EFFECT_SIZE="-0.05121105120466181" MODIFIED="2010-04-19 09:52:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3483954480088567" P_Z="0.6794897847923145" STUDIES="2" TAU2="0.0" TOTAL_1="4744" TOTAL_2="4762" WEIGHT="61.85124345912388" Z="0.41315946568944073">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="1.4564890622555537" CI_START="0.41194118918208655" EFFECT_SIZE="0.7745888175905039" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" LOG_CI_END="0.16330722757000699" LOG_CI_START="-0.3851647816290159" LOG_EFFECT_SIZE="-0.11092877702950446" ORDER="2" O_E="0.0" SE="0.32217517318373823" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.10379684221597171" WEIGHT="52.3800189858784"/>
<DICH_DATA CI_END="5.359766583889277" CI_START="0.43119746469203135" EFFECT_SIZE="1.5202360876897134" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7291458767196008" LOG_CI_START="-0.3653238013312845" LOG_EFFECT_SIZE="0.18191103769415817" MODIFIED="2010-04-19 09:52:52 +0100" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.6428969065993722" STUDY_ID="STD-Belizan-1991" TOTAL_1="593" TOTAL_2="601" VAR="0.41331643251504185" WEIGHT="9.471224473245476"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.211249086927811" CI_END="1.0212685969382025" CI_START="0.8924205562110339" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9546732893092028" ESTIMABLE="YES" EVENTS_1="1345" EVENTS_2="1413" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.009139977960648802" LOG_CI_START="-0.04943043463853419" LOG_EFFECT_SIZE="-0.020145228338942694" METHOD="MH" MODIFIED="2014-02-05 15:01:12 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6342008848183207" P_Q="0.9191020827223293" P_Z="0.17757642211143232" Q="0.01031541847029397" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7608" TOTAL_2="7626" WEIGHT="100.0" Z="1.348254869736538">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.11721431810667983" CI_END="1.0707437613242345" CI_START="0.8425268586944261" DF="2" EFFECT_SIZE="0.9498054420222921" ESTIMABLE="YES" EVENTS_1="428" EVENTS_2="453" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.029685552664355252" LOG_CI_START="-0.07441624547519668" LOG_EFFECT_SIZE="-0.022365346405420712" NO="1" P_CHI2="0.9430771812149111" P_Z="0.3996974591795065" STUDIES="3" TAU2="0.0" TOTAL_1="2484" TOTAL_2="2497" WEIGHT="32.03451153165934" Z="0.8421616963354336">
<NAME>Adequate calcium diet</NAME>
<DICH_DATA CI_END="1.7686999766916593" CI_START="0.5115398312058062" EFFECT_SIZE="0.951188986232791" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.24765417009579002" LOG_CI_START="-0.2911205441621901" LOG_EFFECT_SIZE="-0.021733187033200027" ORDER="1" O_E="0.0" SE="0.3164789341329855" STUDY_ID="STD-Villar-1990" TOTAL_1="94" TOTAL_2="95" VAR="0.10015891574995059" WEIGHT="1.1989700567277564"/>
<DICH_DATA CI_END="1.4533994201446387" CI_START="0.7002196075351725" EFFECT_SIZE="1.0088105726872247" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="46" LOG_CI_END="0.1623849825890192" LOG_CI_START="-0.15476573229548862" LOG_EFFECT_SIZE="0.0038096251467653035" ORDER="2" O_E="0.0" SE="0.1862958998445179" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="0.03470616229887864" WEIGHT="3.2472237333596583"/>
<DICH_DATA CI_END="1.0732819832683889" CI_START="0.8281815122682817" EFFECT_SIZE="0.9428002418293681" ESTIMABLE="YES" EVENTS_1="366" EVENTS_2="390" LOG_CI_END="0.030713839103503032" LOG_CI_START="-0.08187446860481394" LOG_EFFECT_SIZE="-0.025580314750655465" ORDER="3" O_E="0.0" SE="0.06613492926897688" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.004373828869412574" WEIGHT="27.588317741571927"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.081439591464121" CI_END="1.0382932132056915" CI_START="0.8820120570965172" DF="4" EFFECT_SIZE="0.9569676759686843" ESTIMABLE="YES" EVENTS_1="917" EVENTS_2="960" I2="21.282149910445447" ID="CMP-001.08.02" LOG_CI_END="0.016320015261068348" LOG_CI_START="-0.054525478026122745" LOG_EFFECT_SIZE="-0.01910273138252719" MODIFIED="2010-02-04 10:45:05 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.27904298161794805" P_Z="0.2905267765628614" STUDIES="5" TAU2="0.0" TOTAL_1="5124" TOTAL_2="5129" WEIGHT="67.96548846834067" Z="1.0569667533916551">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="1.53038813965401" CI_START="0.024949264442627943" EFFECT_SIZE="0.19540229885057472" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.18480159129604534" LOG_CI_START="-1.6029422537767344" LOG_EFFECT_SIZE="-0.7090703312403446" ORDER="1" O_E="0.0" SE="1.0501295840705065" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="1.1027721433400948" WEIGHT="0.3916535479423584"/>
<DICH_DATA CI_END="2.3546872401700645" CI_START="0.286810877949505" EFFECT_SIZE="0.8217967599410898" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.37193323040815895" LOG_CI_START="-0.5424043810940049" LOG_EFFECT_SIZE="-0.08523557534292295" ORDER="2" O_E="0.0" SE="0.5370864390405431" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.28846184300125105" WEIGHT="0.5067684156179754"/>
<DICH_DATA CI_END="1.286457901445093" CI_START="0.6662554598043865" EFFECT_SIZE="0.9258021390374331" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="66" LOG_CI_END="0.1093955787552719" LOG_CI_START="-0.17635921901122237" LOG_EFFECT_SIZE="-0.0334818201279752" ORDER="3" O_E="0.0" SE="0.16785378271710058" STUDY_ID="STD-Belizan-1991" TOTAL_1="544" TOTAL_2="554" VAR="0.028174892372439617" WEIGHT="4.636965465293812"/>
<DICH_DATA CI_END="1.0364311919308737" CI_START="0.8724859264488966" EFFECT_SIZE="0.9509319790039361" ESTIMABLE="YES" EVENTS_1="809" EVENTS_2="854" LOG_CI_END="0.015540474826728276" LOG_CI_START="-0.059241569658042996" LOG_EFFECT_SIZE="-0.021850547415657385" ORDER="4" O_E="0.0" SE="0.04392734310744497" STUDY_ID="STD-WHO-2006" TOTAL_1="4181" TOTAL_2="4197" VAR="0.0019296114724791928" WEIGHT="60.43535096250752"/>
<DICH_DATA CI_END="2.199528446181204" CI_START="0.8862020513477009" EFFECT_SIZE="1.3961470628137296" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="27" LOG_CI_END="0.342329583016515" LOG_CI_START="-0.05246724901445441" LOG_EFFECT_SIZE="0.14493116700103031" MODIFIED="2010-01-07 12:48:58 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.23190561341082813" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.05378021353145247" WEIGHT="1.9947500769789945"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2590710237131122" CI_START="0.8566992577503265" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0385784570604029" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="194" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.1000502291838669" LOG_CI_START="-0.06717160937448549" LOG_EFFECT_SIZE="0.016439309904690717" METHOD="MH" MODIFIED="2010-05-18 14:23:50 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.6999693724922427" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4151" TOTAL_2="4161" WEIGHT="100.0" Z="0.3853618118502268">
<NAME>Proteinuria (gestational with no proteinuria</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adequate calcium diet</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2590710237131122" CI_START="0.8566992577503265" DF="0" EFFECT_SIZE="1.0385784570604029" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="194" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.1000502291838669" LOG_CI_START="-0.06717160937448549" LOG_EFFECT_SIZE="0.016439309904690717" NO="2" P_CHI2="1.0" P_Z="0.6999693724922427" STUDIES="1" TAU2="0.0" TOTAL_1="4151" TOTAL_2="4161" WEIGHT="100.0" Z="0.3853618118502268">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="1.2590710237131122" CI_START="0.8566992577503265" EFFECT_SIZE="1.0385784570604029" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="194" LOG_CI_END="0.1000502291838669" LOG_CI_START="-0.06717160937448549" LOG_EFFECT_SIZE="0.016439309904690717" ORDER="7" O_E="0.0" SE="0.09822693573062703" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.009648530903028734" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1510507575307347" CI_START="0.48177681680240103" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7446808510638298" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.0610944750020581" LOG_CI_START="-0.3171541021729419" LOG_EFFECT_SIZE="-0.12802981358544185" METHOD="MH" MODIFIED="2010-05-18 14:23:47 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.18456834665070357" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4151" TOTAL_2="4151" WEIGHT="100.0" Z="1.3268196562640142">
<NAME>Severe pre-eclampsia</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adequate calcium diet</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1510507575307347" CI_START="0.48177681680240103" DF="0" EFFECT_SIZE="0.7446808510638298" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="47" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.0610944750020581" LOG_CI_START="-0.3171541021729419" LOG_EFFECT_SIZE="-0.12802981358544185" NO="2" P_CHI2="1.0" P_Z="0.18456834665070357" STUDIES="1" TAU2="0.0" TOTAL_1="4151" TOTAL_2="4151" WEIGHT="100.0" Z="1.3268196562640142">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="1.1510507575307347" CI_START="0.48177681680240103" EFFECT_SIZE="0.7446808510638298" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="47" LOG_CI_END="0.0610944750020581" LOG_CI_START="-0.3171541021729419" LOG_EFFECT_SIZE="-0.12802981358544185" ORDER="7" O_E="0.0" SE="0.22218508659324904" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4151" VAR="0.049366212704449575" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.24529080060822428" CI_END="1.2706839819435696" CI_START="0.4142759541987775" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7255438092250354" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.10403755530379473" LOG_CI_START="-0.3827102737059257" LOG_EFFECT_SIZE="-0.13933635920106546" METHOD="MH" MODIFIED="2010-05-18 14:23:45 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.6204106952114385" P_Q="0.6204137028261514" P_Z="0.26181229752627755" Q="0.24528657961099365" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6719" TOTAL_2="6706" WEIGHT="100.0" Z="1.1221179818167029">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9918686317583294" CI_START="0.25029098458217974" DF="0" EFFECT_SIZE="0.9995642701525055" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.6011762406711416" LOG_CI_START="-0.601554793287204" LOG_EFFECT_SIZE="-1.8927630803115678E-4" NO="1" P_CHI2="1.0" P_Z="0.9995077951830054" STUDIES="1" TAU2="0.0" TOTAL_1="2295" TOTAL_2="2294" WEIGHT="13.810016941505559" Z="6.168872946544833E-4">
<NAME>Adequate calcium diet</NAME>
<DICH_DATA CI_END="3.9918686317583294" CI_START="0.25029098458217974" EFFECT_SIZE="0.9995642701525055" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6011762406711416" LOG_CI_START="-0.601554793287204" LOG_EFFECT_SIZE="-1.8927630803115678E-4" ORDER="6" O_E="0.0" SE="0.706490162961769" STUDY_ID="STD-CPEP-1997" TOTAL_1="2295" TOTAL_2="2294" VAR="0.4991283503617469" WEIGHT="13.810016941505559"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.82008780682193E-31" CI_END="1.260338156518541" CI_START="0.3686554898427059" DF="0" EFFECT_SIZE="0.6816381594796433" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" I2="99.99999999999999" ID="CMP-001.11.02" LOG_CI_END="0.1004870846466125" LOG_CI_START="-0.43337929440528433" LOG_EFFECT_SIZE="-0.1664461048793359" MODIFIED="2010-01-07 12:56:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.22165663434149463" STUDIES="2" TAU2="0.0" TOTAL_1="4424" TOTAL_2="4412" WEIGHT="86.18998305849445" Z="1.2221349151442351">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="1.2603381565185412" CI_START="0.368655489842706" EFFECT_SIZE="0.6816381594796435" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" LOG_CI_END="0.10048708464661259" LOG_CI_START="-0.43337929440528417" LOG_EFFECT_SIZE="-0.1664461048793358" ORDER="7" O_E="0.0" SE="0.31359575373628107" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.09834229676142625" WEIGHT="86.18998305849445"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-07 12:56:15 +0000" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.0" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19272504652674788" CI_END="6.81987278250328" CI_START="1.0454417312711828" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.670164715666329" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.8337762734288927" LOG_CI_START="0.01929983199577457" LOG_EFFECT_SIZE="0.4265380527123337" METHOD="MH" MODIFIED="2010-05-18 14:23:42 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.6606582051251964" P_Q="0.6610834331958209" P_Z="0.04008707038022823" Q="0.19221019201797315" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6446" TOTAL_2="6455" WEIGHT="100.0" Z="2.052850589222771">
<NAME>HELLP syndrome</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.82269104245582" CI_START="0.7275486967952292" DF="0" EFFECT_SIZE="3.498474945533769" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="1.2258954689534618" LOG_CI_START="-0.13813793286897302" LOG_EFFECT_SIZE="0.5438787680422444" NO="1" P_CHI2="1.0" P_Z="0.11805580432485338" STUDIES="1" TAU2="0.0" TOTAL_1="2295" TOTAL_2="2294" WEIGHT="33.36493398965591" Z="1.562986354871652">
<NAME>Adequate calcium diet</NAME>
<DICH_DATA CI_END="16.82269104245582" CI_START="0.7275486967952292" EFFECT_SIZE="3.498474945533769" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2258954689534618" LOG_CI_START="-0.13813793286897302" LOG_EFFECT_SIZE="0.5438787680422444" ORDER="6" O_E="0.0" SE="0.8012399723047333" STUDY_ID="STD-CPEP-1997" TOTAL_1="2295" TOTAL_2="2294" VAR="0.6419854932188898" WEIGHT="33.36493398965591"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.318044158719188" CI_START="0.6951203057862916" DF="0" EFFECT_SIZE="2.2554203806311732" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.8643950257887698" LOG_CI_START="-0.15794002473718904" LOG_EFFECT_SIZE="0.35322750052579033" NO="2" P_CHI2="1.0" P_Z="0.17561635617214041" STUDIES="1" TAU2="0.0" TOTAL_1="4151" TOTAL_2="4161" WEIGHT="66.63506601034409" Z="1.3543762957622927">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="7.318044158719188" CI_START="0.6951203057862916" EFFECT_SIZE="2.2554203806311732" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8643950257887698" LOG_CI_START="-0.15794002473718904" LOG_EFFECT_SIZE="0.35322750052579033" ORDER="7" O_E="0.0" SE="0.6005246693190652" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.36062987846077266" WEIGHT="66.63506601034409"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.07450050381498" CI_START="0.6607560480523931" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8426047154692949" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="138" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.031206623460793347" LOG_CI_START="-0.17995885298057374" LOG_EFFECT_SIZE="-0.0743761147598902" METHOD="MH" MODIFIED="2010-05-18 14:23:39 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.16738165257545734" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4151" TOTAL_2="4161" WEIGHT="100.0" Z="1.3806660889463997">
<NAME>Intensive care unit admission</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adequate calcium diet</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.07450050381498" CI_START="0.6607560480523931" DF="0" EFFECT_SIZE="0.8426047154692949" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="138" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="0.031206623460793347" LOG_CI_START="-0.17995885298057374" LOG_EFFECT_SIZE="-0.0743761147598902" NO="2" P_CHI2="1.0" P_Z="0.16738165257545734" STUDIES="1" TAU2="0.0" TOTAL_1="4151" TOTAL_2="4161" WEIGHT="100.0" Z="1.3806660889463997">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="1.07450050381498" CI_START="0.6607560480523931" EFFECT_SIZE="0.8426047154692949" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="138" LOG_CI_END="0.031206623460793347" LOG_CI_START="-0.17995885298057374" LOG_EFFECT_SIZE="-0.0743761147598902" ORDER="7" O_E="0.0" SE="0.12403964614762558" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.015385833816428166" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3870970233948219" CI_START="0.020122439220783786" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.16706817634304988" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.14210683976923422" LOG_CI_START="-1.6963193757076658" LOG_EFFECT_SIZE="-0.7771062679692158" METHOD="MH" MODIFIED="2010-05-18 14:23:37 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.09752735424004719" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4151" TOTAL_2="4161" WEIGHT="100.0" Z="1.6569610295563515">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adequate calcium diet</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3870970233948219" CI_START="0.020122439220783786" DF="0" EFFECT_SIZE="0.16706817634304988" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="0.14210683976923422" LOG_CI_START="-1.6963193757076658" LOG_EFFECT_SIZE="-0.7771062679692158" NO="2" P_CHI2="1.0" P_Z="0.09752735424004719" STUDIES="1" TAU2="0.0" TOTAL_1="4151" TOTAL_2="4161" WEIGHT="100.0" Z="1.6569610295563515">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="1.3870970233948223" CI_START="0.020122439220783786" EFFECT_SIZE="0.16706817634304988" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14210683976923436" LOG_CI_START="-1.6963193757076658" LOG_EFFECT_SIZE="-0.7771062679692158" ORDER="48349" O_E="0.0" SE="1.0799006593276663" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="1.1661854340163282" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.930671318851829" CI_END="1.006968643506591" CI_START="0.7153730924296039" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8487392252541137" ESTIMABLE="YES" EVENTS_1="810" EVENTS_2="878" I2="49.65093658362974" I2_Q="49.18432914863065" ID="CMP-001.15" LOG_CI_END="0.003015947054029891" LOG_CI_START="-0.1454673991452724" LOG_EFFECT_SIZE="-0.07122572604562132" METHOD="MH" MODIFIED="2010-05-18 14:23:34 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.07722368078832298" P_Q="0.16067158542963766" P_Z="0.06006125936543479" Q="1.967896877569319" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.018384615885394036" TOTALS="YES" TOTAL_1="7433" TOTAL_2="7450" WEIGHT="100.0" Z="1.8803436398147417">
<NAME>Birthweight &lt; 2500 g</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.999468594109723" CI_END="1.1323584967867009" CI_START="0.30938491147356373" DF="2" EFFECT_SIZE="0.5918907274866629" ESTIMABLE="YES" EVENTS_1="203" EVENTS_2="242" I2="71.42640226026496" ID="CMP-001.15.01" LOG_CI_END="0.05398394321970595" LOG_CI_START="-0.5095008704154439" LOG_EFFECT_SIZE="-0.22775846359786903" NO="1" P_CHI2="0.0302054438096796" P_Z="0.11309810770231517" STUDIES="4" TAU2="0.22977387881087374" TOTAL_1="2509" TOTAL_2="2524" WEIGHT="35.54401391762834" Z="1.5844202896833994">
<NAME>Adequate calcium diet</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9467555430520063" CI_START="0.21846339296976747" EFFECT_SIZE="0.45478723404255317" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.023762143498023847" LOG_CI_START="-0.6606213255729906" LOG_EFFECT_SIZE="-0.3421917345355072" ORDER="2" O_E="0.0" SE="0.37409423605462966" STUDY_ID="STD-Villar-1990" TOTAL_1="94" TOTAL_2="95" VAR="0.139946497449297" WEIGHT="4.804679586150966"/>
<DICH_DATA CI_END="0.8866898402634935" CI_START="0.1429723896221125" EFFECT_SIZE="0.35605079036019693" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.05222826767463301" LOG_CI_START="-0.844747824021097" LOG_EFFECT_SIZE="-0.44848804584786506" ORDER="3" O_E="0.0" SE="0.46552991043298686" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="0.21671809750774476" WEIGHT="3.2357358071816544"/>
<DICH_DATA CI_END="1.1127107780152086" CI_START="0.7628376075382945" EFFECT_SIZE="0.9213129912159038" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="205" LOG_CI_END="0.046382294761547475" LOG_CI_START="-0.11756790458283026" LOG_EFFECT_SIZE="-0.03559280491064139" ORDER="4" O_E="0.0" SE="0.09630515866146298" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.009274683584809559" WEIGHT="27.503598524295718"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.918381542068078" CI_END="1.0498595755361726" CI_START="0.8544874271186296" DF="2" EFFECT_SIZE="0.947149305830797" ESTIMABLE="YES" EVENTS_1="607" EVENTS_2="636" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="0.02113121369073856" LOG_CI_START="-0.06829432308153825" LOG_EFFECT_SIZE="-0.023581554695399833" MODIFIED="2010-02-04 10:45:48 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.38320293560337815" P_Z="0.3012826265959764" STUDIES="5" TAU2="0.0" TOTAL_1="4924" TOTAL_2="4926" WEIGHT="64.45598608237165" Z="1.0336867872572526">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-L_x002d_Jaramillo-1989" TOTAL_1="49" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-L_x002d_Jaramillo-1997" TOTAL_1="125" TOTAL_2="135" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2134486027315845" CI_START="0.4920205605183723" EFFECT_SIZE="0.7726847103937219" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="41" LOG_CI_END="0.08402138592318148" LOG_CI_START="-0.308016748588122" LOG_EFFECT_SIZE="-0.11199768133247028" ORDER="3" O_E="0.0" SE="0.23028514083200344" STUDY_ID="STD-Belizan-1991" TOTAL_1="547" TOTAL_2="559" VAR="0.053031246088015654" WEIGHT="10.652119110107336"/>
<DICH_DATA CI_END="1.0967602934013256" CI_START="0.8740412948953478" EFFECT_SIZE="0.9790882427208981" ESTIMABLE="YES" EVENTS_1="512" EVENTS_2="524" LOG_CI_END="0.04011171907098124" LOG_CI_START="-0.0584680482334277" LOG_EFFECT_SIZE="-0.009178164581223206" ORDER="4" O_E="0.0" SE="0.057906243292328" STUDY_ID="STD-WHO-2006" TOTAL_1="3930" TOTAL_2="3938" VAR="0.0033531330122302814" WEIGHT="34.99581634117064"/>
<DICH_DATA CI_END="1.1088309229100197" CI_START="0.6194411755384486" EFFECT_SIZE="0.8287674766548006" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="71" LOG_CI_END="0.044865328975814314" LOG_CI_START="-0.20799992956562632" LOG_EFFECT_SIZE="-0.08156730029490604" MODIFIED="2010-01-19 10:25:36 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.1485343045704592" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.02206243963422994" WEIGHT="18.808050631093682"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7365675225968222" CI_END="1.29242323296313" CI_START="0.8586886735825014" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0534653253051656" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="170" I2="0.0" I2_Q="54.63899423889217" ID="CMP-001.16" LOG_CI_END="0.11140475641539534" LOG_CI_START="-0.06616426556647141" LOG_EFFECT_SIZE="0.02262024542446196" METHOD="MH" MODIFIED="2010-05-18 14:23:31 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.4340488297832048" P_Q="0.13760531977308266" P_Z="0.6175302936435805" Q="2.204536657027548" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6816" TOTAL_2="6799" WEIGHT="100.0" Z="0.499353613131122">
<NAME>Neonate small-for-gestational age as defined by trial authors</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5208889280952107" CI_START="0.9161966959886897" DF="0" EFFECT_SIZE="1.1804378047515303" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="105" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.18209749828920416" LOG_CI_START="-0.03801127872067249" LOG_EFFECT_SIZE="0.07204310978426583" NO="1" P_CHI2="1.0" P_Z="0.19948532719068307" STUDIES="1" TAU2="0.0" TOTAL_1="2295" TOTAL_2="2294" WEIGHT="61.40623470531772" Z="1.2830192637442188">
<NAME>Adequate calcium diet</NAME>
<DICH_DATA CI_END="1.5208889280952107" CI_START="0.9161966959886897" EFFECT_SIZE="1.1804378047515303" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="105" LOG_CI_END="0.18209749828920416" LOG_CI_START="-0.03801127872067249" LOG_EFFECT_SIZE="0.07204310978426583" ORDER="6" O_E="0.0" SE="0.1292929851716199" STUDY_ID="STD-CPEP-1997" TOTAL_1="2295" TOTAL_2="2294" VAR="0.01671667601458873" WEIGHT="61.40623470531772"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.48703050554276384" CI_END="1.2070091074690048" CI_START="0.600617493383694" DF="2" EFFECT_SIZE="0.8514404175391977" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="65" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.08171054707217144" LOG_CI_START="-0.22140202283738886" LOG_EFFECT_SIZE="-0.06984573788260869" MODIFIED="2010-02-04 10:45:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7838675279336853" P_Z="0.3663865274990912" STUDIES="3" TAU2="0.0" TOTAL_1="4521" TOTAL_2="4505" WEIGHT="38.59376529468227" Z="0.903262644398966">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="1.3781239099084992" CI_START="0.4019695304655828" EFFECT_SIZE="0.7442874585731729" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.1392882676225551" LOG_CI_START="-0.39580686545328153" LOG_EFFECT_SIZE="-0.1282592989153632" MODIFIED="2010-01-07 12:53:05 +0000" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.3143175299323739" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.09879550962278874" WEIGHT="12.794083823133253"/>
<DICH_DATA CI_END="1.993263838640101" CI_START="0.2594060898412837" EFFECT_SIZE="0.7190721649484536" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2995647879537404" LOG_CI_START="-0.5860198325949598" LOG_EFFECT_SIZE="-0.1432275223206097" ORDER="48369" O_E="0.0" SE="0.5201967898248778" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.27060470014410815" WEIGHT="4.776025724106728"/>
<DICH_DATA CI_END="1.5098101291323043" CI_START="0.5936363179654376" EFFECT_SIZE="0.9467196659439493" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="36" LOG_CI_END="0.17892233467403315" LOG_CI_START="-0.22647953729524165" LOG_EFFECT_SIZE="-0.023778601310604257" ORDER="48370" O_E="0.0" SE="0.23813506636638307" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.056708309833321674" WEIGHT="21.02365574744229"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9068031923923006" CI_START="0.3887068637587681" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5937007874015748" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="-0.04248695961309882" LOG_CI_START="-0.41037779055926676" LOG_EFFECT_SIZE="-0.22643237508618277" METHOD="MH" MODIFIED="2010-02-05 11:10:28 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.015836217842606373" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="254" TOTAL_2="260" WEIGHT="100.0" Z="2.4126684481990925">
<NAME>Childhood systolic blood pressure &gt; 95th percentile</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adequate calcium diet</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9068031923923006" CI_START="0.3887068637587681" DF="0" EFFECT_SIZE="0.5937007874015748" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="50" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="-0.04248695961309882" LOG_CI_START="-0.41037779055926676" LOG_EFFECT_SIZE="-0.22643237508618277" MODIFIED="2010-02-04 10:46:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.015836217842606373" STUDIES="1" TAU2="0.0" TOTAL_1="254" TOTAL_2="260" WEIGHT="100.0" Z="2.4126684481990925">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="0.9068031923923006" CI_START="0.3887068637587681" EFFECT_SIZE="0.5937007874015748" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="50" LOG_CI_END="-0.04248695961309882" LOG_CI_START="-0.41037779055926676" LOG_EFFECT_SIZE="-0.22643237508618277" ORDER="48385" O_E="0.0" SE="0.2161008951867624" STUDY_ID="STD-Belizan-1991" TOTAL_1="254" TOTAL_2="260" VAR="0.046699596900520064" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.308573949680309" CI_START="0.49704969142524724" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8064900978286805" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.1167982703695698" LOG_CI_START="-0.30360019148194906" LOG_EFFECT_SIZE="-0.0934009605561896" METHOD="MH" MODIFIED="2010-02-05 11:10:28 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.38380874362174267" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="254" TOTAL_2="260" WEIGHT="100.0" Z="0.8709000409056393">
<NAME>Childhood diastolic blood pressure &gt; 95th percentile</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adequate calcium diet</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.308573949680309" CI_START="0.49704969142524724" DF="0" EFFECT_SIZE="0.8064900978286805" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="33" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="0.1167982703695698" LOG_CI_START="-0.30360019148194906" LOG_EFFECT_SIZE="-0.0934009605561896" MODIFIED="2010-02-04 10:46:20 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.38380874362174267" STUDIES="1" TAU2="0.0" TOTAL_1="254" TOTAL_2="260" WEIGHT="100.0" Z="0.8709000409056393">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="1.308573949680309" CI_START="0.49704969142524724" EFFECT_SIZE="0.8064900978286805" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="33" LOG_CI_END="0.1167982703695698" LOG_CI_START="-0.30360019148194906" LOG_EFFECT_SIZE="-0.0934009605561896" ORDER="48386" O_E="0.0" SE="0.24694413749753036" STUDY_ID="STD-Belizan-1991" TOTAL_1="254" TOTAL_2="260" VAR="0.06098140704439918" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8659137416393626" CI_START="0.616369999607185" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7305636540330418" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="-0.06252536825500196" LOG_CI_START="-0.21015850772475358" LOG_EFFECT_SIZE="-0.1363419379898778" METHOD="MH" MODIFIED="2014-02-05 15:02:01 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="2.944595173482502E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="97" WEIGHT="100.0" Z="3.6201260638680015">
<NAME>Childhood dental caries</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8659137416393626" CI_START="0.616369999607185" DF="0" EFFECT_SIZE="0.7305636540330418" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="84" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="-0.06252536825500196" LOG_CI_START="-0.21015850772475358" LOG_EFFECT_SIZE="-0.1363419379898778" MODIFIED="2013-05-24 13:05:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="2.944595173482502E-4" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="97" WEIGHT="100.0" Z="3.6201260638680015">
<NAME>Low calcium diet</NAME>
<DICH_DATA CI_END="0.8659137416393626" CI_START="0.616369999607185" EFFECT_SIZE="0.7305636540330418" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="84" LOG_CI_END="-0.06252536825500196" LOG_CI_START="-0.21015850772475358" LOG_EFFECT_SIZE="-0.1363419379898778" MODIFIED="2012-08-31 19:04:17 +0100" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="0.08672043692035862" STUDY_ID="STD-Belizan-1991" TOTAL_1="98" TOTAL_2="97" VAR="0.007520434179657897" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-02-05 17:00:11 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Routine high-dose calcium supplementation in pregnancy by hypertension risk</NAME>
<DICH_OUTCOME CHI2="42.404500142826535" CI_END="0.8066632530561235" CI_START="0.5279806534607002" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6526121294239836" ESTIMABLE="YES" EVENTS_1="1260" EVENTS_2="1472" I2="74.05935699524844" I2_Q="13.773787047861495" ID="CMP-002.01" LOG_CI_END="-0.09330772656818868" LOG_CI_START="-0.2773819908169394" LOG_EFFECT_SIZE="-0.18534485869256404" METHOD="MH" MODIFIED="2014-02-05 15:02:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.3783092274843867E-5" P_Q="0.28151948894448475" P_Z="7.914126964739128E-5" Q="1.1597401367436477" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0602884436740692" TOTALS="YES" TOTAL_1="7726" TOTAL_2="7744" WEIGHT="99.99999999999997" Z="3.9469857368674144">
<NAME>High blood pressure (with or without proteinuria)</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="28.834236891426436" CI_END="0.8854711894725817" CI_START="0.5707357508679025" DF="7" EFFECT_SIZE="0.710893848753475" ESTIMABLE="YES" EVENTS_1="1235" EVENTS_2="1407" I2="75.7233041180938" ID="CMP-002.01.01" LOG_CI_END="-0.05282556485971278" LOG_CI_START="-0.24356492240748756" LOG_EFFECT_SIZE="-0.1481952436336002" MODIFIED="2010-01-28 09:27:34 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.5511071660923026E-4" P_Z="0.0023222102445797322" STUDIES="8" TAU2="0.046031886986247786" TOTAL_1="7570" TOTAL_2="7573" WEIGHT="76.83719062913633" Z="3.0455941965647417">
<NAME>Low-risk women</NAME>
<DICH_DATA CI_END="3.2386838149791783" CI_START="0.04001625580138121" EFFECT_SIZE="0.36" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5103685509392996" LOG_CI_START="-1.3977635494047251" LOG_EFFECT_SIZE="-0.44369749923271273" ORDER="1" O_E="0.0" SE="1.1208462411483104" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="1.2562962962962962" WEIGHT="0.8879991161439288"/>
<DICH_DATA CI_END="0.6572969199542048" CI_START="0.03633715113456673" EFFECT_SIZE="0.15454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.1822384027873744" LOG_CI_START="-1.439649124772528" LOG_EFFECT_SIZE="-0.8109437637799511" ORDER="2" O_E="0.0" SE="0.738609282377537" STUDY_ID="STD-L_x002d_Jaramillo-1989" TOTAL_1="55" TOTAL_2="51" VAR="0.5455436720142602" WEIGHT="1.9297855877018677"/>
<DICH_DATA CI_END="0.5929732148002642" CI_START="0.13609425669450542" EFFECT_SIZE="0.284077892325315" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.22696492371359167" LOG_CI_START="-0.8661602020451153" LOG_EFFECT_SIZE="-0.5465625628793535" ORDER="3" O_E="0.0" SE="0.37546647055959415" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.14097507051447858" WEIGHT="5.808932086552994"/>
<DICH_DATA CI_END="1.380236711853532" CI_START="0.5902776185343098" EFFECT_SIZE="0.9026199860885694" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.1399535746881291" LOG_CI_START="-0.22894368354370867" LOG_EFFECT_SIZE="-0.044495054427789775" ORDER="4" O_E="0.0" SE="0.21669207555626024" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="0.046955455608879995" WEIGHT="10.901562636562481"/>
<DICH_DATA CI_END="0.910487633755234" CI_START="0.48622208265306216" EFFECT_SIZE="0.6653564409505092" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="87" LOG_CI_END="-0.040725948417479924" LOG_CI_START="-0.3131653207773698" LOG_EFFECT_SIZE="-0.17694563459742485" ORDER="5" O_E="0.0" SE="0.1600322359208424" STUDY_ID="STD-Belizan-1991" TOTAL_1="579" TOTAL_2="588" VAR="0.02561031653382416" WEIGHT="13.610511753519301"/>
<DICH_DATA CI_END="1.004177715946483" CI_START="0.815707589773221" EFFECT_SIZE="0.9050499347432074" ESTIMABLE="YES" EVENTS_1="509" EVENTS_2="565" LOG_CI_END="0.0018105795668501195" LOG_CI_START="-0.08846549676934357" LOG_EFFECT_SIZE="-0.043327458601246704" ORDER="6" O_E="0.0" SE="0.05302861411366513" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.002812033914816004" WEIGHT="18.528006920001562"/>
<DICH_DATA CI_END="1.0548224711363225" CI_START="0.8604231990759956" EFFECT_SIZE="0.9526771357980425" ESTIMABLE="YES" EVENTS_1="613" EVENTS_2="645" LOG_CI_END="0.023179373099550035" LOG_CI_START="-0.06528788850439987" LOG_EFFECT_SIZE="-0.02105425770242488" ORDER="7" O_E="0.0" SE="0.0519661073861678" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.0027004763168707235" WEIGHT="18.560821261746213"/>
<DICH_DATA CI_END="0.658315853479314" CI_START="0.1726357341153547" EFFECT_SIZE="0.33711843711843714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" LOG_CI_END="-0.18156568615707572" LOG_CI_START="-0.7628693040852348" LOG_EFFECT_SIZE="-0.47221749512115524" MODIFIED="2010-01-28 09:27:34 +0000" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.34146062267031707" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.11659535683440066" WEIGHT="6.609571266907998"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.014512495293204" CI_END="0.9739460019490892" CI_START="0.22268821584899484" DF="3" EFFECT_SIZE="0.465710529736342" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="65" I2="72.76320671221735" ID="CMP-002.01.02" LOG_CI_END="-0.0114651208478991" LOG_CI_START="-0.6523027642284853" LOG_EFFECT_SIZE="-0.3318839425381922" NO="2" P_CHI2="0.01164770547502958" P_Z="0.042346906956288274" STUDIES="4" TAU2="0.38299726320279254" TOTAL_1="156" TOTAL_2="171" WEIGHT="23.162809370863645" Z="2.030094770933126">
<NAME>High-risk women</NAME>
<DICH_DATA CI_END="1.4549654839743185" CI_START="0.5680177915521761" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.16285269071210204" LOG_CI_START="-0.24563806102855215" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="1" O_E="0.0" SE="0.2399494896342928" STUDY_ID="STD-Niromanesh-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.057575757575757586" WEIGHT="9.919263635819082"/>
<DICH_DATA CI_END="0.5653174689130992" CI_START="0.06601461466914227" EFFECT_SIZE="0.19318181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="24" LOG_CI_END="-0.24770759416955618" LOG_CI_START="-1.1803599073742332" LOG_EFFECT_SIZE="-0.7140337507718947" ORDER="2" O_E="0.0" SE="0.547844585479835" STUDY_ID="STD-L_x002d_Jaramillo-1990" TOTAL_1="22" TOTAL_2="34" VAR="0.30013368983957217" WEIGHT="3.2437688385694523"/>
<DICH_DATA CI_END="0.8710096324971176" CI_START="0.26410616415560584" EFFECT_SIZE="0.47962382445141066" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.0599770421023101" LOG_CI_START="-0.5782214623768545" LOG_EFFECT_SIZE="-0.3190992522395823" ORDER="3" O_E="0.0" SE="0.30441933782052116" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="0.09267113323908457" WEIGHT="7.643366365259145"/>
<DICH_DATA CI_END="1.3373071704026946" CI_START="0.10053370491086208" EFFECT_SIZE="0.36666666666666664" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.12623117322227295" LOG_CI_START="-0.9976883123451477" LOG_EFFECT_SIZE="-0.4357285695614374" ORDER="4" O_E="0.0" SE="0.6601958693134833" STUDY_ID="STD-Villar-1990" TOTAL_1="90" TOTAL_2="88" VAR="0.43585858585858583" WEIGHT="2.356410531215969"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="40.309494956985176" CI_END="0.647050621117564" CI_START="0.3107089176343305" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4483797476939158" ESTIMABLE="YES" EVENTS_1="379" EVENTS_2="510" I2="70.23033899877593" I2_Q="85.31244811912865" ID="CMP-002.02" LOG_CI_END="-0.1890617415692581" LOG_CI_START="-0.5076462819114136" LOG_EFFECT_SIZE="-0.3483540117403358" METHOD="MH" MODIFIED="2014-02-05 15:02:20 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="6.387881802949469E-5" P_Q="0.009072618036792601" P_Z="1.8174105353508817E-5" Q="6.808486588580989" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1957339649071223" TOTALS="YES" TOTAL_1="7851" TOTAL_2="7879" WEIGHT="100.0" Z="4.286217505393231">
<NAME>Pre-eclampsia</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="23.093168264770803" CI_END="0.8319648477527039" CI_START="0.4122645654234716" DF="7" EFFECT_SIZE="0.5856531622098298" ESTIMABLE="YES" EVENTS_1="370" EVENTS_2="456" I2="69.68800504225887" ID="CMP-002.02.01" LOG_CI_END="-0.07989502316786" LOG_CI_START="-0.38482399166574827" LOG_EFFECT_SIZE="-0.23235950741680414" MODIFIED="2010-01-28 09:37:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.001642076565641415" P_Z="0.002817003995503882" STUDIES="8" TAU2="0.12194382147989702" TOTAL_1="7570" TOTAL_2="7573" WEIGHT="78.9721599382822" Z="2.987031820858684">
<NAME>Low-risk women</NAME>
<DICH_DATA CI_END="3.2386838149791783" CI_START="0.04001625580138121" EFFECT_SIZE="0.36" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5103685509392996" LOG_CI_START="-1.3977635494047251" LOG_EFFECT_SIZE="-0.44369749923271273" ORDER="1" O_E="0.0" SE="1.1208462411483104" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="1.2562962962962962" WEIGHT="2.4118424310577007"/>
<DICH_DATA CI_END="0.6572969199542048" CI_START="0.03633715113456673" EFFECT_SIZE="0.15454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.1822384027873744" LOG_CI_START="-1.439649124772528" LOG_EFFECT_SIZE="-0.8109437637799511" ORDER="2" O_E="0.0" SE="0.738609282377537" STUDY_ID="STD-L_x002d_Jaramillo-1989" TOTAL_1="55" TOTAL_2="51" VAR="0.5455436720142602" WEIGHT="4.724367795168788"/>
<DICH_DATA CI_END="0.7654298803110793" CI_START="0.039700103380788714" EFFECT_SIZE="0.17432052483598875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.11609458809933586" LOG_CI_START="-1.4012083623137712" LOG_EFFECT_SIZE="-0.7586514752065536" ORDER="3" O_E="0.0" SE="0.7548821923893373" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.5698471243865325" WEIGHT="4.57439224156033"/>
<DICH_DATA CI_END="0.9005185378929982" CI_START="0.21363426985509443" EFFECT_SIZE="0.43861329247270636" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" LOG_CI_END="-0.045507342453812105" LOG_CI_START="-0.6703290792878431" LOG_EFFECT_SIZE="-0.35791821087082765" ORDER="4" O_E="0.0" SE="0.36702338113378913" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="0.13470616229887863" WEIGHT="10.598192854970558"/>
<DICH_DATA CI_END="1.2564036801956278" CI_START="0.34913643328973276" EFFECT_SIZE="0.6623113313809417" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.0991291998422843" LOG_CI_START="-0.457004829068703" LOG_EFFECT_SIZE="-0.17893781461320935" ORDER="5" O_E="0.0" SE="0.32667588149015536" STUDY_ID="STD-Belizan-1991" TOTAL_1="579" TOTAL_2="588" VAR="0.10671713154737002" WEIGHT="11.578956850226305"/>
<DICH_DATA CI_END="1.164315856627379" CI_START="0.7667101490907422" EFFECT_SIZE="0.9448242080003523" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="168" LOG_CI_END="0.06607081208552928" LOG_CI_START="-0.11536878786554355" LOG_EFFECT_SIZE="-0.024648987890007152" ORDER="6" O_E="0.0" SE="0.10657851915176493" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.011358980744583125" WEIGHT="16.91061076044606"/>
<DICH_DATA CI_END="1.1291564763039879" CI_START="0.7521460297532139" EFFECT_SIZE="0.9215696178923073" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="186" LOG_CI_END="0.052754129778371656" LOG_CI_START="-0.12369783260104086" LOG_EFFECT_SIZE="-0.03547185141133463" ORDER="7" O_E="0.0" SE="0.10364875615296752" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.010743064652057323" WEIGHT="16.961054712124536"/>
<DICH_DATA CI_END="0.658315853479314" CI_START="0.1726357341153547" EFFECT_SIZE="0.33711843711843714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" LOG_CI_END="-0.18156568615707572" LOG_CI_START="-0.7628693040852348" LOG_EFFECT_SIZE="-0.47221749512115524" MODIFIED="2010-01-28 09:37:58 +0000" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.34146062267031707" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.11659535683440066" WEIGHT="11.212742292727922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2267933498768469" CI_END="0.42038287191797574" CI_START="0.1172182765365784" DF="4" EFFECT_SIZE="0.22198323299682413" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="54" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-0.376354987180062" LOG_CI_START="-0.9310046683507169" LOG_EFFECT_SIZE="-0.6536798277653895" NO="2" P_CHI2="0.8736678936142551" P_Z="3.840859490774251E-6" STUDIES="5" TAU2="0.0" TOTAL_1="281" TOTAL_2="306" WEIGHT="21.027840061717804" Z="4.619813057987903">
<NAME>High-risk women</NAME>
<DICH_DATA CI_END="1.0236399778788619" CI_START="0.019936856420550257" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.01014723875593224" LOG_CI_START="-1.7003433187844461" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="1" O_E="0.0" SE="1.004750620564033" STUDY_ID="STD-Niromanesh-2001" TOTAL_1="15" TOTAL_2="15" VAR="1.0095238095238095" WEIGHT="2.90565907928179"/>
<DICH_DATA CI_END="1.4767841726119282" CI_START="0.005425822032279613" EFFECT_SIZE="0.08951406649616368" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.1693170291692847" LOG_CI_START="-2.265534455260467" LOG_EFFECT_SIZE="-1.0481087130455913" ORDER="2" O_E="0.0" SE="1.4302438146632677" STUDY_ID="STD-L_x002d_Jaramillo-1990" TOTAL_1="22" TOTAL_2="34" VAR="2.0455973693825356" WEIGHT="1.5624946394907322"/>
<DICH_DATA CI_END="0.8375361676745214" CI_START="0.11670668475773119" EFFECT_SIZE="0.31264367816091954" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.07699642956596733" LOG_CI_START="-0.9329042676028722" LOG_EFFECT_SIZE="-0.5049503485844198" ORDER="3" O_E="0.0" SE="0.5027645008750067" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="0.2527721433400946" WEIGHT="7.808295429545985"/>
<DICH_DATA CI_END="2.6660884062158257" CI_START="0.007321947360692846" EFFECT_SIZE="0.13971742543171115" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4258745463138206" LOG_CI_START="-2.135373397694696" LOG_EFFECT_SIZE="-0.8547494256904377" ORDER="4" O_E="0.0" SE="1.5044897206923997" STUDY_ID="STD-Villar-1990" TOTAL_1="90" TOTAL_2="88" VAR="2.263489319669095" WEIGHT="1.4240545854923012"/>
<DICH_DATA CI_END="0.5827111349564926" CI_START="0.07262323440944443" EFFECT_SIZE="0.2057142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="21" LOG_CI_END="-0.23454668294991027" LOG_CI_START="-1.1389244128881042" LOG_EFFECT_SIZE="-0.6867355479190071" ORDER="5" O_E="0.0" SE="0.5312359553076582" STUDY_ID="STD-L_x002d_Jaramillo-1997" TOTAL_1="125" TOTAL_2="135" VAR="0.2822116402116402" WEIGHT="7.3273363279069965"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.03552375208524" CI_END="0.9684314128748296" CI_START="0.6037502692114264" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7646507217259265" ESTIMABLE="YES" EVENTS_1="722" EVENTS_2="795" I2="60.07092153422052" I2_Q="71.26755892335909" ID="CMP-002.03" LOG_CI_END="-0.013931131852219374" LOG_CI_START="-0.21914266258906767" LOG_EFFECT_SIZE="-0.11653689722064355" METHOD="MH" MODIFIED="2014-02-05 14:55:45 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.010202510577607682" P_Q="0.062100353549089715" P_Z="0.02600916321604849" Q="3.4803864987753745" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.049534067416319376" TOTALS="YES" TOTAL_1="7620" TOTAL_2="7655" WEIGHT="100.0" Z="2.2260749247604896">
<NAME>Preterm birth</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="13.046642909052231" CI_END="1.052227560658126" CI_START="0.6718497825254784" DF="5" EFFECT_SIZE="0.840796561479337" ESTIMABLE="YES" EVENTS_1="710" EVENTS_2="763" I2="61.67596496006785" ID="CMP-002.03.01" LOG_CI_END="0.02210967294582427" LOG_CI_START="-0.17272781907862914" LOG_EFFECT_SIZE="-0.07530907306640244" MODIFIED="2010-01-28 09:34:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.022945629636592524" P_Z="0.12973687039194443" STUDIES="7" TAU2="0.03519145665142437" TOTAL_1="7350" TOTAL_2="7357" WEIGHT="88.09372459662546" Z="1.5151403293645256">
<NAME>Low-risk women</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5435702531595743" CI_START="0.06616883962042779" EFFECT_SIZE="0.31958762886597936" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18852640049463437" LOG_CI_START="-1.1793464813585786" LOG_EFFECT_SIZE="-0.49541004043197223" ORDER="2" O_E="0.0" SE="0.8034953018805451" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.6456047001441082" WEIGHT="2.090293231525053"/>
<DICH_DATA CI_END="0.9005185378929982" CI_START="0.21363426985509443" EFFECT_SIZE="0.43861329247270636" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" LOG_CI_END="-0.045507342453812105" LOG_CI_START="-0.6703290792878431" LOG_EFFECT_SIZE="-0.35791821087082765" ORDER="3" O_E="0.0" SE="0.36702338113378913" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="0.13470616229887863" WEIGHT="7.88668068341193"/>
<DICH_DATA CI_END="1.4439272814417574" CI_START="0.5827153416347585" EFFECT_SIZE="0.9172778091184163" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="37" LOG_CI_END="0.15954532199829777" LOG_CI_START="-0.23454354772483224" LOG_EFFECT_SIZE="-0.03749911286326723" ORDER="4" O_E="0.0" SE="0.23148975284673337" STUDY_ID="STD-Belizan-1991" TOTAL_1="527" TOTAL_2="542" VAR="0.053587505673041706" WEIGHT="14.090590526029683"/>
<DICH_DATA CI_END="1.2889032490745085" CI_START="0.9183716999471098" EFFECT_SIZE="1.0879762258063865" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="229" LOG_CI_END="0.11022031846273883" LOG_CI_START="-0.03698150772721611" LOG_EFFECT_SIZE="0.03661940536776136" ORDER="5" O_E="0.0" SE="0.08646708136477087" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.007476556159741905" WEIGHT="25.487247282318116"/>
<DICH_DATA CI_END="1.0392392349245045" CI_START="0.803410716235685" EFFECT_SIZE="0.9137482903244862" ESTIMABLE="YES" EVENTS_1="398" EVENTS_2="436" LOG_CI_END="0.01671553451373544" LOG_CI_START="-0.09506237976020236" LOG_EFFECT_SIZE="-0.03917342262323345" ORDER="6" O_E="0.0" SE="0.06565890015411037" STUDY_ID="STD-WHO-2006" TOTAL_1="4038" TOTAL_2="4042" VAR="0.004311091169447435" WEIGHT="26.98559905785698"/>
<DICH_DATA CI_END="0.937856801490909" CI_START="0.3177553429557519" EFFECT_SIZE="0.5459020146520146" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="32" LOG_CI_END="-0.02786346766560416" LOG_CI_START="-0.49790713818798576" LOG_EFFECT_SIZE="-0.26288530292679496" MODIFIED="2010-01-28 09:34:50 +0000" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.27610597881854143" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.07623451153934484" WEIGHT="11.553313815483707"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7338806805909115" CI_END="0.8341076341401918" CI_START="0.2432529603443494" DF="2" EFFECT_SIZE="0.4504432830561726" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="32" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-0.07877790392219748" LOG_CI_START="-0.6139418657424787" LOG_EFFECT_SIZE="-0.34635988483233804" NO="2" P_CHI2="0.42023571192057185" P_Z="0.011181004025064632" STUDIES="4" TAU2="0.0" TOTAL_1="270" TOTAL_2="298" WEIGHT="11.906275403374533" Z="2.5369903371363263">
<NAME>High-risk women</NAME>
<DICH_DATA CI_END="2.994016851312268" CI_START="0.009548632027969623" EFFECT_SIZE="0.16908212560386474" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.47625424036619707" LOG_CI_START="-2.0200588425794814" LOG_EFFECT_SIZE="-0.7719023011066422" ORDER="1" O_E="0.0" SE="1.4663466618713423" STUDY_ID="STD-L_x002d_Jaramillo-1990" TOTAL_1="22" TOTAL_2="34" VAR="2.1501725327812284" WEIGHT="0.660562577150851"/>
<DICH_DATA CI_END="1.9948580418152504" CI_START="0.26915960180625875" EFFECT_SIZE="0.7327586206896551" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2999119958373661" LOG_CI_START="-0.5699901228626176" LOG_EFFECT_SIZE="-0.13503906351262576" ORDER="2" O_E="0.0" SE="0.5109848106093057" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="0.261105476673428" WEIGHT="4.677588183629408"/>
<DICH_DATA CI_END="0.7968304860933008" CI_START="0.1570224143047178" EFFECT_SIZE="0.3537234042553192" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.09863405850903476" LOG_CI_START="-0.8040383494121157" LOG_EFFECT_SIZE="-0.4513362039605752" ORDER="3" O_E="0.0" SE="0.4143579722840249" STUDY_ID="STD-Villar-1990" TOTAL_1="94" TOTAL_2="95" VAR="0.17169252919532874" WEIGHT="6.568124642594273"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="0.0" STUDY_ID="STD-L_x002d_Jaramillo-1997" TOTAL_1="125" TOTAL_2="135" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8296365279461755" CI_END="1.1792834271009878" CI_START="0.9383680223124948" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0519514519380897" ESTIMABLE="YES" EVENTS_1="530" EVENTS_2="507" I2="0.0" I2_Q="27.7545301601172" ID="CMP-002.04" LOG_CI_END="0.0716181952842911" LOG_CI_START="-0.027626800519400346" LOG_EFFECT_SIZE="0.021995697382445376" METHOD="MH" MODIFIED="2014-02-05 16:59:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4186445337176242" P_Q="0.23939234598950154" P_Z="0.3849703393502748" Q="1.384169834061975" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6689" TOTAL_2="6717" WEIGHT="100.0" Z="0.8687747797321456">
<NAME>Admission to neonatal intensive care unit</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4334091031161487" CI_END="1.185811186728603" CI_START="0.9431123965770468" DF="2" EFFECT_SIZE="1.0575222126288812" ESTIMABLE="YES" EVENTS_1="529" EVENTS_2="503" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.0740155430839883" LOG_CI_START="-0.02543654660053652" LOG_EFFECT_SIZE="0.02428949824172589" NO="1" P_CHI2="0.4883590411838711" P_Z="0.3383773181623543" STUDIES="3" TAU2="0.0" TOTAL_1="6660" TOTAL_2="6683" WEIGHT="99.27124228883807" Z="0.9573763991756423">
<NAME>Low-risk women</NAME>
<DICH_DATA CI_END="1.5438411039912607" CI_START="0.8242470662272912" EFFECT_SIZE="1.128054298642534" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="65" LOG_CI_END="0.18860259961960657" LOG_CI_START="-0.08394258998228117" LOG_EFFECT_SIZE="0.05233000481866273" ORDER="1" O_E="0.0" SE="0.16009439349259572" STUDY_ID="STD-Belizan-1991" TOTAL_1="544" TOTAL_2="554" VAR="0.025630214827762076" WEIGHT="12.746050640672761"/>
<DICH_DATA CI_END="1.2594354555703755" CI_START="0.9501619415395876" EFFECT_SIZE="1.093923049262855" ESTIMABLE="YES" EVENTS_1="343" EVENTS_2="315" LOG_CI_END="0.10017591537689102" LOG_CI_START="-0.022202369107684895" LOG_EFFECT_SIZE="0.03898677313460305" ORDER="2" O_E="0.0" SE="0.07188561008851804" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.0051675409377984465" WEIGHT="62.19328880668738"/>
<DICH_DATA CI_END="1.1921303830254861" CI_START="0.7216633670377222" EFFECT_SIZE="0.9275326550381618" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="123" LOG_CI_END="0.07632375668935042" LOG_CI_START="-0.14166533973085874" LOG_EFFECT_SIZE="-0.03267079152075415" ORDER="3" O_E="0.0" SE="0.12804787430066103" STUDY_ID="STD-WHO-2006" TOTAL_1="3953" TOTAL_2="3956" VAR="0.016396258112917887" WEIGHT="24.331902841477927"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.47771586905389" CI_START="0.034672914866548166" DF="0" EFFECT_SIZE="0.29310344827586204" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.39405150237217457" LOG_CI_START="-1.4600096467415014" LOG_EFFECT_SIZE="-0.5329790721846633" NO="2" P_CHI2="1.0" P_Z="0.25980803089898896" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="34" WEIGHT="0.72875771116193" Z="1.1268450196423014">
<NAME>High-risk women</NAME>
<DICH_DATA CI_END="2.47771586905389" CI_START="0.034672914866548166" EFFECT_SIZE="0.29310344827586204" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.39405150237217457" LOG_CI_START="-1.4600096467415014" LOG_EFFECT_SIZE="-0.5329790721846633" ORDER="48423" O_E="0.0" SE="1.0890846967400782" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="1.186105476673428" WEIGHT="0.72875771116193"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4572920661848912" CI_END="1.089086023845935" CI_START="0.7359751889475499" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8952878264447406" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="205" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.03706218481187657" LOG_CI_START="-0.1331368262668418" LOG_EFFECT_SIZE="-0.04803732072748258" METHOD="MH" MODIFIED="2014-02-05 17:00:11 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9179450759159951" P_Q="0.6044309722877359" P_Z="0.2685670397303679" Q="0.26836460761103575" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7821" TOTAL_2="7844" WEIGHT="100.0" Z="1.1063685733887083">
<NAME>Stillbirth or death before discharge from hospital</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1899225487985539" CI_END="1.0937585243976844" CI_START="0.7384749883262052" DF="4" EFFECT_SIZE="0.8987287207696588" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="204" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.038921450793294794" LOG_CI_START="-0.13166420937824969" LOG_EFFECT_SIZE="-0.04637137929247744" MODIFIED="2010-01-28 09:41:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8797550164402144" P_Z="0.28661409319952014" STUDIES="8" TAU2="0.0" TOTAL_1="7573" TOTAL_2="7580" WEIGHT="99.32510288334575" Z="1.0655788210486767">
<NAME>Low-risk women</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-L_x002d_Jaramillo-1989" TOTAL_1="49" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="22.094875438874084" CI_START="0.18424159473195686" EFFECT_SIZE="2.0176211453744495" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3442915575451948" LOG_CI_START="-0.7346123159237016" LOG_EFFECT_SIZE="0.3048396208107465" ORDER="4" O_E="0.0" SE="1.2211584260157702" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="1.4912279014293135" WEIGHT="0.4852878633642019"/>
<DICH_DATA CI_END="2.575365645010253" CI_START="0.29455421561670153" EFFECT_SIZE="0.8709677419354839" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.41083889797405604" LOG_CI_START="-0.5308347573246267" LOG_EFFECT_SIZE="-0.05999792967528537" ORDER="5" O_E="0.0" SE="0.5531437664822174" STUDY_ID="STD-Belizan-1991" TOTAL_1="558" TOTAL_2="567" VAR="0.3059680263981339" WEIGHT="3.3846840285895685"/>
<DICH_DATA CI_END="1.8632184221114894" CI_START="0.6318153242443422" EFFECT_SIZE="1.08499306518724" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="25" LOG_CI_END="0.27026376952716774" LOG_CI_START="-0.19940984479040225" LOG_EFFECT_SIZE="0.03542696236838276" ORDER="6" O_E="0.0" SE="0.27588860597202736" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.07611452290518858" WEIGHT="12.157538965252657"/>
<DICH_DATA CI_END="1.0699023125806273" CI_START="0.689182101101549" EFFECT_SIZE="0.8586952449837619" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="166" LOG_CI_END="0.029344126242276954" LOG_CI_START="-0.16166601023412344" LOG_EFFECT_SIZE="-0.06616094199592325" ORDER="7" O_E="0.0" SE="0.11220029968166223" STUDY_ID="STD-WHO-2006" TOTAL_1="4181" TOTAL_2="4197" VAR="0.012588907248654814" WEIGHT="80.75814136137478"/>
<DICH_DATA CI_END="3.5704038333440558" CI_START="0.340931634717992" EFFECT_SIZE="1.1032967032967034" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5527173401105586" LOG_CI_START="-0.46733269913474473" LOG_EFFECT_SIZE="0.04269232048790696" MODIFIED="2010-01-28 09:41:53 +0000" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.5991824423818201" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.35901959925864313" WEIGHT="2.539450664764551"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.196087501391649" CI_START="0.01644553380754024" DF="0" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.963603094958133" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.41017446508904926" NO="2" P_CHI2="1.0" P_Z="0.5584168934420334" STUDIES="3" TAU2="0.0" TOTAL_1="248" TOTAL_2="264" WEIGHT="0.6748971166542476" Z="0.5851945775886073">
<NAME>High-risk women</NAME>
<DICH_DATA CI_END="9.196087501391645" CI_START="0.01644553380754024" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9636030949581328" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.41017446508904926" ORDER="1" O_E="0.0" SE="1.6139274781606219" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="2.604761904761905" WEIGHT="0.6748971166542476"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Villar-1990" TOTAL_1="94" TOTAL_2="95" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-L_x002d_Jaramillo-1997" TOTAL_1="125" TOTAL_2="135" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-02-05 17:01:12 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Routine high-dose calcium supplementation in pregnancy by study sample size</NAME>
<DICH_OUTCOME CHI2="42.40450014282654" CI_END="0.8066632530561235" CI_START="0.5279806534607002" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6526121294239836" ESTIMABLE="YES" EVENTS_1="1260" EVENTS_2="1472" I2="74.05935699524844" I2_Q="83.85802086167224" ID="CMP-003.01" LOG_CI_END="-0.09330772656818868" LOG_CI_START="-0.2773819908169394" LOG_EFFECT_SIZE="-0.18534485869256404" METHOD="MH" MODIFIED="2014-02-05 17:00:28 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.3783092274621822E-5" P_Q="0.012811056257204245" P_Z="7.914126964739128E-5" Q="6.195027210917315" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.060288443674069186" TOTALS="YES" TOTAL_1="7726" TOTAL_2="7744" WEIGHT="100.0" Z="3.9469857368674144">
<NAME>High blood pressure (with or without proteinuria)</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="18.264214034688685" CI_END="0.684229938637077" CI_START="0.20651606192590202" DF="6" EFFECT_SIZE="0.37590487144905527" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="107" I2="67.14887381080634" ID="CMP-003.01.01" LOG_CI_END="-0.1647979270810683" LOG_CI_START="-0.6850461651479447" LOG_EFFECT_SIZE="-0.42492204611450646" NO="1" P_CHI2="0.005604755438255338" P_Z="0.0013663284579290274" STUDIES="7" TAU2="0.38000723948944637" TOTAL_1="333" TOTAL_2="342" WEIGHT="31.789526161262437" Z="3.201671224168347">
<NAME>Studies with &lt; 400 participants</NAME>
<DICH_DATA CI_END="3.2386838149791783" CI_START="0.04001625580138121" EFFECT_SIZE="0.36" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5103685509392996" LOG_CI_START="-1.3977635494047251" LOG_EFFECT_SIZE="-0.44369749923271273" ORDER="1" O_E="0.0" SE="1.1208462411483104" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="1.2562962962962962" WEIGHT="0.8879991161439288"/>
<DICH_DATA CI_END="0.5653174689130992" CI_START="0.06601461466914227" EFFECT_SIZE="0.19318181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="24" LOG_CI_END="-0.24770759416955618" LOG_CI_START="-1.1803599073742332" LOG_EFFECT_SIZE="-0.7140337507718947" ORDER="2" O_E="0.0" SE="0.547844585479835" STUDY_ID="STD-L_x002d_Jaramillo-1990" TOTAL_1="22" TOTAL_2="34" VAR="0.30013368983957217" WEIGHT="3.2437688385694523"/>
<DICH_DATA CI_END="0.8710096324971176" CI_START="0.26410616415560584" EFFECT_SIZE="0.47962382445141066" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.0599770421023101" LOG_CI_START="-0.5782214623768545" LOG_EFFECT_SIZE="-0.3190992522395823" ORDER="3" O_E="0.0" SE="0.30441933782052116" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="0.09267113323908457" WEIGHT="7.643366365259145"/>
<DICH_DATA CI_END="0.6572969199542048" CI_START="0.03633715113456673" EFFECT_SIZE="0.15454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.1822384027873744" LOG_CI_START="-1.439649124772528" LOG_EFFECT_SIZE="-0.8109437637799511" ORDER="4" O_E="0.0" SE="0.738609282377537" STUDY_ID="STD-L_x002d_Jaramillo-1989" TOTAL_1="55" TOTAL_2="51" VAR="0.5455436720142602" WEIGHT="1.9297855877018677"/>
<DICH_DATA CI_END="1.3373071704026946" CI_START="0.10053370491086208" EFFECT_SIZE="0.36666666666666664" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.12623117322227295" LOG_CI_START="-0.9976883123451477" LOG_EFFECT_SIZE="-0.4357285695614374" ORDER="5" O_E="0.0" SE="0.6601958693134833" STUDY_ID="STD-Villar-1990" TOTAL_1="90" TOTAL_2="88" VAR="0.43585858585858583" WEIGHT="2.3564105312159693"/>
<DICH_DATA CI_END="0.5929732148002642" CI_START="0.13609425669450542" EFFECT_SIZE="0.284077892325315" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.22696492371359167" LOG_CI_START="-0.8661602020451153" LOG_EFFECT_SIZE="-0.5465625628793535" ORDER="6" O_E="0.0" SE="0.37546647055959415" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.14097507051447858" WEIGHT="5.808932086552994"/>
<DICH_DATA CI_END="1.4549654839743185" CI_START="0.5680177915521761" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.16285269071210204" LOG_CI_START="-0.24563806102855215" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="7" O_E="0.0" SE="0.2399494896342928" STUDY_ID="STD-Niromanesh-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.057575757575757586" WEIGHT="9.919263635819082"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.04745159518722" CI_END="0.9817076689888918" CI_START="0.6994875683468229" DF="4" EFFECT_SIZE="0.8286689991839128" ESTIMABLE="YES" EVENTS_1="1224" EVENTS_2="1365" I2="69.34267223895684" ID="CMP-003.01.02" LOG_CI_END="-0.008017816332962127" LOG_CI_START="-0.15521999960868302" LOG_EFFECT_SIZE="-0.08161890797082258" MODIFIED="2010-01-28 09:46:31 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.011046278380751007" P_Z="0.029744598257924967" STUDIES="5" TAU2="0.019641261438233273" TOTAL_1="7393" TOTAL_2="7402" WEIGHT="68.21047383873757" Z="2.173474829251211">
<NAME>Studies with =/&gt; 400 participants</NAME>
<DICH_DATA CI_END="1.380236711853532" CI_START="0.5902776185343098" EFFECT_SIZE="0.9026199860885694" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.1399535746881291" LOG_CI_START="-0.22894368354370867" LOG_EFFECT_SIZE="-0.044495054427789775" ORDER="1" O_E="0.0" SE="0.21669207555626024" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="0.046955455608879995" WEIGHT="10.901562636562483"/>
<DICH_DATA CI_END="0.910487633755234" CI_START="0.48622208265306216" EFFECT_SIZE="0.6653564409505092" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="87" LOG_CI_END="-0.040725948417479924" LOG_CI_START="-0.3131653207773698" LOG_EFFECT_SIZE="-0.17694563459742485" ORDER="2" O_E="0.0" SE="0.1600322359208424" STUDY_ID="STD-Belizan-1991" TOTAL_1="579" TOTAL_2="588" VAR="0.02561031653382416" WEIGHT="13.610511753519303"/>
<DICH_DATA CI_END="1.004177715946483" CI_START="0.815707589773221" EFFECT_SIZE="0.9050499347432074" ESTIMABLE="YES" EVENTS_1="509" EVENTS_2="565" LOG_CI_END="0.0018105795668501195" LOG_CI_START="-0.08846549676934357" LOG_EFFECT_SIZE="-0.043327458601246704" ORDER="3" O_E="0.0" SE="0.05302861411366513" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.002812033914816004" WEIGHT="18.52800692000157"/>
<DICH_DATA CI_END="1.0548224711363225" CI_START="0.8604231990759956" EFFECT_SIZE="0.9526771357980425" ESTIMABLE="YES" EVENTS_1="613" EVENTS_2="645" LOG_CI_END="0.023179373099550035" LOG_CI_START="-0.06528788850439987" LOG_EFFECT_SIZE="-0.02105425770242488" ORDER="4" O_E="0.0" SE="0.0519661073861678" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.0027004763168707235" WEIGHT="18.560821261746216"/>
<DICH_DATA CI_END="0.658315853479314" CI_START="0.1726357341153547" EFFECT_SIZE="0.33711843711843714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" LOG_CI_END="-0.18156568615707572" LOG_CI_START="-0.7628693040852348" LOG_EFFECT_SIZE="-0.47221749512115524" MODIFIED="2010-01-28 09:46:31 +0000" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.34146062267031707" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.11659535683440066" WEIGHT="6.609571266907998"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="40.30949495698517" CI_END="0.6470506211175637" CI_START="0.3107089176343304" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4483797476939156" ESTIMABLE="YES" EVENTS_1="379" EVENTS_2="510" I2="70.23033899877592" I2_Q="93.42085070866423" ID="CMP-003.02" LOG_CI_END="-0.18906174156925823" LOG_CI_START="-0.5076462819114138" LOG_EFFECT_SIZE="-0.34835401174033603" METHOD="MH" MODIFIED="2014-02-05 17:00:38 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="6.387881802982776E-5" P_Q="9.672863999810044E-5" P_Z="1.8174105353508648E-5" Q="15.199533491616046" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19573396490712225" TOTALS="YES" TOTAL_1="7851" TOTAL_2="7879" WEIGHT="100.0" Z="4.286217505393233">
<NAME>Pre-eclampsia</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7152884874934244" CI_END="0.3575187550179868" CI_START="0.12448150744313967" DF="7" EFFECT_SIZE="0.2109608341940123" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="80" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-0.44670117068199977" LOG_CI_START="-0.9048951611137586" LOG_EFFECT_SIZE="-0.6757981658978791" NO="1" P_CHI2="0.9739084638716206" P_Z="7.400715226871095E-9" STUDIES="8" TAU2="0.0" TOTAL_1="458" TOTAL_2="477" WEIGHT="32.73844252950462" Z="5.7815689146422296">
<NAME>Studies with &lt; 400 participants</NAME>
<DICH_DATA CI_END="1.0236399778788619" CI_START="0.019936856420550257" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.01014723875593224" LOG_CI_START="-1.7003433187844461" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="1" O_E="0.0" SE="1.004750620564033" STUDY_ID="STD-Niromanesh-2001" TOTAL_1="15" TOTAL_2="15" VAR="1.0095238095238095" WEIGHT="2.9056590792817896"/>
<DICH_DATA CI_END="1.4767841726119282" CI_START="0.005425822032279613" EFFECT_SIZE="0.08951406649616368" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.1693170291692847" LOG_CI_START="-2.265534455260467" LOG_EFFECT_SIZE="-1.0481087130455913" ORDER="2" O_E="0.0" SE="1.4302438146632677" STUDY_ID="STD-L_x002d_Jaramillo-1990" TOTAL_1="22" TOTAL_2="34" VAR="2.0455973693825356" WEIGHT="1.562494639490732"/>
<DICH_DATA CI_END="3.2386838149791783" CI_START="0.04001625580138121" EFFECT_SIZE="0.36" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5103685509392996" LOG_CI_START="-1.3977635494047251" LOG_EFFECT_SIZE="-0.44369749923271273" ORDER="3" O_E="0.0" SE="1.1208462411483104" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="1.2562962962962962" WEIGHT="2.4118424310577"/>
<DICH_DATA CI_END="0.8375361676745214" CI_START="0.11670668475773119" EFFECT_SIZE="0.31264367816091954" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.07699642956596733" LOG_CI_START="-0.9329042676028722" LOG_EFFECT_SIZE="-0.5049503485844198" ORDER="4" O_E="0.0" SE="0.5027645008750067" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="0.2527721433400946" WEIGHT="7.808295429545984"/>
<DICH_DATA CI_END="0.6572969199542048" CI_START="0.03633715113456673" EFFECT_SIZE="0.15454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.1822384027873744" LOG_CI_START="-1.439649124772528" LOG_EFFECT_SIZE="-0.8109437637799511" ORDER="5" O_E="0.0" SE="0.738609282377537" STUDY_ID="STD-L_x002d_Jaramillo-1989" TOTAL_1="55" TOTAL_2="51" VAR="0.5455436720142602" WEIGHT="4.724367795168787"/>
<DICH_DATA CI_END="2.6660884062158257" CI_START="0.007321947360692846" EFFECT_SIZE="0.13971742543171115" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4258745463138206" LOG_CI_START="-2.135373397694696" LOG_EFFECT_SIZE="-0.8547494256904377" ORDER="6" O_E="0.0" SE="1.5044897206923997" STUDY_ID="STD-Villar-1990" TOTAL_1="90" TOTAL_2="88" VAR="2.263489319669095" WEIGHT="1.424054585492301"/>
<DICH_DATA CI_END="0.7654298803110793" CI_START="0.039700103380788714" EFFECT_SIZE="0.17432052483598875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.11609458809933586" LOG_CI_START="-1.4012083623137712" LOG_EFFECT_SIZE="-0.7586514752065536" ORDER="7" O_E="0.0" SE="0.7548821923893373" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.5698471243865325" WEIGHT="4.5743922415603295"/>
<DICH_DATA CI_END="0.5827111349564926" CI_START="0.07262323440944443" EFFECT_SIZE="0.2057142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="21" LOG_CI_END="-0.23454668294991027" LOG_CI_START="-1.1389244128881042" LOG_EFFECT_SIZE="-0.6867355479190071" ORDER="8" O_E="0.0" SE="0.5312359553076582" STUDY_ID="STD-L_x002d_Jaramillo-1997" TOTAL_1="125" TOTAL_2="135" VAR="0.2822116402116402" WEIGHT="7.3273363279069965"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.766674680090368" CI_END="0.9657755975379554" CI_START="0.5225598805224433" DF="4" EFFECT_SIZE="0.7104052229966537" ESTIMABLE="YES" EVENTS_1="365" EVENTS_2="430" I2="68.6684269770107" ID="CMP-003.02.02" LOG_CI_END="-0.015123772210158674" LOG_CI_START="-0.28186393624006073" LOG_EFFECT_SIZE="-0.14849385422510972" MODIFIED="2010-01-28 09:48:45 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.012473984446518926" P_Z="0.029093440506553905" STUDIES="5" TAU2="0.0696059338942623" TOTAL_1="7393" TOTAL_2="7402" WEIGHT="67.26155747049538" Z="2.182218094265921">
<NAME>Studies with =/&gt; 400 participants</NAME>
<DICH_DATA CI_END="0.9005185378929982" CI_START="0.21363426985509443" EFFECT_SIZE="0.43861329247270636" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" LOG_CI_END="-0.045507342453812105" LOG_CI_START="-0.6703290792878431" LOG_EFFECT_SIZE="-0.35791821087082765" ORDER="1" O_E="0.0" SE="0.36702338113378913" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="0.13470616229887863" WEIGHT="10.598192854970554"/>
<DICH_DATA CI_END="1.2564036801956278" CI_START="0.34913643328973276" EFFECT_SIZE="0.6623113313809417" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.0991291998422843" LOG_CI_START="-0.457004829068703" LOG_EFFECT_SIZE="-0.17893781461320935" ORDER="2" O_E="0.0" SE="0.32667588149015536" STUDY_ID="STD-Belizan-1991" TOTAL_1="579" TOTAL_2="588" VAR="0.10671713154737002" WEIGHT="11.578956850226305"/>
<DICH_DATA CI_END="1.164315856627379" CI_START="0.7667101490907422" EFFECT_SIZE="0.9448242080003523" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="168" LOG_CI_END="0.06607081208552928" LOG_CI_START="-0.11536878786554355" LOG_EFFECT_SIZE="-0.024648987890007152" ORDER="3" O_E="0.0" SE="0.10657851915176493" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.011358980744583125" WEIGHT="16.91061076044606"/>
<DICH_DATA CI_END="1.1291564763039879" CI_START="0.7521460297532139" EFFECT_SIZE="0.9215696178923073" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="186" LOG_CI_END="0.052754129778371656" LOG_CI_START="-0.12369783260104086" LOG_EFFECT_SIZE="-0.03547185141133463" ORDER="4" O_E="0.0" SE="0.10364875615296752" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.010743064652057323" WEIGHT="16.961054712124536"/>
<DICH_DATA CI_END="0.658315853479314" CI_START="0.1726357341153547" EFFECT_SIZE="0.33711843711843714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" LOG_CI_END="-0.18156568615707572" LOG_CI_START="-0.7628693040852348" LOG_EFFECT_SIZE="-0.47221749512115524" MODIFIED="2010-01-28 09:48:45 +0000" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.34146062267031707" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.11659535683440066" WEIGHT="11.212742292727922"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.03552375208524" CI_END="0.9684314128748296" CI_START="0.6037502692114264" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7646507217259266" ESTIMABLE="YES" EVENTS_1="722" EVENTS_2="795" I2="60.07092153422052" I2_Q="79.60366887738107" ID="CMP-003.03" LOG_CI_END="-0.013931131852219374" LOG_CI_START="-0.21914266258906767" LOG_EFFECT_SIZE="-0.11653689722064348" METHOD="MH" MODIFIED="2014-02-05 17:00:47 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.010202510577607682" P_Q="0.026812660803612887" P_Z="0.02600916321604849" Q="4.902842545495986" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04953406741631936" TOTALS="YES" TOTAL_1="7620" TOTAL_2="7655" WEIGHT="100.00000000000001" Z="2.2260749247604896">
<NAME>Preterm birth</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8922706208976214" CI_END="0.7639121423571686" CI_START="0.24247369547686895" DF="3" EFFECT_SIZE="0.4303819236178428" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="38" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-0.11695658682163884" LOG_CI_START="-0.6153353685210097" LOG_EFFECT_SIZE="-0.3661459776713243" NO="1" P_CHI2="0.5950647143108965" P_Z="0.0039783979284033185" STUDIES="6" TAU2="0.0" TOTAL_1="392" TOTAL_2="418" WEIGHT="13.996568634899583" Z="2.8798695115912407">
<NAME>Studies with &lt; 400 participants</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.994016851312268" CI_START="0.009548632027969623" EFFECT_SIZE="0.16908212560386474" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.47625424036619707" LOG_CI_START="-2.0200588425794814" LOG_EFFECT_SIZE="-0.7719023011066422" ORDER="2" O_E="0.0" SE="1.4663466618713423" STUDY_ID="STD-L_x002d_Jaramillo-1990" TOTAL_1="22" TOTAL_2="34" VAR="2.1501725327812284" WEIGHT="0.6605625771508509"/>
<DICH_DATA CI_END="1.9948580418152504" CI_START="0.26915960180625875" EFFECT_SIZE="0.7327586206896551" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2999119958373661" LOG_CI_START="-0.5699901228626176" LOG_EFFECT_SIZE="-0.13503906351262576" ORDER="3" O_E="0.0" SE="0.5109848106093057" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="0.261105476673428" WEIGHT="4.677588183629407"/>
<DICH_DATA CI_END="1.5435702531595743" CI_START="0.06616883962042779" EFFECT_SIZE="0.31958762886597936" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18852640049463437" LOG_CI_START="-1.1793464813585786" LOG_EFFECT_SIZE="-0.49541004043197223" ORDER="4" O_E="0.0" SE="0.8034953018805451" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.6456047001441082" WEIGHT="2.0902932315250524"/>
<DICH_DATA CI_END="0.7968304860933008" CI_START="0.1570224143047178" EFFECT_SIZE="0.3537234042553192" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.09863405850903476" LOG_CI_START="-0.8040383494121157" LOG_EFFECT_SIZE="-0.4513362039605752" ORDER="5" O_E="0.0" SE="0.4143579722840249" STUDY_ID="STD-Villar-1990" TOTAL_1="94" TOTAL_2="95" VAR="0.17169252919532874" WEIGHT="6.568124642594273"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" O_E="0.0" SE="0.0" STUDY_ID="STD-L_x002d_Jaramillo-1997" TOTAL_1="125" TOTAL_2="135" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.248642748727509" CI_END="1.072904640344651" CI_START="0.6917589486787986" DF="4" EFFECT_SIZE="0.861505302384971" ESTIMABLE="YES" EVENTS_1="708" EVENTS_2="757" I2="64.44015434259839" ID="CMP-003.03.02" LOG_CI_END="0.030561123631837876" LOG_CI_START="-0.16004521406386588" LOG_EFFECT_SIZE="-0.06474204521601398" MODIFIED="2010-01-28 09:50:19 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.02390728426889932" P_Z="0.1830386653638468" STUDIES="5" TAU2="0.03201271514131148" TOTAL_1="7228" TOTAL_2="7237" WEIGHT="86.00343136510043" Z="1.3314570590137438">
<NAME>Studies with =/&gt; 400 participants</NAME>
<DICH_DATA CI_END="0.9005185378929982" CI_START="0.21363426985509443" EFFECT_SIZE="0.43861329247270636" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" LOG_CI_END="-0.045507342453812105" LOG_CI_START="-0.6703290792878431" LOG_EFFECT_SIZE="-0.35791821087082765" ORDER="1" O_E="0.0" SE="0.36702338113378913" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="0.13470616229887863" WEIGHT="7.88668068341193"/>
<DICH_DATA CI_END="1.4439272814417574" CI_START="0.5827153416347585" EFFECT_SIZE="0.9172778091184163" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="37" LOG_CI_END="0.15954532199829777" LOG_CI_START="-0.23454354772483224" LOG_EFFECT_SIZE="-0.03749911286326723" ORDER="2" O_E="0.0" SE="0.23148975284673337" STUDY_ID="STD-Belizan-1991" TOTAL_1="527" TOTAL_2="542" VAR="0.053587505673041706" WEIGHT="14.090590526029683"/>
<DICH_DATA CI_END="1.2889032490745085" CI_START="0.9183716999471098" EFFECT_SIZE="1.0879762258063865" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="229" LOG_CI_END="0.11022031846273883" LOG_CI_START="-0.03698150772721611" LOG_EFFECT_SIZE="0.03661940536776136" ORDER="3" O_E="0.0" SE="0.08646708136477087" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.007476556159741905" WEIGHT="25.487247282318116"/>
<DICH_DATA CI_END="1.0392392349245045" CI_START="0.803410716235685" EFFECT_SIZE="0.9137482903244862" ESTIMABLE="YES" EVENTS_1="398" EVENTS_2="436" LOG_CI_END="0.01671553451373544" LOG_CI_START="-0.09506237976020236" LOG_EFFECT_SIZE="-0.03917342262323345" ORDER="4" O_E="0.0" SE="0.06565890015411037" STUDY_ID="STD-WHO-2006" TOTAL_1="4038" TOTAL_2="4042" VAR="0.004311091169447435" WEIGHT="26.985599057856987"/>
<DICH_DATA CI_END="0.937856801490909" CI_START="0.3177553429557519" EFFECT_SIZE="0.5459020146520146" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="32" LOG_CI_END="-0.02786346766560416" LOG_CI_START="-0.49790713818798576" LOG_EFFECT_SIZE="-0.26288530292679496" MODIFIED="2010-01-28 09:50:19 +0000" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.27610597881854143" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.07623451153934484" WEIGHT="11.553313815483705"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8296365279461755" CI_END="1.1792834271009878" CI_START="0.9383680223124948" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0519514519380897" ESTIMABLE="YES" EVENTS_1="530" EVENTS_2="507" I2="0.0" I2_Q="27.7545301601172" ID="CMP-003.04" LOG_CI_END="0.0716181952842911" LOG_CI_START="-0.027626800519400346" LOG_EFFECT_SIZE="0.021995697382445376" METHOD="MH" MODIFIED="2014-02-05 17:01:03 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4186445337176242" P_Q="0.23939234598950154" P_Z="0.3849703393502747" Q="1.384169834061975" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6689" TOTAL_2="6717" WEIGHT="100.0" Z="0.8687747797321457">
<NAME>Admission to neonatal intensive care unit</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.47771586905389" CI_START="0.034672914866548166" DF="0" EFFECT_SIZE="0.29310344827586204" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.39405150237217457" LOG_CI_START="-1.4600096467415014" LOG_EFFECT_SIZE="-0.5329790721846633" NO="1" P_CHI2="1.0" P_Z="0.25980803089898896" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="34" WEIGHT="0.72875771116193" Z="1.1268450196423014">
<NAME>Studies with &lt; 400 participants</NAME>
<DICH_DATA CI_END="2.47771586905389" CI_START="0.034672914866548166" EFFECT_SIZE="0.29310344827586204" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.39405150237217457" LOG_CI_START="-1.4600096467415014" LOG_EFFECT_SIZE="-0.5329790721846633" ORDER="1" O_E="0.0" SE="1.0890846967400782" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="1.186105476673428" WEIGHT="0.72875771116193"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4334091031161487" CI_END="1.185811186728603" CI_START="0.9431123965770468" DF="2" EFFECT_SIZE="1.0575222126288812" ESTIMABLE="YES" EVENTS_1="529" EVENTS_2="503" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.0740155430839883" LOG_CI_START="-0.02543654660053652" LOG_EFFECT_SIZE="0.02428949824172589" NO="2" P_CHI2="0.4883590411838711" P_Z="0.3383773181623543" STUDIES="3" TAU2="0.0" TOTAL_1="6660" TOTAL_2="6683" WEIGHT="99.27124228883807" Z="0.9573763991756424">
<NAME>Studies with =/&gt; 400 participants</NAME>
<DICH_DATA CI_END="1.5438411039912607" CI_START="0.8242470662272912" EFFECT_SIZE="1.128054298642534" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="65" LOG_CI_END="0.18860259961960657" LOG_CI_START="-0.08394258998228117" LOG_EFFECT_SIZE="0.05233000481866273" ORDER="1" O_E="0.0" SE="0.16009439349259572" STUDY_ID="STD-Belizan-1991" TOTAL_1="544" TOTAL_2="554" VAR="0.025630214827762076" WEIGHT="12.746050640672761"/>
<DICH_DATA CI_END="1.2594354555703755" CI_START="0.9501619415395876" EFFECT_SIZE="1.093923049262855" ESTIMABLE="YES" EVENTS_1="343" EVENTS_2="315" LOG_CI_END="0.10017591537689102" LOG_CI_START="-0.022202369107684895" LOG_EFFECT_SIZE="0.03898677313460305" ORDER="2" O_E="0.0" SE="0.07188561008851804" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.0051675409377984465" WEIGHT="62.19328880668738"/>
<DICH_DATA CI_END="1.1921303830254861" CI_START="0.7216633670377222" EFFECT_SIZE="0.9275326550381618" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="123" LOG_CI_END="0.07632375668935042" LOG_CI_START="-0.14166533973085874" LOG_EFFECT_SIZE="-0.03267079152075415" ORDER="3" O_E="0.0" SE="0.12804787430066103" STUDY_ID="STD-WHO-2006" TOTAL_1="3953" TOTAL_2="3956" VAR="0.016396258112917887" WEIGHT="24.331902841477927"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4572920661848912" CI_END="1.0890860238459352" CI_START="0.7359751889475501" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8952878264447408" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="205" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.03706218481187666" LOG_CI_START="-0.13313682626684167" LOG_EFFECT_SIZE="-0.04803732072748247" METHOD="MH" MODIFIED="2014-02-05 17:01:12 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9179450759159951" P_Q="0.6044309722877357" P_Z="0.2685670397303689" Q="0.2683646076110358" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7821" TOTAL_2="7844" WEIGHT="100.00000000000001" Z="1.1063685733887059">
<NAME>Stillbirth or death before discharge from hospital</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.196087501391649" CI_START="0.01644553380754024" DF="0" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.963603094958133" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.41017446508904926" NO="1" P_CHI2="1.0" P_Z="0.5584168934420334" STUDIES="6" TAU2="0.0" TOTAL_1="419" TOTAL_2="427" WEIGHT="0.6748971166542476" Z="0.5851945775886073">
<NAME>Studies with &lt; 400 participants</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.196087501391645" CI_START="0.01644553380754024" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9636030949581328" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.41017446508904926" ORDER="2" O_E="0.0" SE="1.6139274781606219" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="2.604761904761905" WEIGHT="0.6748971166542476"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-L_x002d_Jaramillo-1989" TOTAL_1="49" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="0.0" STUDY_ID="STD-Villar-1990" TOTAL_1="94" TOTAL_2="95" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" O_E="0.0" SE="0.0" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" O_E="0.0" SE="0.0" STUDY_ID="STD-L_x002d_Jaramillo-1997" TOTAL_1="125" TOTAL_2="135" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.189922548798554" CI_END="1.0937585243976844" CI_START="0.7384749883262053" DF="4" EFFECT_SIZE="0.8987287207696589" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="204" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.038921450793294794" LOG_CI_START="-0.1316642093782496" LOG_EFFECT_SIZE="-0.046371379292477394" MODIFIED="2010-01-28 09:52:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8797550164402143" P_Z="0.2866140931995207" STUDIES="5" TAU2="0.0" TOTAL_1="7402" TOTAL_2="7417" WEIGHT="99.32510288334576" Z="1.0655788210486754">
<NAME>Studies with =/&gt; 400 participants</NAME>
<DICH_DATA CI_END="22.094875438874084" CI_START="0.18424159473195686" EFFECT_SIZE="2.0176211453744495" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3442915575451948" LOG_CI_START="-0.7346123159237016" LOG_EFFECT_SIZE="0.3048396208107465" ORDER="1" O_E="0.0" SE="1.2211584260157702" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="1.4912279014293135" WEIGHT="0.4852878633642019"/>
<DICH_DATA CI_END="2.575365645010253" CI_START="0.29455421561670153" EFFECT_SIZE="0.8709677419354839" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.41083889797405604" LOG_CI_START="-0.5308347573246267" LOG_EFFECT_SIZE="-0.05999792967528537" ORDER="2" O_E="0.0" SE="0.5531437664822174" STUDY_ID="STD-Belizan-1991" TOTAL_1="558" TOTAL_2="567" VAR="0.3059680263981339" WEIGHT="3.3846840285895685"/>
<DICH_DATA CI_END="1.8632184221114894" CI_START="0.6318153242443422" EFFECT_SIZE="1.08499306518724" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="25" LOG_CI_END="0.27026376952716774" LOG_CI_START="-0.19940984479040225" LOG_EFFECT_SIZE="0.03542696236838276" ORDER="3" O_E="0.0" SE="0.27588860597202736" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.07611452290518858" WEIGHT="12.157538965252657"/>
<DICH_DATA CI_END="1.0699023125806273" CI_START="0.689182101101549" EFFECT_SIZE="0.8586952449837619" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="166" LOG_CI_END="0.029344126242276954" LOG_CI_START="-0.16166601023412344" LOG_EFFECT_SIZE="-0.06616094199592325" ORDER="4" O_E="0.0" SE="0.11220029968166223" STUDY_ID="STD-WHO-2006" TOTAL_1="4181" TOTAL_2="4197" VAR="0.012588907248654814" WEIGHT="80.75814136137478"/>
<DICH_DATA CI_END="3.5704038333440558" CI_START="0.340931634717992" EFFECT_SIZE="1.1032967032967034" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5527173401105586" LOG_CI_START="-0.46733269913474473" LOG_EFFECT_SIZE="0.04269232048790696" MODIFIED="2010-01-28 09:52:11 +0000" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.5991824423818201" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.35901959925864313" WEIGHT="2.539450664764551"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-02-05 17:01:25 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Routine high-dose calcium supplementation in pregnancy by baseline dietary calcium and study sample size (not pre-specified)</NAME>
<DICH_OUTCOME CHI2="40.309494956985176" CI_END="0.6470506211175638" CI_START="0.31070891763433045" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4483797476939157" ESTIMABLE="YES" EVENTS_1="379" EVENTS_2="510" I2="70.23033899877593" I2_Q="61.106759082968416" ID="CMP-004.01" LOG_CI_END="-0.18906174156925815" LOG_CI_START="-0.5076462819114137" LOG_EFFECT_SIZE="-0.3483540117403359" METHOD="MH" MODIFIED="2014-02-05 17:01:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="6.387881802949469E-5" P_Q="0.03589760960124344" P_Z="1.8174105353508716E-5" Q="10.28456334747968" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1957339649071223" TOTALS="YES" TOTAL_1="7851" TOTAL_2="7879" WEIGHT="100.0" Z="4.286217505393232">
<NAME>Pre-eclampsia</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.26116719759549034" CI_END="1.495109292334797" CI_START="0.044106580288107766" DF="1" EFFECT_SIZE="0.2567959463111922" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.1746729407026083" LOG_CI_START="-1.3554966130349566" LOG_EFFECT_SIZE="-0.5904118361661742" NO="1" P_CHI2="0.6093194488069293" P_Z="0.13040830417280963" STUDIES="2" TAU2="0.0" TOTAL_1="115" TOTAL_2="115" WEIGHT="3.835897016550002" Z="1.512493739148505">
<NAME>Adequate calcium/small study</NAME>
<DICH_DATA CI_END="3.2386838149791783" CI_START="0.04001625580138121" EFFECT_SIZE="0.36" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5103685509392996" LOG_CI_START="-1.3977635494047251" LOG_EFFECT_SIZE="-0.44369749923271273" ORDER="1" O_E="0.0" SE="1.1208462411483104" STUDY_ID="STD-Villar-1987" TOTAL_1="25" TOTAL_2="27" VAR="1.2562962962962962" WEIGHT="2.4118424310577007"/>
<DICH_DATA CI_END="2.6660884062158257" CI_START="0.007321947360692846" EFFECT_SIZE="0.13971742543171115" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4258745463138206" LOG_CI_START="-2.135373397694696" LOG_EFFECT_SIZE="-0.8547494256904377" ORDER="2" O_E="0.0" SE="1.5044897206923997" STUDY_ID="STD-Villar-1990" TOTAL_1="90" TOTAL_2="88" VAR="2.263489319669095" WEIGHT="1.4240545854923012"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.036110200543691" CI_END="1.4558936096968083" CI_START="0.3342199623718137" DF="1" EFFECT_SIZE="0.6975591067789391" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="191" I2="75.22366956518448" ID="CMP-004.01.02" LOG_CI_END="0.1631296398054648" LOG_CI_START="-0.47596761402069215" LOG_EFFECT_SIZE="-0.15641898710761365" NO="2" P_CHI2="0.044536450334975664" P_Z="0.33735629650940957" STUDIES="2" TAU2="0.2217349353690638" TOTAL_1="2390" TOTAL_2="2402" WEIGHT="27.508803615416618" Z="0.959401967051952">
<NAME>Adequate calcium/large study</NAME>
<DICH_DATA CI_END="0.9005185378929982" CI_START="0.21363426985509443" EFFECT_SIZE="0.43861329247270636" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" LOG_CI_END="-0.045507342453812105" LOG_CI_START="-0.6703290792878431" LOG_EFFECT_SIZE="-0.35791821087082765" ORDER="1" O_E="0.0" SE="0.36702338113378913" STUDY_ID="STD-Crowther-1999" TOTAL_1="227" TOTAL_2="229" VAR="0.13470616229887863" WEIGHT="10.598192854970558"/>
<DICH_DATA CI_END="1.164315856627379" CI_START="0.7667101490907422" EFFECT_SIZE="0.9448242080003523" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="168" LOG_CI_END="0.06607081208552928" LOG_CI_START="-0.11536878786554355" LOG_EFFECT_SIZE="-0.024648987890007152" ORDER="2" O_E="0.0" SE="0.10657851915176493" STUDY_ID="STD-CPEP-1997" TOTAL_1="2163" TOTAL_2="2173" VAR="0.011358980744583125" WEIGHT="16.91061076044606"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2552438926533784" CI_END="0.3799579905061684" CI_START="0.12005542778782054" DF="4" EFFECT_SIZE="0.21357906988190273" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="67" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="-0.4202644178566347" LOG_CI_START="-0.9206182004131849" LOG_EFFECT_SIZE="-0.6704413091349098" NO="3" P_CHI2="0.8689220156057216" P_Z="1.5009179967124484E-7" STUDIES="5" TAU2="0.0" TOTAL_1="328" TOTAL_2="347" WEIGHT="25.996886433672834" Z="5.252446830473575">
<NAME>Low calcium/small study</NAME>
<DICH_DATA CI_END="1.4767841726119282" CI_START="0.005425822032279613" EFFECT_SIZE="0.08951406649616368" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.1693170291692847" LOG_CI_START="-2.265534455260467" LOG_EFFECT_SIZE="-1.0481087130455913" ORDER="1" O_E="0.0" SE="1.4302438146632677" STUDY_ID="STD-L_x002d_Jaramillo-1990" TOTAL_1="22" TOTAL_2="34" VAR="2.0455973693825356" WEIGHT="1.5624946394907322"/>
<DICH_DATA CI_END="0.8375361676745214" CI_START="0.11670668475773119" EFFECT_SIZE="0.31264367816091954" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.07699642956596733" LOG_CI_START="-0.9329042676028722" LOG_EFFECT_SIZE="-0.5049503485844198" ORDER="2" O_E="0.0" SE="0.5027645008750067" STUDY_ID="STD-S_x002d_Ramos-1994" TOTAL_1="29" TOTAL_2="34" VAR="0.2527721433400946" WEIGHT="7.808295429545985"/>
<DICH_DATA CI_END="0.6572969199542048" CI_START="0.03633715113456673" EFFECT_SIZE="0.15454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.1822384027873744" LOG_CI_START="-1.439649124772528" LOG_EFFECT_SIZE="-0.8109437637799511" ORDER="3" O_E="0.0" SE="0.738609282377537" STUDY_ID="STD-L_x002d_Jaramillo-1989" TOTAL_1="55" TOTAL_2="51" VAR="0.5455436720142602" WEIGHT="4.724367795168788"/>
<DICH_DATA CI_END="0.7654298803110793" CI_START="0.039700103380788714" EFFECT_SIZE="0.17432052483598875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.11609458809933586" LOG_CI_START="-1.4012083623137712" LOG_EFFECT_SIZE="-0.7586514752065536" ORDER="4" O_E="0.0" SE="0.7548821923893373" STUDY_ID="STD-Purwar-1996" TOTAL_1="97" TOTAL_2="93" VAR="0.5698471243865325" WEIGHT="4.57439224156033"/>
<DICH_DATA CI_END="0.5827111349564926" CI_START="0.07262323440944443" EFFECT_SIZE="0.2057142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="21" LOG_CI_END="-0.23454668294991027" LOG_CI_START="-1.1389244128881042" LOG_EFFECT_SIZE="-0.6867355479190071" ORDER="5" O_E="0.0" SE="0.5312359553076582" STUDY_ID="STD-L_x002d_Jaramillo-1997" TOTAL_1="125" TOTAL_2="135" VAR="0.2822116402116402" WEIGHT="7.3273363279069965"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.470911857179487" CI_END="1.137042655398395" CI_START="0.3477082408753745" DF="2" EFFECT_SIZE="0.628775875418929" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="239" I2="76.3897909254609" ID="CMP-004.01.04" LOG_CI_END="0.05577675726175887" LOG_CI_START="-0.4587850161781476" LOG_EFFECT_SIZE="-0.2015041294581944" MODIFIED="2010-01-28 09:54:16 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.014473235592045608" P_Z="0.12476981750565845" STUDIES="3" TAU2="0.20516468276917693" TOTAL_1="5003" TOTAL_2="5000" WEIGHT="39.752753855078765" Z="1.5350570402225228">
<NAME>Low calcium/large study</NAME>
<DICH_DATA CI_END="1.2564036801956278" CI_START="0.34913643328973276" EFFECT_SIZE="0.6623113313809417" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.0991291998422843" LOG_CI_START="-0.457004829068703" LOG_EFFECT_SIZE="-0.17893781461320935" ORDER="1" O_E="0.0" SE="0.32667588149015536" STUDY_ID="STD-Belizan-1991" TOTAL_1="579" TOTAL_2="588" VAR="0.10671713154737002" WEIGHT="11.578956850226305"/>
<DICH_DATA CI_END="1.1291564763039879" CI_START="0.7521460297532139" EFFECT_SIZE="0.9215696178923073" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="186" LOG_CI_END="0.052754129778371656" LOG_CI_START="-0.12369783260104086" LOG_EFFECT_SIZE="-0.03547185141133463" ORDER="2" O_E="0.0" SE="0.10364875615296752" STUDY_ID="STD-WHO-2006" TOTAL_1="4151" TOTAL_2="4161" VAR="0.010743064652057323" WEIGHT="16.961054712124536"/>
<DICH_DATA CI_END="0.658315853479314" CI_START="0.1726357341153547" EFFECT_SIZE="0.33711843711843714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" LOG_CI_END="-0.18156568615707572" LOG_CI_START="-0.7628693040852348" LOG_EFFECT_SIZE="-0.47221749512115524" MODIFIED="2010-01-28 09:54:16 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.34146062267031707" STUDY_ID="STD-Kumar-2009" TOTAL_1="273" TOTAL_2="251" VAR="0.11659535683440066" WEIGHT="11.212742292727922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0236399778788619" CI_START="0.019936856420550257" DF="0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-004.01.05" LOG_CI_END="0.01014723875593224" LOG_CI_START="-1.7003433187844461" LOG_EFFECT_SIZE="-0.8450980400142568" NO="5" P_CHI2="1.0" P_Z="0.05278085445299506" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.90565907928179" Z="1.936709576713618">
<NAME>Dietary calcium not specified</NAME>
<DICH_DATA CI_END="1.0236399778788619" CI_START="0.019936856420550257" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.01014723875593224" LOG_CI_START="-1.7003433187844461" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="1" O_E="0.0" SE="1.004750620564033" STUDY_ID="STD-Niromanesh-2001" TOTAL_1="15" TOTAL_2="15" VAR="1.0095238095238095" WEIGHT="2.90565907928179"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-08-02 13:00:13 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Routine calcium supplementation in pregnancy by other outcomes (not pre-specified)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.008942092807542445" CI_START="-0.020942092807542455" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.006000000000000005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2010-03-03 11:06:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4312678920708264" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="184" TOTAL_2="188" UNITS="" WEIGHT="100.0" Z="0.7870238833816002">
<NAME>Uterine artery RI at 32 weeks</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.008942092807542445" CI_START="-0.020942092807542455" EFFECT_SIZE="-0.006000000000000005" ESTIMABLE="YES" MEAN_1="0.492" MEAN_2="0.498" MODIFIED="2010-03-03 11:06:18 +0000" MODIFIED_BY="[Empty name]" ORDER="209" SD_1="0.071" SD_2="0.076" SE="0.00762365682502524" STUDY_ID="STD-WHO-2006" TOTAL_1="184" TOTAL_2="188" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.008925335001693784" CI_START="-0.020925335001693794" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.006000000000000005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2010-03-03 11:10:03 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.43075080042043534" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="186" TOTAL_2="187" UNITS="" WEIGHT="100.0" Z="0.7879075347994391">
<NAME>Umbilical artery RI at 32 weeks</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.008925335001693784" CI_START="-0.020925335001693794" EFFECT_SIZE="-0.006000000000000005" ESTIMABLE="YES" MEAN_1="0.655" MEAN_2="0.661" MODIFIED="2010-03-03 11:10:03 +0000" MODIFIED_BY="[Empty name]" ORDER="210" SD_1="0.071" SD_2="0.076" SE="0.007615106766972723" STUDY_ID="STD-WHO-2006" TOTAL_1="186" TOTAL_2="187" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.183126033805611" CI_START="0.6337739612836287" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1762688614540466" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.3390788086391927" LOG_CI_START="-0.19806560784552577" LOG_EFFECT_SIZE="0.07050660039683347" METHOD="MH" MODIFIED="2013-08-02 12:57:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6068764468350021" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="324" TOTAL_2="343" WEIGHT="100.0" Z="0.5145372201931193">
<NAME>Low platelet count at 35 weeks</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.183126033805611" CI_START="0.6337739612836287" EFFECT_SIZE="1.1762688614540466" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.3390788086391927" LOG_CI_START="-0.19806560784552577" LOG_EFFECT_SIZE="0.07050660039683347" MODIFIED="2010-03-03 11:21:15 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.3155212891508676" STUDY_ID="STD-WHO-2006" TOTAL_1="324" TOTAL_2="343" VAR="0.0995536839074254" WEIGHT="100.0">
<FOOTNOTE>*Reported by Hofmeyr 2008; low platelets defined as &lt;150X10<SUP>9</SUP>/l</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5714135175268733" CI_START="0.6381779213340446" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0014196983141082" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.1962904846890337" LOG_CI_START="-0.1950582249132019" LOG_EFFECT_SIZE="6.161298879159262E-4" METHOD="MH" MODIFIED="2013-08-02 13:00:00 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9950759351744107" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="342" WEIGHT="100.0" Z="0.006171439233011935">
<NAME>High serum uric acid at 35 weeks</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5714135175268733" CI_START="0.6381779213340447" EFFECT_SIZE="1.0014196983141082" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" LOG_CI_END="0.1962904846890337" LOG_CI_START="-0.19505822491320185" LOG_EFFECT_SIZE="6.161298879159262E-4" MODIFIED="2010-03-03 11:29:02 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.2298801692277086" STUDY_ID="STD-WHO-2006" TOTAL_1="322" TOTAL_2="342" VAR="0.052844892204159936" WEIGHT="100.0">
<FOOTNOTE>*Reported by Hofmeyr 2008; high uric acid defined as &gt;0.32 mmol/L</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3445560374797485" CI_START="0.7605112212377532" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0112121212121212" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.12857890716257958" LOG_CI_START="-0.11889437360876903" LOG_EFFECT_SIZE="0.004842266776905279" METHOD="MH" MODIFIED="2013-08-02 13:00:13 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.9388617662660307" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="308" TOTAL_2="329" WEIGHT="100.0" Z="0.07670055091755978">
<NAME>High urine protein/creatinine ratio at 35 weeks</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3445560374797485" CI_START="0.7605112212377532" EFFECT_SIZE="1.0112121212121212" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="75" LOG_CI_END="0.12857890716257958" LOG_CI_START="-0.11889437360876903" LOG_EFFECT_SIZE="0.004842266776905279" MODIFIED="2010-03-03 11:28:41 +0000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.14536703013758676" STUDY_ID="STD-WHO-2006" TOTAL_1="308" TOTAL_2="329" VAR="0.021131573451022057" WEIGHT="100.0">
<FOOTNOTE>*Reported by Hofmeyr 2008; high protein/creatinine ratio defined as &gt;34mg/mmol</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.040380863912947734" CI_START="-0.040380863912947734" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.06" MODIFIED="2010-03-15 15:58:15 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="186" TOTAL_2="191" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Ultrasound estimate of fetal growth at 32 weeks: femur length (cm)*</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.04038086391294774" CI_START="-0.04038086391294774" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="6.2" MODIFIED="2010-03-04 10:08:00 +0000" MODIFIED_BY="[Empty name]" ORDER="215" SD_1="0.2" SD_2="0.2" SE="0.020602860170629074" STUDY_ID="STD-WHO-2006" TOTAL_1="186" TOTAL_2="191" WEIGHT="100.0">
<FOOTNOTE>*Reported by Abalos 2010</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.06057129586942161" CI_START="-0.06057129586942161" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2010-03-15 15:58:21 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="186" TOTAL_2="191" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Ultrasound estimate of fetal growth at 32 weeks: biparietal diameter (cm)*</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0605712958694216" CI_START="-0.0605712958694216" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="8.0" MODIFIED="2010-03-04 10:10:37 +0000" MODIFIED_BY="[Empty name]" ORDER="216" SD_1="0.3" SD_2="0.3" SE="0.030904290255943604" STUDY_ID="STD-WHO-2006" TOTAL_1="186" TOTAL_2="191" WEIGHT="100.0">
<FOOTNOTE>*Reported by Abalos 2010</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.2624756154341603" CI_START="-0.2624756154341603" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.08" MODIFIED="2010-03-15 15:58:26 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="186" TOTAL_2="191" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Ultrasound estimate of fetal growth at 32 weeks: abdominal circumference (cm)*</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2624756154341603" CI_START="-0.2624756154341603" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="27.9" MEAN_2="27.9" MODIFIED="2010-03-04 10:12:56 +0000" MODIFIED_BY="[Empty name]" ORDER="217" SD_1="1.3" SD_2="1.3" SE="0.13391859110908896" STUDY_ID="STD-WHO-2006" TOTAL_1="186" TOTAL_2="191" WEIGHT="100.0">
<FOOTNOTE>*Reported by Abalos 2010</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2014-06-12 14:07:53 +0100" MODIFIED_BY="Heather Maxwell" NO="6">
<NAME>Low-dose calcium supplementation (&lt; 1 g/day) with or without co-supplements</NAME>
<DICH_OUTCOME CHI2="2.5458664359612735" CI_END="0.7369578027389071" CI_START="0.37856260677438136" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5281899912792375" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="65" I2="0.0" I2_Q="5.221158525643458" ID="CMP-006.01" LOG_CI_END="-0.13255737857554392" LOG_CI_START="-0.42186228649893154" LOG_EFFECT_SIZE="-0.27720983253723774" METHOD="MH" MODIFIED="2014-02-05 17:02:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6364420696869897" P_Q="0.3481620361803336" P_Z="1.726188985688996E-4" Q="2.1101756139751107" RANDOM="NO" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-06" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="393" TOTAL_2="272" WEIGHT="100.0" Z="3.756046116419465">
<NAME>High blood pressure (with or without pre-eclampsia)</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.382883499272244" CI_END="0.8211077651977664" CI_START="0.39391783115981116" DF="2" EFFECT_SIZE="0.5687257599363542" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="47" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-0.08559984073759365" LOG_CI_START="-0.4045943598889055" LOG_EFFECT_SIZE="-0.24509710031324958" MODIFIED="2013-05-19 00:43:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8257677830184735" P_Z="0.002596626514973532" STUDIES="3" TAU2="0.0" TOTAL_1="340" TOTAL_2="218" WEIGHT="76.45204026219632" Z="3.011847918937478">
<NAME>Calcium supplementation alone</NAME>
<DICH_DATA CI_END="1.4604040009414607" CI_START="0.24994272877628368" EFFECT_SIZE="0.6041666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.16447301407803128" LOG_CI_START="-0.6021594930312936" LOG_EFFECT_SIZE="-0.21884323947663115" MODIFIED="2013-05-19 00:43:47 +0100" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.4503237295681308" STUDY_ID="STD-Bassaw-1998" TOTAL_1="84" TOTAL_2="87" VAR="0.20279146141215104" WEIGHT="15.540289418496627"/>
<DICH_DATA CI_END="1.043902674543396" CI_START="0.19398360109439677" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.018660010276341052" LOG_CI_START="-0.7122349827256537" LOG_EFFECT_SIZE="-0.3467874862246563" MODIFIED="2012-09-16 15:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.42933133687793723" STUDY_ID="STD-Cong-1995" TOTAL_1="112" TOTAL_2="56" VAR="0.18432539682539684" WEIGHT="17.575327318537855"/>
<DICH_DATA CI_END="0.9535274285705997" CI_START="0.3828074056121239" EFFECT_SIZE="0.6041666666666666" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="25" LOG_CI_END="-0.020666809796236047" LOG_CI_START="-0.41701966915702626" LOG_EFFECT_SIZE="-0.21884323947663115" MODIFIED="2012-10-25 14:06:11 +0100" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.23281963156682442" STUDY_ID="STD-Rogers-1999" TOTAL_1="144" TOTAL_2="75" VAR="0.054204980842911865" WEIGHT="43.336423525161834"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.746930752819818" CI_START="0.2392934758924859" DF="0" EFFECT_SIZE="0.646551724137931" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.24227569017796086" LOG_CI_START="-0.6210691418483977" LOG_EFFECT_SIZE="-0.1893967258352184" MODIFIED="2013-07-25 10:20:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.38982419009089697" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="10.366464248900293" Z="0.8599362564215862">
<NAME>Calcium plus vitamin D</NAME>
<DICH_DATA CI_END="1.746930752819818" CI_START="0.2392934758924859" EFFECT_SIZE="0.646551724137931" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.24227569017796086" LOG_CI_START="-0.6210691418483977" LOG_EFFECT_SIZE="-0.1893967258352184" MODIFIED="2012-09-16 16:54:21 +0100" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="0.5071330279581256" STUDY_ID="STD-Li-2000" TOTAL_1="29" TOTAL_2="30" VAR="0.257183908045977" WEIGHT="10.366464248900293"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8182191777111687" CI_START="0.04888665664363101" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="-0.0871303455703156" LOG_CI_START="-1.3108096631017219" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2012-09-16 16:18:34 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.02515091424777103" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="13.18149548890339" Z="2.2390768809202197">
<NAME>Calcium plus linoleic acid</NAME>
<DICH_DATA CI_END="0.8182191777111687" CI_START="0.04888665664363101" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.0871303455703156" LOG_CI_START="-1.3108096631017219" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2012-09-16 16:18:34 +0100" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.7187952884282609" STUDY_ID="STD-Herrera-2006" TOTAL_1="24" TOTAL_2="24" VAR="0.5166666666666667" WEIGHT="13.18149548890339"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.986423601591914" CI_END="1.8746169946686955" CI_START="0.2425894041533511" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6743606006821755" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="64" I2="76.8989516125729" I2_Q="76.80712324822278" ID="CMP-006.02" LOG_CI_END="0.272912549880784" LOG_CI_START="-0.6151281722172877" LOG_EFFECT_SIZE="-0.1711078111682518" METHOD="MH" MODIFIED="2014-02-05 17:02:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.004666070600258032" P_Q="0.004779299990236963" P_Z="0.45007364061008914" Q="12.935006002522373" RANDOM="YES" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-06" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.6687577849617108" TOTALS="YES" TOTAL_1="595" TOTAL_2="595" WEIGHT="100.00000000000003" Z="0.7552922721177141">
<NAME>Preterm birth</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7527017704206531" CI_START="0.20857579746461063" DF="0" EFFECT_SIZE="0.3962264150943397" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="-0.12337706246577214" LOG_CI_START="-0.6807360872679672" LOG_EFFECT_SIZE="-0.4020565748668697" MODIFIED="2012-09-16 15:38:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0046886688838050136" STUDIES="1" TAU2="0.0" TOTAL_1="212" TOTAL_2="210" WEIGHT="35.0678960874629" Z="2.8276797231955144">
<NAME>Calcium supplementation alone</NAME>
<DICH_DATA CI_END="0.7527017704206531" CI_START="0.20857579746461063" EFFECT_SIZE="0.39622641509433965" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" LOG_CI_END="-0.12337706246577214" LOG_CI_START="-0.6807360872679672" LOG_EFFECT_SIZE="-0.40205657486686974" MODIFIED="2012-09-16 15:38:54 +0100" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.32739545014047833" STUDY_ID="STD-Almirante-1998" TOTAL_1="212" TOTAL_2="210" VAR="0.10718778077268644" WEIGHT="35.0678960874629"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.41196781390331" CI_START="0.9982918455040118" DF="0" EFFECT_SIZE="1.5517241379310345" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="29" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.38237150813749543" LOG_CI_START="-7.424763847202295E-4" LOG_EFFECT_SIZE="0.1908145158763876" MODIFIED="2013-07-25 10:20:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.050894630382060706" STUDIES="1" TAU2="0.0" TOTAL_1="330" TOTAL_2="330" WEIGHT="37.82415454296636" Z="1.95236714896519">
<NAME>Calcium plus vitamin D</NAME>
<DICH_DATA CI_END="2.41196781390331" CI_START="0.9982918455040117" EFFECT_SIZE="1.5517241379310345" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="29" LOG_CI_END="0.38237150813749543" LOG_CI_START="-7.424763847202778E-4" LOG_EFFECT_SIZE="0.1908145158763876" MODIFIED="2012-10-23 16:41:46 +0100" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.22504305095315835" STUDY_ID="STD-Taherian-2002" TOTAL_1="330" TOTAL_2="330" VAR="0.05064437478230582" WEIGHT="37.82415454296636"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.153502458036732" CI_START="0.048510697731429714" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-006.02.03" LOG_CI_END="0.7121024875250384" LOG_CI_START="-1.3141624788530009" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-09-16 16:20:39 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5603241438828968" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="13.048076830332676" Z="0.582360115342955">
<NAME>Calcium plus linoleic acid</NAME>
<DICH_DATA CI_END="5.153502458036732" CI_START="0.048510697731429714" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7121024875250384" LOG_CI_START="-1.3141624788530009" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-09-16 16:20:39 +0100" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="1.1902380714238083" STUDY_ID="STD-Herrera-2006" TOTAL_1="24" TOTAL_2="24" VAR="1.4166666666666665" WEIGHT="13.048076830332676"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.892633674950726E-32" CI_END="3.2345221380429106" CI_START="0.03925317174749747" DF="0" EFFECT_SIZE="0.3563218390804598" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="100.0" ID="CMP-006.02.04" LOG_CI_END="0.5098101279288101" LOG_CI_START="-1.4061252454975017" LOG_EFFECT_SIZE="-0.4481575587843458" MODIFIED="2012-10-16 10:37:54 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.3591884337325403" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="14.059872539238084" Z="0.916912633692749">
<NAME>Calcium plus antioxidants</NAME>
<DICH_DATA CI_END="3.2345221380429106" CI_START="0.03925317174749747" EFFECT_SIZE="0.3563218390804598" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5098101279288101" LOG_CI_START="-1.4061252454975017" LOG_EFFECT_SIZE="-0.4481575587843458" MODIFIED="2012-10-16 10:37:54 +0100" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="1.1254299223836706" STUDY_ID="STD-Rumiris-2006" TOTAL_1="29" TOTAL_2="31" VAR="1.2665925101965145" WEIGHT="14.059872539238084"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9903071694363149" CI_START="0.19571851332426293" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.44025157232704404" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-0.004230076816572425" LOG_CI_START="-0.7083680917958168" LOG_EFFECT_SIZE="-0.3562990843061946" METHOD="MH" MODIFIED="2014-02-05 17:02:22 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.04731018187085666" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-06" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="210" WEIGHT="100.0" Z="1.9835127719537382">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9903071694363149" CI_START="0.19571851332426293" DF="0" EFFECT_SIZE="0.44025157232704404" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="-0.004230076816572425" LOG_CI_START="-0.7083680917958168" LOG_EFFECT_SIZE="-0.3562990843061946" MODIFIED="2012-09-16 15:39:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04731018187085666" STUDIES="1" TAU2="0.0" TOTAL_1="212" TOTAL_2="210" WEIGHT="100.0" Z="1.9835127719537382">
<NAME>Calcium supplementation alone</NAME>
<DICH_DATA CI_END="0.9903071694363149" CI_START="0.19571851332426293" EFFECT_SIZE="0.44025157232704404" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.004230076816572425" LOG_CI_START="-0.7083680917958168" LOG_EFFECT_SIZE="-0.3562990843061946" MODIFIED="2012-09-16 15:39:31 +0100" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.41361415553819636" STUDY_ID="STD-Almirante-1998" TOTAL_1="212" TOTAL_2="210" VAR="0.1710766696615753" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-07-25 10:21:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Calcium plus vitamin D</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-16 15:34:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Calcium plus linoleic acid</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9889683381639791" CI_END="1.670297486296196" CI_START="0.13527130559123726" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4753349573690621" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.22279382752542168" LOG_CI_START="-0.8687943182953929" LOG_EFFECT_SIZE="-0.3230002453849857" METHOD="MH" MODIFIED="2013-08-02 11:25:22 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9114641682086452" P_Q="0.874291312209469" P_Z="0.24608782471220214" Q="0.6953748290811583" RANDOM="NO" SCALE="100.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-06" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="510" TOTAL_2="515" WEIGHT="100.0" Z="1.1599042191432714">
<NAME>Stillbirth or death before discharge</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.291392028450723" CI_START="0.06584483878107655" DF="0" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="1.2119581944648" LOG_CI_START="-1.181478261351326" LOG_EFFECT_SIZE="0.015239966556736905" MODIFIED="2012-10-16 11:27:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9800870699175518" STUDIES="1" TAU2="0.0" TOTAL_1="84" TOTAL_2="87" WEIGHT="13.215590742996344" Z="0.024959748151420286">
<NAME>Calcium supplementation alone</NAME>
<DICH_DATA CI_END="16.291392028450723" CI_START="0.06584483878107655" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2119581944648" LOG_CI_START="-1.181478261351326" LOG_EFFECT_SIZE="0.015239966556736905" MODIFIED="2012-10-16 11:27:09 +0100" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="1.4059164218479259" STUDY_ID="STD-Bassaw-1998" TOTAL_1="84" TOTAL_2="87" VAR="1.9766009852216748" WEIGHT="13.215590742996344"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.149967977411219" CI_START="0.009638628591286696" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-006.04.02" LOG_CI_END="0.6180447455585361" LOG_CI_START="-2.0159847542305736" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-07-25 10:21:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2982479615430287" STUDIES="1" TAU2="0.0" TOTAL_1="330" TOTAL_2="330" WEIGHT="33.62895858708892" Z="1.0401979437831552">
<NAME>Calcium plus vitamin D</NAME>
<DICH_DATA CI_END="4.149967977411219" CI_START="0.009638628591286696" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6180447455585361" LOG_CI_START="-2.0159847542305736" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2012-10-23 16:42:38 +0100" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="1.5472419668324318" STUDY_ID="STD-Taherian-2002" TOTAL_1="330" TOTAL_2="330" VAR="2.393957703927492" WEIGHT="33.62895858708892"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2679507192884927" CI_END="4.408274185889665" CI_START="0.08166461177762376" DF="1" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-006.04.03" LOG_CI_END="0.6442685989371114" LOG_CI_START="-1.0879660981698243" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2012-09-16 16:42:19 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6047098204827709" P_Z="0.6156475030411086" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="67" WEIGHT="33.62895858708892" Z="0.50202846068088">
<NAME>Calcium plus linoleic acid</NAME>
<DICH_DATA CI_END="7.961364031061661" CI_START="0.013956290740833538" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-09-16 16:42:19 +0100" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Herrera-1998" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="20.177375152253347"/>
<DICH_DATA CI_END="15.08117485055269" CI_START="0.06630783144612584" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1784351751702022" LOG_CI_START="-1.1784351751702022" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-16 16:22:11 +0100" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="1.3844373104863457" STUDY_ID="STD-Herrera-2006" TOTAL_1="24" TOTAL_2="24" VAR="1.9166666666666665" WEIGHT="13.451583434835566"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8947819981289315E-32" CI_END="8.394184190041871" CI_START="0.0150603977973694" DF="0" EFFECT_SIZE="0.3555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" ID="CMP-006.04.04" LOG_CI_END="0.9239784945205959" LOG_CI_START="-1.822163556759434" LOG_EFFECT_SIZE="-0.44909253111941894" MODIFIED="2012-10-16 10:40:12 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.5214911455142894" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="19.526492082825822" Z="0.6410485475867602">
<NAME>Calcium plus antioxidants</NAME>
<DICH_DATA CI_END="8.394184190041877" CI_START="0.015060397797369413" EFFECT_SIZE="0.35555555555555557" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9239784945205962" LOG_CI_START="-1.8221635567594336" LOG_EFFECT_SIZE="-0.4490925311194189" MODIFIED="2012-10-16 10:40:12 +0100" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="1.6130974345442786" STUDY_ID="STD-Rumiris-2006" TOTAL_1="29" TOTAL_2="31" VAR="2.6020833333333333" WEIGHT="19.526492082825822"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-08-02 11:30:24 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Placental abruption</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calciuml</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-10-16 10:35:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Calcium plus antioxidants</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-10-16 10:35:31 +0100" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.0" STUDY_ID="STD-Rumiris-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.4844884267820175" CI_END="1.1547121610709525" CI_START="0.45641997059451983" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7259708607107717" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="66" I2="59.91710015523585" I2_Q="14.536787472679627" ID="CMP-006.06" LOG_CI_END="0.062473739693353694" LOG_CI_START="-0.3406353613413516" LOG_EFFECT_SIZE="-0.13908081082399892" METHOD="MH" MODIFIED="2014-02-05 17:02:40 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.05795839526775315" P_Q="0.2793819603529074" P_Z="0.1762299310950581" Q="1.170094091279714" RANDOM="YES" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-06" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1335686751822779" TOTALS="YES" TOTAL_1="323" TOTAL_2="198" WEIGHT="100.0" Z="1.3524546057430629">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.090391988790062" CI_END="2.218151189555928" CI_START="0.39676125403000956" DF="1" EFFECT_SIZE="0.9381238977855577" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="33" I2="80.35514745814908" ID="CMP-006.06.01" LOG_CI_END="0.34599114440650686" LOG_CI_START="-0.4014707457481251" LOG_EFFECT_SIZE="-0.027739800670809077" MODIFIED="2012-09-18 09:43:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.024058787655294234" P_Z="0.8843347945372162" STUDIES="2" TAU2="0.31038342729417395" TOTAL_1="256" TOTAL_2="131" WEIGHT="53.87689298611313" Z="0.14547634058469028">
<NAME>Calcium supplementation alone</NAME>
<DICH_DATA CI_END="0.9976913704391486" CI_START="0.38410671476475355" EFFECT_SIZE="0.6190476190476191" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="21" LOG_CI_END="-0.0010037842083281978" LOG_CI_START="-0.41554810064583675" LOG_EFFECT_SIZE="-0.20827594242708247" MODIFIED="2012-09-16 15:10:04 +0100" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.24350538350285358" STUDY_ID="STD-Cong-1995" TOTAL_1="112" TOTAL_2="56" VAR="0.0592948717948718" WEIGHT="29.07168880431805"/>
<DICH_DATA CI_END="2.6781416890555256" CI_START="0.8131287833886702" EFFECT_SIZE="1.4756944444444444" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="12" LOG_CI_END="0.4278335499527493" LOG_CI_START="-0.08984066537058782" LOG_EFFECT_SIZE="0.16899644229108068" MODIFIED="2012-09-18 09:43:26 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.304084396609622" STUDY_ID="STD-Rogers-1999" TOTAL_1="144" TOTAL_2="75" VAR="0.09246732026143789" WEIGHT="24.805204181795077"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-07-25 10:20:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Calcium plus vitamin D</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.031157374301632748" CI_END="0.8663694428115964" CI_START="0.34623325463657356" DF="1" EFFECT_SIZE="0.5476914385877634" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="33" I2="0.0" ID="CMP-006.06.03" LOG_CI_END="-0.06229687384849882" LOG_CI_START="-0.4606312218113761" LOG_EFFECT_SIZE="-0.2614640478299375" MODIFIED="2012-09-16 16:39:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8598897858192555" P_Z="0.010081685156416106" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="67" WEIGHT="46.123107013886866" Z="2.5730149539928417">
<NAME>Calcium plus linoleic acid</NAME>
<DICH_DATA CI_END="1.1046327813290278" CI_START="0.2956010520093708" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.043217927298900075" LOG_CI_START="-0.5292940246714891" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2012-09-16 16:20:01 +0100" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="0.33629635456727464" STUDY_ID="STD-Herrera-2006" TOTAL_1="24" TOTAL_2="24" VAR="0.11309523809523811" WEIGHT="22.730803808778095"/>
<DICH_DATA CI_END="0.996630793406446" CI_START="0.27794476357940295" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="-0.0014656983410667285" LOG_CI_START="-0.5560415035645913" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2012-09-16 16:39:47 +0100" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.3257605731828081" STUDY_ID="STD-Herrera-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.10611995104039167" WEIGHT="23.39230320510877"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0023575775831063224" CI_END="1.2069933558320303" CI_START="0.09623994862176871" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3408239700374532" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="0.0817048794317087" LOG_CI_START="-1.0166446175186719" LOG_EFFECT_SIZE="-0.46746986904348165" METHOD="MH" MODIFIED="2013-08-02 11:30:20 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9612740324692695" P_Q="0.9612758345289952" P_Z="0.09524322749967437" Q="0.0023573580021252942" RANDOM="NO" SCALE="100.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-06" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="74" WEIGHT="99.99999999999999" Z="1.6683653240190288">
<NAME>Severe pre-eclampsia</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-16 15:11:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Calcium supplementation alone</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-07-25 10:20:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Calcium plus vitamin D</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5602683752205928" CI_START="0.07121282009923585" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-006.07.03" LOG_CI_END="0.19319930595243365" LOG_CI_START="-1.1474418153917585" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-09-16 16:40:14 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.16299636421104724" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="67.41573033707864" Z="1.3950645860713005">
<NAME>Calcium plus linoleic acid</NAME>
<DICH_DATA CI_END="1.5602683752205928" CI_START="0.07121282009923585" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19319930595243365" LOG_CI_START="-1.1474418153917585" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-09-16 16:40:14 +0100" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.7874992309581577" STUDY_ID="STD-Herrera-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.6201550387596898" WEIGHT="67.41573033707864"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.892633674950726E-32" CI_END="3.234522138042911" CI_START="0.03925317174749747" DF="0" EFFECT_SIZE="0.35632183908045983" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="100.0" ID="CMP-006.07.04" LOG_CI_END="0.5098101279288102" LOG_CI_START="-1.4061252454975017" LOG_EFFECT_SIZE="-0.44815755878434577" MODIFIED="2012-10-16 10:37:04 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.3591884337325404" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="32.58426966292134" Z="0.9169126336927488">
<NAME>Calcium plus antioxidants</NAME>
<DICH_DATA CI_END="3.2345221380429106" CI_START="0.03925317174749747" EFFECT_SIZE="0.3563218390804598" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5098101279288101" LOG_CI_START="-1.4061252454975017" LOG_EFFECT_SIZE="-0.4481575587843458" MODIFIED="2012-10-16 10:37:04 +0100" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="1.1254299223836706" STUDY_ID="STD-Rumiris-2006" TOTAL_1="29" TOTAL_2="31" VAR="1.2665925101965145" WEIGHT="32.58426966292134"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.764676979965272" CI_END="0.5153634713538443" CI_START="0.2825791497622437" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.38161626217142236" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="136" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="-0.28788636722024313" LOG_CI_START="-0.5488598859314261" LOG_EFFECT_SIZE="-0.4183731265758346" METHOD="MH" MODIFIED="2014-02-05 14:59:34 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6735723916692877" P_Q="0.44738685640945497" P_Z="3.296865910055815E-10" Q="2.658146373704327" RANDOM="NO" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-06" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1178" TOTAL_2="1056" WEIGHT="100.0" Z="6.2841338403804565">
<NAME>Pre-eclampsia</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8115929382101463" CI_END="0.5705740958216102" CI_START="0.22645920269077144" DF="3" EFFECT_SIZE="0.35946036612646143" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="57" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="-0.24368794928796123" LOG_CI_START="-0.6450100260668598" LOG_EFFECT_SIZE="-0.44434898767741043" MODIFIED="2013-05-19 00:44:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.612415590185575" P_Z="1.423564065312454E-5" STUDIES="4" TAU2="0.0" TOTAL_1="552" TOTAL_2="428" WEIGHT="43.34784803722618" Z="4.340194884889769">
<NAME>Calcium supplementation alone</NAME>
<DICH_DATA CI_END="1.3839351325145015" CI_START="0.06327441082745995" EFFECT_SIZE="0.29591836734693877" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.1411157344478902" LOG_CI_START="-1.1987718900349678" LOG_EFFECT_SIZE="-0.5288280777935388" MODIFIED="2013-05-19 00:44:32 +0100" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.7870566231719404" STUDY_ID="STD-Bassaw-1998" TOTAL_1="84" TOTAL_2="87" VAR="0.6194581280788177" WEIGHT="4.919290175750341"/>
<DICH_DATA CI_END="1.5784325557353134" CI_START="0.22446850119460507" EFFECT_SIZE="0.5952380952380952" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.19822602981534057" LOG_CI_START="-0.6488445932670663" LOG_EFFECT_SIZE="-0.22530928172586287" MODIFIED="2012-09-18 09:42:09 +0100" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="0.49757347706581495" STUDY_ID="STD-Rogers-1999" TOTAL_1="144" TOTAL_2="75" VAR="0.2475793650793651" WEIGHT="6.58472501020202"/>
<DICH_DATA CI_END="2.0664800393911547" CI_START="0.004925174259183515" EFFECT_SIZE="0.10088495575221239" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3152312146870985" LOG_CI_START="-2.307578398980993" LOG_EFFECT_SIZE="-0.9961735921469471" MODIFIED="2012-09-16 15:07:17 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="1.5406513501856134" STUDY_ID="STD-Cong-1995" TOTAL_1="112" TOTAL_2="56" VAR="2.3736065828287534" WEIGHT="2.377337036465182"/>
<DICH_DATA CI_END="0.6016469978662017" CI_START="0.19015750545711363" EFFECT_SIZE="0.33824206166589965" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="41" LOG_CI_END="-0.22065824602557474" LOG_CI_START="-0.7208865284470846" LOG_EFFECT_SIZE="-0.4707723872363297" MODIFIED="2012-09-16 15:38:00 +0100" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="0.293836569264328" STUDY_ID="STD-Almirante-1998" TOTAL_1="212" TOTAL_2="210" VAR="0.08633992943703021" WEIGHT="29.46649581480863"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2059436642842787" CI_END="0.7790674553738665" CI_START="0.30843567351197154" DF="1" EFFECT_SIZE="0.49019607843137253" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="51" I2="17.077386811970623" ID="CMP-006.08.02" LOG_CI_END="-0.10842493741301135" LOG_CI_START="-0.5108353974387861" LOG_EFFECT_SIZE="-0.3096301674258988" MODIFIED="2013-07-25 10:20:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.27213702572679144" P_Z="0.002560115231434708" STUDIES="2" TAU2="0.0" TOTAL_1="530" TOTAL_2="530" WEIGHT="36.48055240027102" Z="3.0161441461685583">
<NAME>Calcium plus vitamin D</NAME>
<DICH_DATA CI_END="1.347409010364073" CI_START="0.32985117438420164" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.12949944723093357" LOG_CI_START="-0.4816819653422961" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2012-09-16 14:50:59 +0100" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.3590109871423003" STUDY_ID="STD-Marya-1987" TOTAL_1="200" TOTAL_2="200" VAR="0.1288888888888889" WEIGHT="12.875489082448595"/>
<DICH_DATA CI_END="0.7347964361729148" CI_START="0.211198964036371" EFFECT_SIZE="0.3939393939393939" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="33" LOG_CI_END="-0.13383295872740364" LOG_CI_START="-0.6753082164146977" LOG_EFFECT_SIZE="-0.40457058757105074" MODIFIED="2012-10-23 16:41:00 +0100" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="0.3180652467112702" STUDY_ID="STD-Taherian-2002" TOTAL_1="330" TOTAL_2="330" VAR="0.10116550116550116" WEIGHT="23.605063317822424"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12835713054553638" CI_END="0.6003800874000533" CI_START="0.08870120609835828" DF="1" EFFECT_SIZE="0.23076923076923078" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="19" I2="0.0" ID="CMP-006.08.03" LOG_CI_END="-0.22157372028567446" LOG_CI_START="-1.0520704748886742" LOG_EFFECT_SIZE="-0.6368220975871743" MODIFIED="2012-09-16 16:39:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7201416184562264" P_Z="0.002648940597769644" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="67" WEIGHT="13.948446505985977" Z="3.0057874854110964">
<NAME>Calcium plus linoleic acid</NAME>
<DICH_DATA CI_END="0.6869722716283387" CI_START="0.09097892677946884" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.16306079208431215" LOG_CI_START="-1.0410591905716127" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2012-09-16 16:39:12 +0100" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.5157406054336068" STUDY_ID="STD-Herrera-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.2659883720930233" WEIGHT="11.44487918439875"/>
<DICH_DATA CI_END="2.6246806717009323" CI_START="0.007775484265703283" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4190764730927677" LOG_CI_START="-2.1092725531212815" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2012-09-16 16:19:12 +0100" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="1.48516473352766" STUDY_ID="STD-Herrera-2006" TOTAL_1="24" TOTAL_2="24" VAR="2.2057142857142855" WEIGHT="2.5035673215872265"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0087418825007004" CI_START="0.0559399805983758" DF="0" EFFECT_SIZE="0.23754789272030652" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" ID="CMP-006.08.04" LOG_CI_END="0.0037800529104616174" LOG_CI_START="-1.2522776885905158" LOG_EFFECT_SIZE="-0.6242488178400271" MODIFIED="2012-10-16 10:31:29 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.05139496892574639" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="6.2231530565168205" Z="1.9481671262916311">
<NAME>Calcium plus antioxidants</NAME>
<DICH_DATA CI_END="1.0087418825007004" CI_START="0.0559399805983758" EFFECT_SIZE="0.23754789272030652" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="0.0037800529104616174" LOG_CI_START="-1.2522776885905158" LOG_EFFECT_SIZE="-0.6242488178400271" MODIFIED="2012-10-16 10:31:29 +0100" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="0.7378145349437706" STUDY_ID="STD-Rumiris-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.5443702879742925" WEIGHT="6.2231530565168205"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.06242668024354" CI_START="0.006959287513368529" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.168141592920354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="0.6087855357954248" LOG_CI_START="-2.1574352208566063" LOG_EFFECT_SIZE="-0.7743248425305908" METHOD="MH" MODIFIED="2013-08-02 11:30:12 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.27252236229556603" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-06" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="112" TOTAL_2="56" WEIGHT="100.0" Z="1.0972723706486995">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.06242668024354" CI_START="0.006959287513368529" DF="0" EFFECT_SIZE="0.168141592920354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.09.01" LOG_CI_END="0.6087855357954248" LOG_CI_START="-2.1574352208566063" LOG_EFFECT_SIZE="-0.7743248425305908" MODIFIED="2012-09-16 15:14:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.27252236229556603" STUDIES="1" TAU2="0.0" TOTAL_1="112" TOTAL_2="56" WEIGHT="100.0" Z="1.0972723706486995">
<NAME>Calcium supplementation alone</NAME>
<DICH_DATA CI_END="4.06242668024354" CI_START="0.006959287513368529" EFFECT_SIZE="0.168141592920354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6087855357954248" LOG_CI_START="-2.1574352208566063" LOG_EFFECT_SIZE="-0.7743248425305908" MODIFIED="2012-09-16 15:14:31 +0100" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="1.6248917654709867" STUDY_ID="STD-Cong-1995" TOTAL_1="112" TOTAL_2="56" VAR="2.64027324949542" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-07-25 10:20:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Calcium plus vitamin D</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-16 15:13:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Calcium plus linoleic acid</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0404597892402094" CI_START="0.003783853416214888" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.06274509803921569" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="0.017225300647079615" LOG_CI_START="-2.4220656962031404" LOG_EFFECT_SIZE="-1.2024201977780304" METHOD="MH" MODIFIED="2013-08-02 11:30:36 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.05332458356427554" Q="0.0" RANDOM="NO" SCALE="141.8467367486994" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="31" WEIGHT="100.0" Z="1.9322830158202542">
<NAME>Miscarriage</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0404597892402094" CI_START="0.003783853416214888" DF="0" EFFECT_SIZE="0.06274509803921569" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" I2="0.0" ID="CMP-006.10.01" LOG_CI_END="0.017225300647079615" LOG_CI_START="-2.4220656962031404" LOG_EFFECT_SIZE="-1.2024201977780304" MODIFIED="2012-10-16 10:42:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05332458356427554" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="100.0" Z="1.9322830158202542">
<NAME>Calcium plus antioxidants</NAME>
<DICH_DATA CI_END="1.0404597892402099" CI_START="0.003783853416214885" EFFECT_SIZE="0.06274509803921569" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.017225300647079802" LOG_CI_START="-2.422065696203141" LOG_EFFECT_SIZE="-1.2024201977780304" MODIFIED="2012-10-16 10:42:21 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="1.4328516062349919" STUDY_ID="STD-Rumiris-2006" TOTAL_1="29" TOTAL_2="31" VAR="2.0530637254901962" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8755563691575496" CI_START="0.04568523673522876" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="0.0" I2_Q="100.0" ID="CMP-006.11" LOG_CI_END="-0.05771588838578086" LOG_CI_START="-1.3402241202862568" LOG_EFFECT_SIZE="-0.6989700043360187" METHOD="MH" MODIFIED="2013-08-02 11:30:36 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.03264926998674244" Q="8.68730209778987E-32" RANDOM="NO" SCALE="100.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-06" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0" Z="2.1363699673761047">
<NAME>Birthweight &lt; 2500 g</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-16 15:21:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Calcium supplementation alone</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-07-25 10:20:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Calcium plus vitamin D</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8755563691575496" CI_START="0.04568523673522876" DF="1" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="0.0" ID="CMP-006.11.03" LOG_CI_END="-0.05771588838578086" LOG_CI_START="-1.3402241202862568" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2012-09-16 16:40:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.03264926998674244" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0" Z="2.1363699673761047">
<NAME>Calcium plus linoleic acid</NAME>
<DICH_DATA CI_END="1.6414412977456805" CI_START="0.02436882759982653" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.21522535583112912" LOG_CI_START="-1.6131653645031665" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2012-09-16 16:40:45 +0100" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="1.0740057598043984" STUDY_ID="STD-Herrera-1998" TOTAL_1="43" TOTAL_2="43" VAR="1.1534883720930231" WEIGHT="50.0"/>
<DICH_DATA CI_END="1.5867756228414716" CI_START="0.02520835297959216" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.20051551991734207" LOG_CI_START="-1.5984555285893796" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2012-09-16 16:21:06 +0100" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="1.0567244989431572" STUDY_ID="STD-Herrera-2006" TOTAL_1="24" TOTAL_2="24" VAR="1.1166666666666665" WEIGHT="50.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0555045656339925" CI_END="1.2138459954420242" CI_START="0.5402387262149085" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8097941802696947" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="47" I2="0.0" I2_Q="1.334367005563052" ID="CMP-006.12" LOG_CI_END="0.08416358989213059" LOG_CI_START="-0.2674142872744143" LOG_EFFECT_SIZE="-0.09162534869114183" METHOD="MH" MODIFIED="2014-06-12 14:07:53 +0100" MODIFIED_BY="Heather Maxwell" NO="12" P_CHI2="0.560966848915746" P_Q="0.36293780891027083" P_Z="0.3069799582674291" Q="2.027048263211128" RANDOM="NO" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-06" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="426" TOTAL_2="428" WEIGHT="99.99999999999999" Z="1.0215795427907017">
<NAME>Neonate small-for-gestational age</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-16 15:21:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Calcium supplementation alone</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.379707731658661" CI_START="0.583740433952883" DF="0" EFFECT_SIZE="0.8974358974358975" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" I2="0.0" ID="CMP-006.12.02" LOG_CI_END="0.13978709801645434" LOG_CI_START="-0.23378022336890147" LOG_EFFECT_SIZE="-0.046996562676223555" MODIFIED="2013-07-25 10:20:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6219096016705032" STUDIES="1" TAU2="0.0" TOTAL_1="330" TOTAL_2="330" WEIGHT="83.03761533002128" Z="0.4931457596504231">
<NAME>Calcium plus vitamin D</NAME>
<DICH_DATA CI_END="1.379707731658661" CI_START="0.583740433952883" EFFECT_SIZE="0.8974358974358975" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.13978709801645434" LOG_CI_START="-0.23378022336890147" LOG_EFFECT_SIZE="-0.046996562676223555" MODIFIED="2012-10-23 16:42:23 +0100" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="0.21943529376982218" STUDY_ID="STD-Taherian-2002" TOTAL_1="330" TOTAL_2="330" VAR="0.048151848151848156" WEIGHT="83.03761533002128"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03374938594091079" CI_END="1.3189871097808266" CI_START="0.06189041003955619" DF="1" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-006.12.03" LOG_CI_END="0.12024055128676536" LOG_CI_START="-1.2083766399873168" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2012-09-16 16:41:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8542409698953322" P_Z="0.10844793817407715" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="67" WEIGHT="14.904187366926898" Z="1.6052084514172176">
<NAME>Calcium plus linoleic acid</NAME>
<DICH_DATA CI_END="2.0765517369088404" CI_START="0.03009797390988083" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3173427559487198" LOG_CI_START="-1.5214627386046446" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2012-09-16 16:21:42 +0100" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Herrera-2006" TOTAL_1="24" TOTAL_2="24" VAR="1.1666666666666665" WEIGHT="8.516678495386799"/>
<DICH_DATA CI_END="3.0794003013622344" CI_START="0.03608206151761396" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4884661479394589" LOG_CI_START="-1.4427086573787837" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-09-16 16:41:31 +0100" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="1.1343816401133953" STUDY_ID="STD-Herrera-1998" TOTAL_1="43" TOTAL_2="43" VAR="1.2868217054263564" WEIGHT="6.387508871540099"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.31130518173396" CI_START="0.07005492597433315" DF="0" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.12.04" LOG_CI_END="1.2124887133729667" LOG_CI_START="-1.1545613215023336" LOG_EFFECT_SIZE="0.028963695935316558" MODIFIED="2012-10-16 10:39:01 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9617441206590881" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="2.0581973030518097" Z="0.04796501979763198">
<NAME>Calcium plus antioxidants</NAME>
<DICH_DATA CI_END="16.31130518173396" CI_START="0.07005492597433315" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2124887133729667" LOG_CI_START="-1.1545613215023336" LOG_EFFECT_SIZE="0.028963695935316558" MODIFIED="2012-10-16 10:39:01 +0100" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="1.3904169075723947" STUDY_ID="STD-Rumiris-2006" TOTAL_1="29" TOTAL_2="31" VAR="1.9332591768631813" WEIGHT="2.0581973030518097"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-06-12 14:05:37 +0100" MODIFIED_BY="Heather Maxwell">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-06-12 14:05:26 +0100" MODIFIED_BY="Heather Maxwell" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias'[ summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATEAAAPqCAIAAAB0Yf/6AAA0bElEQVR42u2dsW4bufaHBQQIUqhQ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-06-12 14:05:37 +0100" MODIFIED_BY="Heather Maxwell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias'[ graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-03-05 16:10:42 +0000" MODIFIED_BY="Leanne V Jones" NO="3" REF_ID="CMP-002.01" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 2 Routine high-dose calcium supplementation in pregnancy by hypertension risk, outcome: 2.1 High blood pressure (with or without proteinuria).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-03-05 16:10:42 +0000" MODIFIED_BY="Leanne V Jones" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Routine high-dose calcium supplementation in pregnancy by baseline dietary calcium, outcome: 1.1 High blood pressure (with or without proteinuria).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-02-05 20:57:32 +0000" MODIFIED_BY="Leanne V Jones" NO="5" REF_ID="CMP-003.01" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 3 Routine high-dose calcium supplementation in pregnancy by study sample size, outcome: 3.1 High blood pressure (with or without proteinuria).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2014-02-05 20:57:32 +0000" MODIFIED_BY="Leanne V Jones" NO="6" REF_ID="CMP-001.02" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Routine high-dose calcium supplementation in pregnancy by baseline dietary calcium, outcome: 1.2 Pre-eclampsia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2014-02-05 20:59:53 +0000" MODIFIED_BY="Leanne V Jones" NO="7" REF_ID="CMP-002.02" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 2 Routine high-dose calcium supplementation in pregnancy by hypertension risk, outcome: 2.2 Pre-eclampsia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2014-03-05 13:26:00 +0000" MODIFIED_BY="Leanne V Jones" NO="8" REF_ID="CMP-004.01" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 4 Routine high-dose calcium supplementation in pregnancy by baseline dietary calcium and study sample size (not pre-specified), outcome: 4.1 Pre-eclampsia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2014-03-05 13:26:00 +0000" MODIFIED_BY="Leanne V Jones" NO="9" REF_ID="CMP-001.03" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Routine high-dose calcium supplementation in pregnancy by baseline dietary calcium, outcome: 1.3 Preterm birth.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2014-03-05 13:25:57 +0000" MODIFIED_BY="Leanne V Jones" NO="10" REF_ID="CMP-002.03" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 2 Routine high-dose calcium supplementation in pregnancy by hypertension risk, outcome: 2.3 Preterm birth.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2014-03-05 13:25:54 +0000" MODIFIED_BY="Leanne V Jones" NO="11" REF_ID="CMP-003.03" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 3 Routine high-dose calcium supplementation in pregnancy by study sample size, outcome: 3.3 Preterm birth.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2013-05-24 10:54:22 +0100" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2011-01-19 16:01:12 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-01-06 13:43:55 +0000" MODIFIED_BY="Sonja L  Henderson">Stones</TITLE>
<DATE_SUBMITTED>
<DATE DAY="7" MONTH="12" YEAR="2010"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2011-01-19 15:43:54 +0000" MODIFIED_BY="[Empty name]">
<P>Noting that public health programs are now starting to include calcium supplementation, I wonder if the statements in the abstract and plain language summary that "there were no other clear benefits, or harms"/"No adverse effects have been found" should be revised to include mention of the increased risk of HELLP syndrome associated with calcium supplementation. At the very least it would prompt programmers to include surveillance and reporting for this life threatening complication and would help to clarify whether this is a real association.</P>
<P>(Feedback submitted by William Stones, December 2010)</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2011-01-19 16:01:12 +0000" MODIFIED_BY="[Empty name]">
<P>We agree with the above feedback. We have added emphasis to the effect on HELLP syndrome to the discussion, and added to "Implications for practice":<BR/>"..........The increase in the risk of HELLP syndrome was small in terms of absolute numbers, and therefore we considered it to be outweighed by the overall reduction in death or severe morbidity; and to "Implications for research": <BR/>"The increase in the risk of HELLP syndrome identified by this review requires further investigation."</P>
<P>To the abstract results we have added "There was an anomalous increase in the risk of HELLP syndrome (two trials, 12,901 women: RR 2.67, 95% CI 1.05 to 6.82)."; and to the abstract conclusions we have added "We considered the latter benefit to outweigh the increase in HELLP syndrome, which was small in absolute numbers".</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2011-01-19 15:45:52 +0000" MODIFIED_BY="[Empty name]">
<P>Feedback: William Stones</P>
<P>Reply: G Justus Hofmeyr</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2013-05-24 10:54:22 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-01-06 13:43:43 +0000" MODIFIED_BY="Sonja L  Henderson">Walkinshaw</TITLE>
<DATE_SUBMITTED>
<DATE DAY="2" MONTH="11" YEAR="2010"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2011-01-19 16:00:01 +0000" MODIFIED_BY="[Empty name]">
<P>I feel that the conclusion drawn for high-risk women go beyond the data.  Five trials are cited for high-risk women. Of these one trial assessed risk by roll over test, another by roll over test plus angiotensin II infusion, and a third by roll over test plus at least one risk factor. All three of these trials excluded chronic medical conditions.  For the two other trials, data for high-risk women come either from a subgroup analysis or are unpublished data. <LINK REF="STD-Villar-1990" TYPE="STUDY">Villar 1990</LINK> includes mainly nulliparous women and excluded medical disease; <LINK REF="STD-L_x002d_Jaramillo-1990" TYPE="STUDY">L-Jaramillo 1990</LINK> includes nulliparous women and also excludes underlying medical disease. Thus three of the five trials do not describe high risk in any meaningfully clinically translatable way, and exclude the highest risk women (such as those with previous pre-eclampsia, chronic hypertension, or renal disease). The two additional studies also largely exclude clinical high-risk factors.<BR/>
</P>
<P>To draw a broad conclusion using the very impressive risk reduction in 'high risk' from this is not really translatable to clinical high risk. I think it will confuse clinicians, who will not look at the detail of the trials used and assume that high risk means the usual suspects, when it manifestly does not. The authors should consider some caveat to their conclusion. I actually think the current conclusion misleads.<BR/>
<BR/>During the genesis of the NICE guidance we looked in some detail at this to determine if there was evidence of benefit for clinically high-risk women, and concluded that at present those studies had not been performed. I do not feel that it is enough to rely on studies selecting women using research techniques to assess risk.</P>
<P> The issue in low-risk women is more contentious and I make no comment on that part.<BR/>
</P>
<P>(Summary of comment from Stephen Walkinshaw, Obstetrician and Chair of NICE guideline development group for Hypertension in Pregnancy, November 2010)</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-05-24 10:54:22 +0100" MODIFIED_BY="[Empty name]">
<P>We agree with the points made, and have added the following to the results section: "Five studies enrolled women considered to be at high risk of pre-eclampsia. The definitions of high risk and the actual risk (rate of pre-eclampsia in the placebo group) were variable: positive 'roll-over test at 28-30 weeks (8/34) (<LINK REF="STD-L_x002d_Jaramillo-1990" TYPE="STUDY">L-Jaramillo 1990</LINK>); teenagers 17 years or younger (3/88) (<LINK REF="STD-Villar-1990" TYPE="STUDY">Villar 1990</LINK>); positive 'roll-over' test at 28-32 weeks plus one clinical risk factor (7/15) (<LINK REF="STD-Niromanesh-2001" TYPE="STUDY">Niromanesh 2001</LINK>); positive 'roll-over' and positive angiotensin II infusion test (15/34) (<LINK REF="STD-S_x002d_Ramos-1994" TYPE="STUDY">S-Ramos 1994</LINK>); and nulliparous teenagers 17.5 years or younger (21/135) (<LINK REF="STD-L_x002d_Jaramillo-1997" TYPE="STUDY">L-Jaramillo 1997</LINK>). The clinical usefulness of the pooled results in this subgroup is therefore limited." To the abstract we have added: "The varied methods of selecting women as being at high-risk limit the clinical usefulness of these pooled results."</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2011-01-19 15:43:19 +0000" MODIFIED_BY="[Empty name]">
<P>Feedback: Stephen Walkinshaw</P>
<P>Reply: G Justus Hofmeyr</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2014-06-12 14:06:44 +0100" MODIFIED_BY="Heather Maxwell">
<APPENDIX ID="APP-01" MODIFIED="2013-08-02 12:37:09 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-08-02 12:36:37 +0100" MODIFIED_BY="[Empty name]">Searches carried out in previous version 2010</TITLE>
<APPENDIX_BODY MODIFIED="2013-08-02 12:37:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Search methods for identification of studies</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches</HEADING>
<P>We searched the Cochrane Pregnancy and Childbirth Group Trials Register by contacting the Trials Search Co-ordinator (May 2010).</P>
<P>Tne Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>.</P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Searching other resources</HEADING>
<P>We included additional information obtained from the authors in the previous version of this review (<A HREF="http://archie.cochrane.org/sections/documents/view?version=94070073716137748309110119171450&amp;format=REVMAN_GRAPHS#REF-Duley-1995">Duley 1995</A>) for five studies (<A HREF="http://archie.cochrane.org/sections/documents/view?version=94070073716137748309110119171450&amp;format=REVMAN_GRAPHS#STD-Belizan-1991">Belizan 1991</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=94070073716137748309110119171450&amp;format=REVMAN_GRAPHS#STD-L_x002d_Jaramillo-1989">L-Jaramillo 1989</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=94070073716137748309110119171450&amp;format=REVMAN_GRAPHS#STD-Marya-1987">Marya 1987</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=94070073716137748309110119171450&amp;format=REVMAN_GRAPHS#STD-Villar-1987">Villar 1987</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=94070073716137748309110119171450&amp;format=REVMAN_GRAPHS#STD-Villar-1990">Villar 1990</A>). We obtained additional information from the authors of the new inclusion (<A HREF="http://archie.cochrane.org/sections/documents/view?version=94070073716137748309110119171450&amp;format=REVMAN_GRAPHS#STD-Kumar-2009">Kumar 2009</A>).</P>
<P>We did not apply any language restrictions.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-06-12 14:06:44 +0100" MODIFIED_BY="Heather Maxwell" NO="2">
<TITLE MODIFIED="2013-08-02 12:23:45 +0100" MODIFIED_BY="Jill V Hampson">Methods used in previous version 2010</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-12 14:06:44 +0100" MODIFIED_BY="Heather Maxwell">
<P>For this update (2010) we used the following methods when assessing the trials identified by the updated search.</P>
<P>Two review authors independently assessed the methodological quality and other inclusion criteria of the identified trials. We resolved disagreements by consensus. The primary assessment for inclusion was based on concealment of allocation and whether the trial was placebo-controlled.</P>
<P>Two authors independently extracted and cross-checked the data. Descriptive data included authors, year of publication, country, time span of the trial, maternal age, parity, type of placebo, baseline dietary calcium intake, type, dose, onset and duration of calcium supplementation, compliance, co-interventions, trial quality assessments, and number randomised and analysed.</P>
<P>We compared categorical data using risk ratios and their 95% confidence intervals. We tested for statistical heterogeneity among trials using the I² statistic, with values greater than 50% indicating significant heterogeneity. In the absence of significant heterogeneity, we pooled data using a fixed-effect model. For continuous data, we calculated pooled estimates of effect size from a weighted average, with weight based on the inverse of the variance (<LINK REF="REF-Early-Breast-Cancer-Trialists_x0027_--Group-1990" TYPE="REFERENCE">Early Breast Cancer Trialists' Group 1990</LINK>). We identified comparisons, outcomes and subgroups other than those prespecified in the original protocol as 'post hoc' analyses.</P>
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>Two review authors (TA Lawrie (TAL) and GJ Hofmeyr (GJH)) independently assessed for inclusion all the potential studies we identified as a result of the search strategy. We would have resolved any disagreement through discussion or, if required, by consulting L Duley (LD).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction and management</HEADING>
<P>We designed a form to extract data. For eligible studies, TAL and GJH extracted the data using the agreed form. We would have resolved discrepancies through discussion or, if required, by consulting LD. We entered data into Review Manager software (<A HREF="http://archie.cochrane.org/sections/documents/view?version=94070073716137748309110119171450&amp;format=REVMAN_GRAPHS#REF-RevMan-2008">RevMan 2008</A>) and checked it for accuracy.</P>
<P>When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies</HEADING>
<P>TAL and GJH independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<A HREF="http://archie.cochrane.org/sections/documents/view?version=94070073716137748309110119171450&amp;format=REVMAN_GRAPHS#REF-Higgins-2009">Higgins 2009</A>). We resolved any disagreement by discussion.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Sequence generation (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>adequate (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>inadequate (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to conceal the allocation sequence and determine whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>inadequate (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Blinding (checking for possible performance bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding could not have affected the results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate, inadequate or unclear for participants;</LI>
<LI>adequate, inadequate or unclear for personnel;</LI>
<LI>adequate, inadequate or unclear for outcome assessors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</HEADING>
<P>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we have re-included missing data in the analyses which we undertook. The cut-off level of missing data that was used to assess that a study is adequate was 20%. We assessed methods as:</P>
<UL>
<LI>adequate;</LI>
<LI>inadequate;</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting bias</HEADING>
<P>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>inadequate (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other sources of bias</HEADING>
<P>We described for each included study any important concerns we had about other possible sources of bias, e.g. whether the trial was stopped early due to some data-dependent process, whether there was extreme baseline imbalance or whether there was a potential source of bias related to the specific study design.</P>
<P>We assessed whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>yes;</LI>
<LI>no;</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Handbook</I> (<A HREF="http://archie.cochrane.org/sections/documents/view?version=94070073716137748309110119171450&amp;format=REVMAN_GRAPHS#REF-Higgins-2009">Higgins 2009</A>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it likely to impact on the findings. We explored the impact of the level of bias through undertaking sensitivity analyses - <I>see </I>
<A HREF="http://archie.cochrane.org/sections/documents/view?version=94070073716137748309110119171450&amp;format=REVMAN_GRAPHS#SENSITIVITY_ANALYSIS">Sensitivity analysis</A>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of treatment effect</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we present results as summary risk ratio with 95% confidence intervals.<I> </I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we used the mean difference if outcomes are measured in the same way between trials. We used the standardised mean difference to combine trials that measure the same outcome but used different methods.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unit of analysis issues</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>Cluster-randomised trials would be included in the analyses along with individually-randomised trials. We would adjust their sample sizes using the methods described in the Handbook (section 16.3.4) using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we used ICCs from other sources, we would report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identified both cluster-randomised trials and individually-randomised trials, we would synthesise the relevant information. We would consider it reasonable to combine the results from both if there was little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit was considered to be unlikely.</P>
<P>We would acknowledge heterogeneity in the randomisation unit and perform sensitivity analyses to investigate the effects of the randomisation unit.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dealing with missing data</HEADING>
<P>For included studies, we noted levels of attrition. We explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.</P>
<P>For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants would be analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity</HEADING>
<P>We assessed statistical heterogeneity in each meta-analysis using the T², I² and Chi² statistics. We regarded heterogeneity as substantial if T² was greater than zero and either I² was greater than 30% or there was a low P-value (less than 0.10) in the Chi² test for heterogeneity.<B> </B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of reporting biases</HEADING>
<P>We investigated reporting biases (such as publication bias) by doing a subgroup analysis based on the sample sizes of the trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis</HEADING>
<P>We carried out statistical analysis using the Review Manager software (<A HREF="http://archie.cochrane.org/sections/documents/view?version=94070073716137748309110119171450&amp;format=REVMAN_GRAPHS#REF-RevMan-2008">RevMan 2008</A>). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials&#8217; populations and methods were judged sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to produce an overall summary if an average treatment effect across trials is considered clinically meaningful. The random-effects summary was treated as the average range of possible treatment effects and we would discuss the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful we would not combine trials.</P>
<P>When we used random-effects analyses, the results were presented as the average treatment effect with its 95% confidence interval, and the estimates of T² and I².</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis and investigation of heterogeneity</HEADING>
<P>When we identified substantial heterogeneity, we investigated it using subgroup analyses. We considered whether an overall summary was meaningful, and if it was, used random-effects analysis to produce it.</P>
<P>We carried out the following subgroup analyses.</P>
<OL>
<LI>Trials in populations with low versus adequate dietary calcium intake.</LI>
<LI>Trials in participants with low/average versus high hypertensive risk.</LI>
<LI>Trials with small versus larger sample sizes.</LI>
</OL>
<P>We used only primary outcomes in subgroup analyses 2 and 3.</P>
<P>For fixed-effect inverse variance meta-analyses we assessed differences between subgroups by interaction tests. For random-effects, we assessed differences between subgroups by inspection of the subgroups&#8217; confidence intervals; non-overlapping confidence intervals indicate a statistically significant difference in treatment effect between the subgroups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>We undertook sensitivity analysis by considering the results of the larger sample size trials versus the overall results for primary outcomes.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>